


# Pharmacy Drug Coverage Policy Manual

Published By:

Medical Services Division  
North Dakota Department of Health and Human Services  
600 E Boulevard Ave Dept 325  
Bismarck, ND 58505-0250

Version 2023.2  
Effective: January 1, 2023



## [Preferred Drug List \(PDL\)](#)

This contains coverage rules for medications including prior authorization criteria for medications billed by pharmacy point of sale systems and for HCPCS codes billed by a physician/clinic through an 837P transactions

## [Preferred Diabetes Supply List \(PDSL\)](#)

This is a list of diabetes supplies billed by pharmacy point of sale systems

## [Prior Authorization Review Dates](#)

Please see DUR Board found at [www.hidesigns.com/ndmedicaid](http://www.hidesigns.com/ndmedicaid)

# Preferred Drug List (PDL)

## Rules

1. Requests for non-preferred brand name agents with a generic formulation available must meet the Dispense as Written (DAW1) criteria for approval in addition to as any other applicable coverage criteria/rule (unless otherwise noted).
2. Non-solid dosage preparations must meet [Non-Solid Dosage Preparations](#) prior authorization criteria even if they are preferred in the clinical category.
3. [Renewal Request Criteria](#) must be met for all renewal requests.
4. The use of all preferred and non-preferred agents must meet recommendations found in the FDA label or compendia (e.g., diagnosis, age, dosage, frequency, route). Compendia supported use is defined as at least of level of IIa efficacy rating and IIb recommendation. ND Medicaid uses DrugDex ® compendia. Requests outside of FDA approved or compendia supported use are not reviewable by prior authorization and the request will be dismissed on PA review. Sec. 1927. [42 U.S.C. 1396r-8] (d).
5. Clinical justification may be provided when criteria does not encompass a standard of care or guideline supported therapy or a member's unique scenario, by faxing supporting chart notes and evidence to 701-328-1544.
6. Grandfathering may be allowed in cases where the clinical condition has been verified by a specialist, member is currently receiving FDA or compendia approved medication, and there is clinical evidence for decompensation of member's condition if agent is switched (subject to clinical review).
7. A trial will be considered a failure if a product was not effective at maximum tolerated dose with good compliance, as evidenced by paid claims or pharmacy print outs. If alternative preferred product(s) are available that the member does not have a documented contraindication, intolerance, or adverse reaction to the same active ingredient, trial requirements must be met with alternative preferred product(s). A trial for preferred product(s) will not be required for which a documented contraindication exists. Intolerance and adverse reaction mitigation efforts must be provided with a request to bypass a trial for a preferred product(s), subject to clinical review.
8. The use of pharmaceutical samples will not be considered when evaluating the member's medical condition or prior prescription history for drugs that require prior authorization.
9. Unless otherwise specified, the listing of a brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified.
10. Please use the following forms unless otherwise indicated:
  - Pharmacy Point of Sale: [General Prior Authorization Form](#)
  - Medical Office Billing: [Medical Service Authorization Request](#)
  - Requested product is same active ingredient as preferred product: [MedWatch Form](#)
11. For pharmacy billed medication: Please use the [NDC Drug Lookup](#) tool to access PA form, view coverage status, quantity limits, copay, and prior authorization information for all medications.
12. For medical billed medications: Please see the full list of medical drugs that require PA at <https://www.hhs.nd.gov/human-services/medicaid/provider> under the "Codes Requiring Service Authorization" tab at the bottom of the page.

## Prior Authorization Updates

Drug name	PA Status	Class
betamethasone valerate foam 0.12%	remove PA	Topical Steroids
desoximetasone spray 0.25%	remove PA	Topical Steroids
Dexcom 7	PA	Continuous Glucose Monitoring
hydrocortisone valerate cream 0.20%	remove PA	Topical Steroids
insulin NPH human/regular insulin human	PA	Insulin
NPH insulin	PA	Insulin
Rebyota	PA	C.difficile associated diarrhea (CDAD)
Tascenso ODT	PA	Multiple Sclerosis
Winlevi	PA	Acne Vulgaris

## Version Changes

Category	Change
Long-Acting Opioid Analgesics	Criteria updated
Clostridioides difficile-associated diarrhea (CDAD)	Name change and prevention added
Opioid with Opioid Use Disorder	Override information updated

## General Policies

### Biosimilar Agents

#### *Prior Authorization Criteria*

##### Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review)

### Combination Agents

#### *Prior Authorization Criteria*

##### Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided for combination products that are comprised of components available and more cost effective when prescribed separately (subject to clinical review).

### Dispense as Written (DAW1)

*The member or prescriber preference is NOT criteria considered for approval*

#### *Prior Authorization Criteria*

##### Initial Criteria - Approval Duration: 12 months

- Request must meet one of the following (A or B):
  - Primary insurance requires a ND Medicaid non-preferred branded product

- B. All the following are met (1-4):
1. The requested brand-name product must not have an authorized generic available
  2. The member must have failed a 30-day trial of each pharmaceutically equivalent generic product at maximum tolerated dose from each available manufacturer, as evidenced by paid claims or pharmacy print outs
  3. Clinical justification is provided for the different clinical outcome expected for the requested brand and other alternatives (e.g., medications in same class) are not an option for the member (subject to clinical review)
  4. A MedWatch form for each trial of each product from the available manufacturer(s) is filled out and attached to request

## Generic Non-Preferred Requests

*The member or prescriber preference is NOT criteria considered for approval*

### *Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months (1 month for short-term request)

- Request must meet one of the following (A, B, or C):
  - A. Primary insurance requires a ND Medicaid non-preferred generic product
  - B. Pharmacy requests a short-term approval due to dose titration or supply issue
  - C. All the following are met (1-3):
    1. The member must have failed a 30-day trial of preferred brand product, as evidenced by paid claims or pharmacy print outs
    2. Clinical justification is provided for the different clinical outcome expected for the requested generic and other alternatives (e.g., medications in same class) are not an option for the member (subject to clinical review)
    3. A MedWatch form for each trial of each product from the available manufacturer(s) is filled out and attached to request

## Medications that cost over \$3000/month

### *Prior Authorization Criteria*

Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a specialist in the area of the member's treated diagnosis
- As applicable, documentation must be attached to confirm serum marker or pathogenic gene variants amenable to treatment

### **CLINICAL PA REQUIRED**

ABECMA (idecabtagene vicleucel) – *Medical Billing Only*

BLINCYTO (blinatumomab) – *Medical Billing Only*

BREYANZI (lisocabtagene maraleucel) – *Medical Billing Only*

CERDELGA (eliglustat)

CYSTADROPS (cysteamine)

CYSTARAN (cysteamine)
DANYELZA (naxitamab-ggqk) – <i>Medical Billing Only</i>
DOJOVI (triheptanoin)
ENSPRYNG (satralizumab)
FIRDAPSE (amifampridine)
GATTEX (teduglutide)
INCRELEX (mecasermin)
MYCAPSSA (octreotide)
NULIBRY (fosdenopterin)
OXERVATE (cenegermin-bkbj)
PHEBURANE (sodium phenylbutyrate)
PYRUKYND (mitapivat)
RAVICTI (glycerol phenylbutyrate)
REZUROCK (belumosudil)
SAMSCA (tolvaptan)
TAVNEOS (avacopan)
TECARTUS (brexucabtagene autoleucel) – <i>Medical Billing Only</i>
TIVDAK (tisotumab vedotin-tftv)
VIJOICE (alpelisib)
WELIREG (belzutifan)
YESCARTA (axicabtagene ciloleucel) – <i>Medical Billing Only</i>
ZOKINVY (lonafamib)
ZYNLONTA (loncastuximab tesirine-lpyl) – <i>Medical Billing Only</i>

## Non-Solid Dosage Forms

### *Electronic Age Verification*

- Non-Solid Dosage Forms that do not require prior authorization for clinical criteria will reject at the point of sale for members 10 years and older to verify they meet Non-Solid Dosage Form prior authorization criteria

### *Prior Authorization Criteria*

#### Initial Criteria - Approval Duration: 2 years (1 month for short-term restriction)

- One of the following criteria is met:
  - The member has a feeding tube placed and the medication is not available in a dosage form that can be crushed or poured into the tube
  - The member does not have a feeding tube placement but one of the following apply:
    - Swallow study documentation has been submitted showing inability to swallow
    - Permanent disability of swallowing solid dosage forms
    - Short-term restriction (e.g., mouth surgery)
    - The member is 9 years old or younger

## Renewal Requests

### *Prior Authorization Criteria*

#### Renewal Criteria

- The member must have experienced and maintained clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review).
- The member must continue to meet applicable initial criteria. Additional criteria may apply as indicated under specific category
- One of the following must be met:
  1. Approval Duration: regular renewal approval duration
    - The member was at least 80% adherent to medication
    - The member had a claim gap due to hospitalization or eligibility
  2. Approval Duration: 3 months
    - All the following must be met -
      - Clinical justification must be provided for the non-adherence.
      - A method to improve adherence must be provided such as addressing adherence barriers, implementing a treatment plan, medication therapy management (MTM), etc.
      - Medical justification must be provided to continue treatment and how efficacy is assessed despite non-adherence

## Allergy/Immunology

### Therapeutic Duplication

- One strength of one medication is allowed at a time

## Chronic Idiopathic Urticaria

### CLINICAL PA REQUIRED

XOLAIR (omalizumab) SYRINGES

XOLAIR (omalizumab) VIALS – *Medical Billing Only*

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 3 months

- The requested medication must be prescribed by, or in consult with, an allergist/immunologist.
- The member must have failed a 30-day trial of a type 1 (H1) antihistamine at maximally tolerated dose either non-sedating (e.g., cetirizine, fexofenadine, loratadine, desloratadine, or levocetirizine) or sedating (e.g., diphenhydramine, chlorpheniramine, cyproheptadine) in addition to one of the following:
  - Leukotriene receptor antagonist (e.g., montelukast, zafirlukast, zileuton)
  - Histamine H2-receptor (e.g., ranitidine, famotidine, nizatidine, cimetidine)

## Deficiency of IL-A Receptor Antagonists (DIRA)

### Interleukin (IL) -1 Receptor Inhibitors

#### PREFERRED AGENTS (NO PA REQUIRED)

KINERET (anakinra)

#### NON-PREFERRED AGENTS (PA REQUIRED)

ARCALYST (riloncept)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months

- The member must have failed a 30-day trial of a preferred agent, as evidenced by paid claims or pharmacy printouts.

## Eosinophilic Granulomatosis with Polyangiitis (EGPA)

### CLINICAL PA REQUIRED

NUCALA (mepolizumab)

#### *Prior Authorization Criteria*

##### Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, a pulmonologist, rheumatologist, or allergy/immunology specialist.
- The member must have active, non-severe disease defined as vasculitis without life- or organ-threatening manifestations (e.g., rhinosinusitis, asthma, mild systemic symptoms, uncomplicated cutaneous disease, mild inflammatory arthritis)
- The member must have received at least 4 weeks of a stable corticosteroid dose to control relapsing or refractory disease.
- The member must have asthma poorly controlled on moderate doses of inhaled glucocorticoids
- The member must have blood eosinophil level  $\geq 1500$  cells per microliter and/or  $\geq 10$  percent of leukocytes within the previous 6 weeks, as evidenced by laboratory documentation attached to the request
- The member must have at least 2 of the following:
  - Paranasal sinusitis
  - Pulmonary infiltrates, sometimes transient
  - Histologic evidence of vasculitis with extravascular eosinophils
  - Multiple mononeuropathy or polyneuropathy

##### Renewal Criteria - Approval Duration: 12 months

- The member must have experienced a decrease in relapses\* and corticosteroid dose, and an increase of time of remission since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review).

\*Relapse is defined as active vasculitis, active asthma symptoms, active nasal or sinus disease requiring the use of glucocorticoids or immunosuppressants.

#### References

1. Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Care Res (Hoboken)* 2021; 73: 1088– 1105.
2. Jennette, J.C., Falk, R.J., Bacon, P.A., Basu, N., Cid, M.C., Ferrario, F., Flores-Suarez, L.F., Gross, W.L., Guillevin, L., Hagen, E.C., Hoffman, G.S., Jayne, D.R., Kallenberg, C.G.M., Lamprecht, P., Langford, C.A., Luqmani, R.A., Mahr, A.D., Matteson, E.L., Merkel, P.A., Ozen, S., Pusey, C.D., Rasmussen, N., Rees, A.J., Scott, D.G.I., Specks, U., Stone, J.H., Takahashi, K. and Watts, R.A. (2013), 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis & Rheumatism*, 65: 1-11. <https://doi.org/10.1002/art.37715>

## Hypereosinophilic Syndrome (HES)

### CLINICAL PA REQUIRED

NUCALA (mepolizumab)

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, a hematologist, or allergy/immunology specialist
- The member must have experienced at least 2 HES flares within the past 12 months despite a 3-month trial with each the following:
  - oral corticosteroids
  - steroid sparing therapy (e.g., hydroxyurea)
- The member must have a blood eosinophil count of 1000 cells/mcL or higher, as evidenced by laboratory documentation attached to the request

### Renewal Criteria - Approval Duration: 12 months

- The member must have experienced a decrease in HES flares\* and a blood eosinophil count < 1000 cells/mcL since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review).

\*HES flares are defined as worsening of clinical signs and symptoms of HES or increasing eosinophils, resulting in the need to increase OCS or increase/add cytotoxic or immunosuppressive HES therapy.

## Nasal Polyps

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DUPIXENT (dupilumab)	NUCALA (mepolizumab)
XOLAIR (omalizumab) SYRINGES	

## Prior Authorization Criteria

### Prior Authorization Form - Nasal Polyps

#### Initial Criteria - Approval Duration: 3 months

- The requested medication must be prescribed by, or in consult with, an ear/nose/throat specialist or allergist/immunologist.
- The member must have failed a 12-week trial of each the following:
  - intranasal corticosteroids
  - oral corticosteroids
- The member must have bilateral polyps confirmed by sinus CT, sinus MRI, or nasal endoscopy
- Member must have documentation of at least two of the following symptoms:
  - nasal obstruction or nasal discharge (anterior/posterior nasal drip)
  - facial pain or pressure
  - reduction in or loss of smell

#### Non-Preferred Agent Criteria:

- The member must have failed a 90-day trial with 1 preferred agent, as evidenced by paid claims or pharmacy printouts

#### Renewal Criteria - Approval Duration: 12 months

- Documentation must be provided including that the member has achieved a significant reduction in nasal polyp size and symptoms since treatment initiation.
- The member must be receiving intranasal steroids



## Gout

### Colchicine

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
COLCRYS (colchicine) TABLETS – <i>Brand Required</i>	colchicine capsules
	colchicine tablets
	GLOPERBA (colchicine) ORAL SOLUTION
	MITIGARE (colchicine) CAPSULE

#### Prior Authorization Criteria

- See applicable [Preferred Dosage Form](#) or [Non-Solid Oral Dosage Form](#) criteria

### Uricosuric Drugs

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
probenecid-colchicine tablets	
probenecid tablets	

### Xanthine Oxidase Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
6-mercaptopurine (6-MP)	allopurinol 200 mg tablet
allopurinol 100 mg tablet	azathioprine 75 mg
allopurinol 300 mg tablet	azathioprine 100 mg
azathioprine 50mg	febuxostat
	ULORIC (febuxostat) TABLET
	ZYLOPRIM (allopurinol) TABLET

#### Prior Authorization Criteria

##### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of allopurinol, as evidenced by paid claims or pharmacy printouts
- Azathioprine: See [Preferred Dosage Form](#) Criteria

### Uricase Drugs

PREFERRED AGENTS (CLINICAL PA REQUIRED)
KRYSTEXXA (pegloticase) – <i>Medical Billing Only</i>

#### Prior Authorization Criteria

##### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a rheumatologist

- The member must have failed a 30-day trial of each of the following, as evidenced by paid claims or pharmacy printouts:
  - allopurinol at 300 mg/day (or maximally tolerated dose) in combination with probenecid
  - febuxostat in combination with probenecid
- The failure of previous trials must be documented by each of the following:
  - Serum uric acid level  $\geq$  6 mg/dL within the past month
  - At least two gout flares within the past year or at least one nonrevolving tophaceous deposit

**Renewal Criteria - Approval Duration: 12 months**

- The member must have experienced and maintained clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including both of the following:
  - Serum uric acid level  $\geq$  6 mg/dL within the past month
  - Decrease in gout flares or nonrevolving tophaceous deposits

## Hereditary Angioedema

### Acute Attack

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BERINERT (C1 Esterase Inhibitor)	FIRAZYR (icatibant)
Icatibant	KALBITOR (ecallantide)
RUCONEST (C1 Esterase Inhibitor)	

### Prophylaxis

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
HAEGARDA (C1 Esterase Inhibitor)	CINRYZE (C1 Esterase Inhibitor)
ORLADEYO (berotrlastat)	
TAKHZYRO (lanadelumab-flyo)	

### *Prior Authorization Criteria*

**Initial Criteria - Approval Duration: 12 months**

- The requested medication must be prescribed by, or in consult with, an allergist/immunologist or rheumatologist

***Non-Preferred Agent Criteria:***

- The member must have a contraindication to or failed a trial of all preferred agents with the same indication for use (prophylaxis or acute treatment), as evidenced by paid claims or pharmacy printouts with required trial durations as follows:
  - Agents for acute attacks: a single trial
  - Agents for attack prophylaxis: 3 months

### *Quantity Override Request*

- Takhyzro: The number of attacks in the last 6 months must be included if the requested dose is 300 mg every 2 weeks

## Immune Globulins

### IM

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
GAMASTAN (immune globul G (IgG)/glycine)	
GAMASTAN S-D (immune globul G (IgG)/glycine)	

### IVIG

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BIVIGAM (human immunoglobulin gamma)	ASCENIV (human immune globulin G- slra)
FLEBOGAMMA DIF (human immunoglobulin gamma)	GAMMAPLEX (human immunoglobulin gamma)
GAMMAGARD S-D (human immunoglobulin gamma)	OCTAGAM (human immunoglobulin gamma)
PRIVIGEN (human immunoglobulin gamma)	PANZYGA (Immune Globulin- ifas)

### IVIG/SCIG

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
GAMMAGARD LIQUID (human immunoglobulin gamma)	GAMMAKED (human immunoglobulin gamma)
GAMUNEX-C (human immunoglobulin gamma)	

### SCIG

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
HIZENTRA (human immunoglobulin gamma)	CUTAQUIG (human immune globulin G - hipp)
	CUVITRU (human immunoglobulin gamma)
	HYQVIA (human immune globulin G and hyaluronidase)
	XEMBIFY (immune globulin,gamma(IgG)klhw)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- If the member's BMI > 30, adjusted body weight must be provided along with the calculated dose

#### Non-Preferred Agent Criteria:

- The member must meet one of the following criteria:
  - The member must have failed a trial of each of the preferred products, as evidenced by paid claims or pharmacy printouts.
  - The member is stable on current therapy (have had a paid claim for requested therapy in the past 45 days)

## Peanut Allergy

CLINICAL PA REQUIRED
PALFORZIA (peanut allergen powder)

### [Prior Authorization Form - Palforzia](#)

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, an allergist/immunologist
- The provider must attest that the member has access to injectable epinephrine, and that the member/caregiver has been instructed and trained on its appropriate use
- The member must not have any of the following:
  - Uncontrolled asthma
  - A history of eosinophilic esophagitis or another eosinophilic GI disease
  - Severe or life-threatening anaphylaxis in the 60 days prior to the request
- The member must have a clinical history of allergy to peanuts or peanut-containing foods AND one of the following:
  - The member has had a serum immunoglobulin E (IgE) to peanut  $\geq 0.35$  kUA/L
  - Skin prick test (SPT) to peanut  $\geq 3$ mm compared to control
  - Allergic reaction produced during a provider observed intake of peanuts

### Renewal Criteria - Approval Duration: 6 months for continued up-titration or 12 months for maintenance the 300 mg dose

- The member must have been adherent with therapy (last 6 fills must have been on time).
- One of the following must be met:
  - The member has been able to tolerate the maintenance dose of Palforzia (300 mg daily)
  - OR
  - An up-titration plan to a final dose of 300 mg daily has been submitted and this is a first request for an up-titration renewal

## Steroids – Nasal Spray

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BECONASE AQ (beclomethasone)	flunisolide
fluticasone	mometasone
OMNARIS (ciclesonide)	QNASL CHILDREN (beclomethasone)
QNASL (beclomethasone)	RYALTRIS (olopatadine/mometasone)
ZETONNA (ciclesonide)	XHANCE (fluticasone)

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of each preferred agent, as evidenced by paid claims or pharmacy printouts
- Xhance (fluticasone) Only: Clinical justification must be provided explaining why the member is unable to use another product with the same active ingredient (subject to clinical review)

## Cardiology

### Therapeutic Duplication

- One Strength of one medication is allowed at a time
  - Exceptions:

- carvedilol IR 25mg allowed with all other strengths
- warfarin strengths are allowed together
- prazosin strengths are allowed together
- Medication classes not payable together:
  - Entresto, ACE Inhibitors, ARBs, and Renin Inhibitors are not allowed with each other
  - sildenafil, tadalafil, Adempas, nitrates are not allowed with each other
  - carvedilol and labetalol are not allowed with other alpha blockers (Alfuzosin ER, doxazosin, dutasteride-tamsulosin, prazosin, terazosin, and tamsulosin)
    - carvedilol and labetalol are nonselective beta blockers with alpha 1 blocking activity
  - tizanidine is not allowed with other alpha 2 agonists (clonidine, clonidine/chlorthalidone, guanfacine, methyl dopa)
    - tizanidine is also an alpha 2 agonist
  - clopidogrel is not covered with esomeprazole or omeprazole. Other PPIs such as pantoprazole are covered with clopidogrel.
    - clopidogrel is a substrate for 2C19 and esomeprazole and omeprazole are strong 2C19 inhibitors and can decrease effectiveness of clopidogrel.
  - clopidogrel, prasugrel, ticagrelor, and ticlopidine are not covered with morphine. Other opioid analgesics are covered with clopidogrel, prasugrel, ticagrelor, and ticlopidine.
    - Morphine may diminish the antiplatelet effect and serum concentrations of P2Y12 Inhibitor antiplatelet agents (clopidogrel, prasugrel, ticagrelor, and ticlopidine).

## Beta Blockers – Override Request

Overrides may be available for beta blockers with slightly different mechanisms of action for use within the cardiac or nephrology specialty: non-selective or selective beta blocking activity; with or without alpha-1 blocker activity. Please request an override by calling provider relations at 1-800-755-2604.

- The prescribers of each medication must be aware of each other
- The requested medications must be prescribed by, or in consult with, a cardiologist or nephrologist

## Anticoagulants - Oral:

### Underutilization

- Eliquis, Pradaxa, Xarelto, and Savaysa must be used adherently and will reject on point of sale for late fill

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ELIQUIS (Apixaban)	dabigatran
PRADAXA (dabigatran) – <i>Brand Required</i>	SAVAYSA (edoxaban)
warfarin	
XARELTO (rivaroxaban) 10 mg, 15 mg, 20 mg, 1 mg/mL suspension	
XARELTO (rivaroxaban) STARTER PACK	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of each preferred agent, as evidenced by paid claims or pharmacy printouts.

## Reduction of Risk of Major Cardiovascular Events in Chronic CAD or PAD

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
XARELTO (rivaroxaban) 2.5 mg	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Xarelto 2.5 mg: The request must include medical documentation (e.g., clinical notes) to verify diagnosis.

## Anticoagulants – Injectable

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
enoxaparin	ARIXTRA (fondaparinux)
fondaparinux	FRAGMIN (dalteparin)
	LOVENOX (enoxaparin)

### Electronic Diagnosis Verification

- Fondaparinux: Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of enoxaparin, as evidenced by paid claims or pharmacy printouts.

## Calcium Channel Blockers

### Non-solid oral dosage forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
diltiazem ER degradable	VERELAN (verapamil) ER PELLETS
KATERZIA (amlodipine) SUSPENSION	DILT-XR (diltiazem) ER DEGRADABLE
NORLIQVA (amlodipine) SOLUTION	
verapamil ER pellets	

### Solid oral dosage forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
amlodipine	CALAN SR (verapamil)
CARTIA XR (diltiazem)	CARDIZEM (diltiazem)
diltiazem	nisoldipine ER 20 mg, 30 mg, 40 mg
DILT-XR (diltiazem)	NORVASC (amlodipine)
felodipine ER	PROCARDIA XL (nifedipine)
isradipine	SULAR (nisoldipine)
MATZIM LA (diltiazem) ER	TIAZAC (diltiazem)
nicardipine	VERELAN (verapamil)
nifedipine	
nimodipine	
nisoldipine ER 8.5 mg, 17 mg, 25.5 mg, 34 mg	

TAZTIA XT (diltiazem)	
TIADYLT ER (diltiazem)	
verapamil	

### Prior Authorization Criteria

- Nisoldipine ER 20 mg, 30 mg, 40 mg: See [Preferred Dosage Form](#) Criteria

## Diuretics - Loop

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
furosemide	ethacrynic acid
bumetanide	SOAANZ (torsemide)
torsemide	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Ethacrynic acid: One of the following must be met:
  - The member must have a documented sulfa allergy
  - The member must have failed a 30-day trial of each preferred agent, as evidenced by paid claims or pharmacy print outs.
- Soaanz: See [Preferred Dosage Form](#) Criteria

## Diuretics – Aldosterone Antagonist

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
amiloride	ALDACTONE (spironolactone)
CAROSPIR (spironolactone) SUSPENSION	INSPRA (eplerone)
eplerone	
spironolactone	
triamterene	

## Heart Failure

### First Line Agents

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ACE (angiotensin-converting enzyme) inhibitors - <i>all oral agents preferred</i>	
ARBs (angiotensin receptor blockers) - <i>all oral agents preferred</i>	
Beta blockers - <i>all oral agents preferred</i>	
ENTRESTO (sacubitril/valsartan)	
FARXIGA (dapagliflozin)	
JARDIANCE (empagliflozin)	

### Second Line Agents

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CORLANOR (ivabradine)	

VERQUVO (vericiguat)	
----------------------	--

*Electronic Diagnosis Verification*

- Corlanor, Entresto, and Verquvo: Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- Corlanor Only:
  - The requested medication must be prescribed by, or in consult with, a cardiologist
  - The member must have a resting HR  $\geq 70$  beats per minute on maximally tolerated or target beta blocker dose in sinus rhythm
- Verquvo Only:
  - The requested medication must be prescribed by, or in consult with, a cardiologist
  - The member must have left ventricular ejection fraction (LVEF)  $< 45\%$  at initiation
  - Documentation of a recent hospitalization or need for IV diuretics within the past 6 months must be provided with request
  - The member is receiving concurrent Entresto, a beta-blocker, a SGLT-2 Inhibitor, and a mineralocorticoid receptor antagonist.

**Hypertrophic Cardiomyopathy**

<b>CLINICAL PA REQUIRED</b>
CAMZYOS (mavacamten)

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- The requested medication must be prescribed by, or in consult with, a cardiologist
- The member must have left ventricular ejection fraction (LVEF)  $< 55\%$  at initiation and  $< 50\%$  at renewal
- The member has a peak left ventricular outflow tract (LVOT) gradient  $\geq 50$  mmHg at rest or with provocation
- The member is receiving concurrent a beta-blocker and a nondihydropyridine calcium channel blocker.

Renewal Criteria - Approval Duration: 12 months

- Member has an improved  $pVO_2$  by  $\geq 1.5$  mL/kg/min plus improvement in NYHA class by at least 1 or improvement of  $pVO_2$  by  $\geq 3$  mL/kg/min and no worsening in NYHA class.

**Inappropriate Sinus Tachycardia**

<b>CLINICAL PA REQUIRED</b>
CORLANOR (ivabradine)

*Electronic Diagnosis Verification*

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale



### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The request must include medical documentation (e.g., clinical notes) to verify diagnosis.

## Lipid-Lowering Agents

### ACL(ATP Citrate Lyase) Inhibitors

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
NEXLETOL (bempedioic acid)	
NEXLIZET (bempedioic acid and ezetimibe)	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 3 months

- The member must have LDL levels of >70 mg/dL after a 120-day trial of one of the following, as evidenced by paid claims or pharmacy printouts:
  - Crestor (rosuvastatin) ≥20 mg
  - Lipitor (atorvastatin) ≥ 40 mg

### Electronic Step Care and Concurrent Medications

- A total of 90 days of Crestor (rosuvastatin) or Lipitor (atorvastatin) must be paid within 120 days prior to Nexletol or Nexlizet's date of service or intolerance to statins justification must be provided (subject to clinical review)

### Cholesterol Absorption Inhibitor - 2-Azetidinone

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ezetimibe	ZETIA (ezetimibe)

### Eicosapentaenoic acid (ESA) Ethyl Ester

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
VASCEPA (icosapent ethyl) – Brand Required	icosapent ethyl

### Fenofibrate

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
fenofibrate capsules 50mg, 150mg	ANTARA (fenofibrate, micronized)
fenofibrate, micronized 43mg, 67mg, 130mg, 134mg, 200mg	fenofibrate, micronized 30mg, 90mg
fenofibrate, nanocrystallized 48mg, 145mg	fenofibrate tablets 40mg, 120mg
fenofibrate tablets 54mg, 160mg	FENOGLIDE (fenofibrate)
fenofibric acid	LIPOFEN (fenofibrate)
	TRICOR (fenofibrate, nanocrystallized)
	TRIGLIDE (fenofibrate)
	TRILIPIX (fenofibric acid)

### Prior Authorization Criteria

- See [Preferred Dosage Form](#) Criteria

*MTP (Microsomal Triglyceride Transfer Protein) Inhibitor*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	JUXTAPID (lomitapide)

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 3 months

- Clinical justification must be provided explaining why the member is unable to use all other products to lower their cholesterol (subject to clinical review)

*PCSK9 (Proptien Convertase Subtilisin/Kexin Type 9) Inhibitors*

PREFERRED AGENTS (ELECTRONIC STEP REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
PRALUENT PEN (alirocumab)	REPATHA PUSHTRONEX (evolocumab)
	REPATHA SURECLICK (evolocumab)
	REPATHA SYRINGE (evolocumab)

*Underutilization*

- Praluent and Repatha must be used adherently and will reject on point of sale for late fill

*Electronic Step Care and Concurrent Medications*

- Praluent: A total of 90 days of Crestor (rosuvastatin) or Lipitor (atorvastatin) must be paid within 120 days prior to Praluent's date of service or intolerance to statins justification must be provided (subject to clinical review)

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 3 months

- One of the following must be met:
  - The member is age 10 or greater and younger than 18 years old and is concurrently on a statin, as evidenced by paid claims or pharmacy printouts.
  - The member must have LDL levels of >70 mg/dL after a 90-day trial of the following, as evidenced by paid claims or pharmacy printouts:
    - Praluent combined with Crestor (rosuvastatin) ≥20 mg or Lipitor (atorvastatin) ≥ 40 mg
    - Nexlizet combined with Crestor (rosuvastatin) ≥20 mg or Lipitor (atorvastatin) ≥ 40 mg

*Statins (HMG-CoA (3-hydroxy-3-methylglutaryl-CoA Reductase Inhibitors)*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
amlodipine/atorvastatin	ALTROPREV (lovastatin)
atorvastatin	CADUET (amlodipine/atorvastatin)
ezetimibe/simvastatin	CRESTOR (rosuvastatin)
fluvastatin	EZALLOR SPRINKLE (rosuvastatin)
LIVALO (pitavastatin)	fluvastatin ER
lovastatin	LESCOL XL (fluvastatin)
pravastatin	LIPITOR (atorvastatin)
rosuvastatin	PRAVACHOL (pravastatin)
simvastatin	VYTORIN (ezetimibe/simvastatin)

	ZOCOR (simvastatin)
	ZYPITAMAG (pitavastatin)

*Prior Authorization Criteria*

- See applicable [Preferred Dosage Form](#) or [Non-Solid Dosage Form](#) criteria

*Angiopoietin-like 3 (ANGPTL3) Inhibitor*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	EVKEEZA (evinacumab-dgnb) – <i>Medical Billing Only</i>

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a cardiologist, endocrinologist, or lipid specialist
- Documentation of one of the following must be provided:
  - Genetic testing confirming two mutant alleles at the low-density lipoprotein receptor (LDLR), apolipoprotein B (apo B), proprotein convertase subtilisin kexin type 9 (PCSK9) or low-density lipoprotein receptor adaptor protein 1 (LDLRAP1) gene locus
  - Untreated total cholesterol of > 500mg/dL with one of the following:
    - Cutaneous or tendon xanthoma before age 10 years
    - Evidence of heterozygous familial hypercholesterolemia in both parents
  - Low-density lipoprotein cholesterol (LDL-C) level greater than 100 mg/dL after a 90-day trial of each of the following, as evidenced by paid claims or pharmacy printouts or clinical justification as to why a treatment is unable to be used (subject to clinical review):
    - PCSK9 inhibitor and ezetimibe combined with rosuvastatin ≥20 mg or atorvastatin ≥ 40 mg
    - Nexlizet and ezetimibe combined with rosuvastatin ≥20 mg or atorvastatin ≥ 40 mg

Renewal Criteria - Approval Duration: 12 months

- The member has an LDL-C level less than 100 mg/dL or has achieved a 40% reduction

*siRNA (small interfering RNA) therapy*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	LEQVIO (inclisiran) – <i>Medical Billing Only</i>

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 6 months

- The member must have LDL levels of >70 mg/dL after a 90-day trial of the following, as evidenced by paid claims or pharmacy printouts:
  - Praluent combined with Crestor (rosuvastatin) ≥20 mg or Lipitor (atorvastatin) ≥ 40 mg
  - Nexlizet combined with Crestor (rosuvastatin) ≥20 mg or Lipitor (atorvastatin) ≥ 40 mg

Renewal Criteria - Approval Duration: 12 months

- The member has an LDL-C level less than 100 mg/dL or has achieved a 40% reduction

- The member must currently be receiving a maximally tolerated statin (HMG-CoA reductase inhibitor) agent, as evidenced by paid claims or pharmacy printouts

## Platelet Aggregation Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
aspirin	clopidogrel 300mg
aspirin/dipyridamole ER	EFFIENT (prasugrel)
BRILINTA (ticagrelor)	PLAVIX (clopidogrel)
clopidogrel 75 mg	ZONTIVITY (vorapaxar)
dipyridamole	
prasugrel	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed 30-day trials of at least 2 preferred platelet aggregation inhibitor agents, as evidenced by paid claims or pharmacy printouts.

## Pulmonary Hypertension

### PDE-5 Inhibitors

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
REVATIO (sildenafil) SUSPENSION – <i>Brand Required</i>	ADCIRCA (tadalafil) TABLET
sildenafil tablet	ALYQ (tadalafil)
tadalafil tablet	REVATIO (sildenafil) TABLET
	sildenafil suspension
	TADLIQ (tadalafil) SUSPENSION

### Electronic Age Verification

- Sildenafil/tadalafil: Prior authorization is not required for ages less than 18 years old
- Revatio suspension: Prior authorization is not required for ages less than 9 years old

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The request must include medical documentation (e.g., clinical notes) to verify diagnosis.

## Soluble Guanylate Cyclase Stimulators

NO PA REQUIRED
ADEMPAS (riociguat)

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

## Endothelin Receptor Antagonists

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ambrisentan	bosentan
TRACLEER (bosentan) SUSPENSION	LETAIRIS (ambrisentan)
TRACLEER (bosentan) TABLETS - <i>Brand Required</i>	OPSUMIT (macitentan)

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of ambrisentan, as evidenced by paid claims or pharmacy printouts.

## Prostacyclins

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ORENITRAM ER (treprostinil) TABLET	REMODULIN (treprostinil) INJECTION
treprostinil injection	
TYVASO (treprostinil) DPI	
TYVASO (treprostinil) INHALATION	
UPTRAVI (selexipag) TABLET	
UPTRAVI (selexipag) VIAL	
VENTAVIS (iloprost) INHALATION	

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

## Vecamyl

CLINICAL PA REQUIRED
VECAMYL (mecamylamine)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have documented history of failure to achieve blood pressure goals (using maximum tolerated doses) of all first- and second-line agents as defined by the most recent JNC report.

## Dermatology

### Acne

### Electronic Age Verification

- The member must be between 12 and 35 years of age

## Adapalene

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
adapalene cream	
adapalene gel	
adapalene gel with pump	
adapalene/benzoyl peroxide 0.1%-2.5%	
adapalene/benzoyl peroxide 0.3%-2.5%	

### Therapeutic Duplication

- One strength of one benzoyl peroxide containing medication is allowed at a time

## Androgen Receptor Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	WINLEVI (clascoterone) CREAM

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 3-month trial of two preferred agent of a unique active ingredient, as evidenced by paid claims or pharmacy printouts.

## Clindamycin

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
clindamycin capsule	CLEOCIN T (clindamycin) GEL
clindamycin gel	CLEOCIN T (clindamycin) LOTION
clindamycin lotion	CLEOCIN T (clindamycin) MED SWAB
clindamycin solution	CLINDACIN P (clindamycin) MED SWAB
clindamycin med. swab	CLINDACIN ETZ (clindamycin) MED SWAB
EVOCLIN (clindamycin) FOAM – <i>Brand Required</i>	CLINDAGEL (clindamycin) GEL DAILY
ZIANA (clindamycin-tretinoin 1.2%-0.025%) - <i>Brand Required</i>	clindamycin gel daily
	clindamycin foam
	clindamycin-tretinoin 1.2%-0.025%

## Clindamycin-Benzoyl Peroxide

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
clindamycin-benzoyl peroxide 1.2%-2.5%	ACANYA (clindamycin-benzoyl peroxide) 1.2%-2.5%
clindamycin-benzoyl peroxide 1%-5% with pump	BENZACLIN (clindamycin/benzoyl peroxide without pump) 1%-5%
clindamycin-benzoyl peroxide 1.2%-5%	BENZACLIN (clindamycin/benzoyl peroxide with pump) 1%-5%
clindamycin/benzoyl peroxide 1%-5% without pump	NEUAC (clindamycin/benzoyl peroxide) 1.2%-5%
ONEXTON (clindamycin/benzoyl peroxide) 1.2%-3.75%	

### Therapeutic Duplication

- One strength of one benzoyl peroxide containing medication is allowed at a time

### Retinoid

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ALTRENO (tretinoin) LOTION	AKLIEF (trifarotene) CREAM 0.005%
FABIOR (tazarotene) 0.1% FOAM - <i>Brand Required</i>	ATRALIN (tretinoin) 0.05% GEL
RETIN-A MICRO PUMP (tretinoin microsphere) 0.04%, 0.1% - <i>Brand Required</i>	ARAZLO (tazarotene) 0.045% LOTION
tretinoin cream	clindamycin-tretinoin 1.2%-0.025%
tretinoin gel	RETIN-A (tretinoin) CREAM
tretinoin microsphere without pump	RETIN-A (tretinoin) GEL
ZIANA (clindamycin-tretinoin 1.2%-0.025%) - <i>Brand Required</i>	RETIN-A MICRO PUMP (tretinoin microsphere) 0.06%, 0.08%
	RETIN-A MICRO (tretinoin microsphere) GEL WITHOUT PUMP
	tazarotene 0.1% cream
	tazarotene 0.1% foam
	tazarotene gel
	tretinoin microsphere with pump
	TWYNEO (tretinoin/benzoyl peroxide) 0.1%-0.3% CREAM

### Therapeutic Duplication

- One strength of one retinoid medication is allowed at a time
- One strength of one benzoyl peroxide containing medication is allowed at a time

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review)

### Tetracyclines

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
doxycycline hyclate capsule	AMZEEQ (minocycline) Foam
doxycycline hyclate tablet 20 mg, 100 mg	demeclocycline
doxycycline monohydrate 25 mg/5 mL suspension	DORYX (doxycycline hyclate) TABLET DR
doxycycline monohydrate tablet 50 mg, 75 mg, 100 mg	DORYX MPC (doxycycline hyclate) TABLET DR
doxycycline monohydrate capsule 50 mg, 100 mg	doxycycline monohydrate capsule 75 mg, 150 mg
minocycline capsule	doxycycline hyclate tablet 50 mg, 75 mg, 150 mg
tetracycline	doxycycline monohydrate tablet 150 mg
VIBRAMYCIN (doxycycline calcium) 50 mg/5 mL SYRUP	doxycycline hyclate tablet DR

	MINOCIN (minocycline) CAPSULE
	minocycline tablet
	minocycline tablet ER
	MINOLIRA ER (minocycline) TABLET
	MORGIDOX (doxycycline hyclate) CAPSULE
	SOLODYN ER (minocycline) TABLET
	VIBRAMYCIN (doxycycline monohydrate) 25 mg/5 mL SUSPENSION
	XIMINO (minocycline) CAPSULE ER

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review)

**Sulfonamide**

<b>PREFERRED AGENTS (NO PA REQUIRED)</b>	<b>NON-PREFERRED AGENTS (PA REQUIRED)</b>
BP 10-1 (sodium sulfacetamide/sulfur cleanser) 10%-1%	ACZONE (dapsons) GEL WITH PUMP 7.5%
Cleansing Wash (sulfacetamide sodium/sulfur/urea) 10%-4%-10%	BP 10-1 (sulfacetamide sodium/sulfur) CLEANSER
dapsone gel without pump 5%	dapsone gel pump 7.5%
SSS 10-5 (sulfacetamide) FOAM	SSS 10-5 (sulfacetamide) CLEANSER
sulfacetamide 10% suspension	sodium sulfacetamide/sulfur pads 10%-4%
sodium sulfacetamide/sulfur cleanser 10%-5% (W/W)	sodium sulfacetamide/sulfur cream 10%-2%
sodium sulfacetamide/sulfur cleanser 9%-4%	SUMAXIN (sodium sulfacetamide/sulfur pads) PADS 10%-4%
sodium sulfacetamide/sulfur cleanser 9%-4.5%	SUMAXIN TS (sodium sulfacetamide/sulfur) SUSPENSION 8%-4%
sodium sulfacetamide/sulfur cleanser 9.8% -4.8%	
sodium sulfacetamide/sulfur cleanser 10%-2%	
sodium sulfacetamide/sulfur cleanser 10%-5%-10%	
sodium sulfacetamide/sulfur cream 10%-5% (W/W)	
sodium sulfacetamide/sulfur suspension 8%-4%	
SUMAXIN (sodium sulfacetamide/sulfur) CLEANSER 9%-4%	

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review)



## Actinic Keratosis

### Fluorouracil

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CARAC (fluorouracil) 0.5% CREAM – <i>Brand Required</i>	EFUDEX (fluorouracil) 5% CREAM
fluorouracil 5% cream	fluorouracil 0.5% cream
fluorouracil 2% solution	
fluorouracil 5% solution	

### Imiquimod

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
imiquimod 5% cream packet	imiquimod 3.75% cream packet
ZYCLARA (imiquimod) 3.75% CREAM PUMP – <i>Brand Required</i>	imiquimod 3.75% cream pump
	ZYCLARA (imiquimod) 3.75% CREAM PACKET
	ZYCLARA (imiquimod) 2.5% CREAM PUMP

### Diclofenac

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
diclofenac 3% sodium gel	

#### Electronic Diagnosis Verification

- Diclofenac 3% sodium gel: Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

#### Prior Authorization Criteria

##### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 6-month trial of each preferred agent of a unique active ingredient, as evidenced by paid claims or pharmacy printouts.
- If requested product has preferred option with same active ingredient, clinical justification must be provided explaining why the member is unable to use preferred product (subject to clinical review)

## Antifungals – Topical

### Cream

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
butenafine cream	CICLODAN (ciclopirox) CREAM
ciclopirox cream	ERTACZO (sertraconazole) CREAM
clotrimazole cream	EXELDERM (sulconazole) CREAM
econazole cream	LOPROX (ciclopirox) CREAM
ketoconazole cream	luliconazole cream
miconazole cream	LUZU (luliconazole) CREAM
nystatin cream	MENTAX (butenafine) CREAM
nystatin – triamcinolone cream	naftifine cream
	NAFTIN (naftifine) CREAM

	oxiconazole cream
	OXISTAT (oxiconazole) CREAM
	sulconazole cream

### Foam

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
EXTINA (ketoconazole) FOAM – <i>Brand Required</i>	KETODAN (ketoconazole) FOAM
	ketoconazole foam

### Gel

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ciclopirox gel	NAFTIN (naftifine) GEL

### Lotion

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	OXISTAT (oxiconazole) LOTION

### Ointment

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ALEVAZOL (clotrimazole) OINTMENT	miconazole/zinc oxide/white petrolatum ointment
nystatin ointment	VUSION (miconazole/zinc/white petrolatum) OINTMENT
nystatin – triamcinolone ointment	

### Powder

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
nystatin powder	
NYAMYC (nystatin) POWDER	
NYSTOP (nystatin) POWDER	

### Shampoo

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ciclopirox shampoo	LOPROX (ciclopirox) SHAMPOO
ketoconazole shampoo	

### Solution

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ciclopirox solution	CICLODAN (ciclopirox) SOLUTION
clotrimazole solution	EXELDERM (sulconazole) SOLUTION
	JUBLIA (efinaconazole) SOLUTION
	KERYDIN (tavaborole) SOLUTION
	tavaborole solution

### Suspension

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ciclopirox suspension	LOPROX (ciclopirox) SUSPENSION

### Prior Authorization Criteria

Initial Criteria - Approval Duration: 12 months

- Onychomycosis Only:
  - Diagnosis must be confirmed by potassium hydroxide (KOH) preparation
  - The member must have had a trial of one oral agent (terbinafine, fluconazole, or itraconazole), for the length of recommended treatment time for member's particular infection, as evidenced by paid claims or pharmacy printouts
  - Adequate time must have passed since treatment cessation to accurately assess healthy toenail outgrowth (at least 6 months)
  - One of the following must be met (A or B):
    - [Preferred Dosage Form](#) Criteria
    - The active ingredient of the requested product is not available in a preferred formulation
- Other Diagnosis:
  - The member must have failed a trial of 3 preferred agents, for the length of recommended treatment time for member's particular infection, as evidenced by paid claims or pharmacy printouts
  - One of the following must be met (A or B):
    - [Preferred Dosage Form](#) Criteria
    - The active ingredient of the requested product is not available in a preferred formulation

## Eczema / Atopic Dermatitis

### Oral

#### First Line Agents

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
azathioprine 50mg	azathioprine 75mg
cyclosporine	azathioprine 100mg
methotrexate	
systemic oral corticosteroids	

#### Prior Authorization Criteria

- Azathioprine: See [Preferred Dosage Forms](#) Criteria

### Topical

#### Calcineurin Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ELIDEL (pimecrolimus) CREAM – <i>Brand Required</i>	pimecrolimus
tacrolimus 0.03%	
tacrolimus 0.1%	

#### Electronic Age Verification

- Tacrolimus ointment 0.1%: The member must be 16 years of age or older

#### Janus Kinase (JAK) inhibitor

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
---	------------------------------------

OPZELURA (ruxolitinib) 1.5% CREAM	
-----------------------------------	--

## Phosphodiesterase 4 (PDE-4) inhibitor

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
EUCRISA (crisaborole) OINTMENT	

## Topical Corticosteroids

Please see the [Preferred Drug List of Topical Corticosteroids](#)

## Systemic

### Interleukin (IL)-4/13 Inhibitor

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DUPIXENT (dupilumab) INJECTION	

### Interleukin (IL)-13 Inhibitor

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ADBRY (tralokinumab-idrm) INJECTION	

### Janus Kinase (JAK) inhibitor

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	CIBINQO (abrocitinib) TABLET
	RINVOQ ER (upadacitinib) TABLET

### Prior Authorization Criteria

#### [Prior Authorization Form - Atopic Dermatitis](#)

#### Initial Criteria - Approval Duration: 3 months

- Member must have failed a 6-week trial of tacrolimus or pimecrolimus as evidenced by paid claims or pharmacy printouts:
- One of the following must be met:
  - The member has failed a two 2-week trials of topical corticosteroids of medium or higher potency, as evidenced by paid claims or pharmacy printouts.  
OR
  - The member meets both of the following (1 AND 2):
    - Affected area is on face, groin, axilla, or under occlusion
    - Member must have failed two 2-week trials of topical corticosteroids of low or higher potency, as evidenced by paid claims or pharmacy printouts.

#### *Systemic Janus Kinase (JAK) Inhibitors Only*

- The member must have failed a 3-month trial of Adbry and Dupixent, as evidenced by paid claims or pharmacy printouts.

## Hidradenitis Suppurativa

NO PA REQUIRED
HUMIRA (adalimumab)

### Electronic Diagnosis Verification

Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

## Infantile Hemangioma

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
propranolol oral solution	HEMANGEOL (propranolol) ORAL SOLUTION

### Electronic Age Verification

- Hemangeol: The patient must be less than 1 years of age

### Electronic Diagnosis Verification

- Hemangeol: Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### Prior Authorization Criteria

- See [Preferred Dosage Form](#) Criteria

## Lice

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
EURAX (crotamiton) CREAM	CROTAN (crotamiton)
NATROBA (spinosad) – <i>Brand Required</i>	ELIMITE (permethrin) CREAM
LICE KILLING SHAMPOO (piperonyl butoxide/pyrethrins)	EURAX (crotamiton) LOTION
NIX 1% (permethrin) CRÈME RINSE LIQUID	lindane shampoo
permethrin 5% cream	malathion
SM LICE TREATMENT (permethrin) 1% CRÈME RINSE LIQUID	OVIDE (malathion)
	spinosad

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- One of the following must be met:
  - The member must have failed a 28-day/2-application trial of each preferred agent, as evidenced by paid claims or pharmacy printouts
  - There is a documented community breakout of a strain that is not susceptible to a preferred agent

## Plaque Psoriasis

### Biologics

#### Interleukin (IL)-12/IL-23 Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	STELARA (ustekinumab)

### Interleukin (IL)-17 Inhibitor

PREFERRED AGENTS (ELECTRONIC STEP REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TALTZ (ixekizumab)	COSENTYX (secukinumab)

### Interleukin (IL)-17 Receptor Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	SILIQ (brodalumab)

### Interleukin (IL)-23/IL-39 Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	SKYRIZI (risankizumab-rzaa)
	TREMFYA (guselkumab)

### TNF Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AVSOLA (infliximab-axxq) – <i>Medical Billing Only</i>	INFLECTRA (infliximab-dyyb) – <i>Medical Billing Only</i>
CIMZIA (certolizumab pegol)	infliximab – <i>Medical Billing Only</i>
ENBREL (etanercept)	REMICADE (infliximab) – <i>Medical Billing Only</i>
HUMIRA (adalimumab)	
RENFLEXIS (infliximab-abda) – <i>Medical Billing Only</i>	

### Interleukin (IL)-23/IL-39 inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	ILUMYA (tildrakizumab-asmn) – <i>Medical Billing Only</i>

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### Electronic Step Care and Concurrent Medications

- Taltz: A total of 84 days of a TNF Inhibitor must be paid within 120 days prior to Taltz's date of service.

### Prior Authorization

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 3-month trial of a TNF inhibitor and an Interleukin (IL)-17 Inhibitor, as evidenced by paid claims or pharmacy printouts.
- Remicade, infliximab, and Inflectra Only: See [Preferred Dosage Form](#) Criteria
- Stelara and Cosentyx Only: The member must have failed a 3-month trial of an Interleukin (IL)-23/IL-39 Inhibitor, as evidenced by paid claims or pharmacy printouts

## Oral

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
acitretin 10 mg, 25 mg	acitretin 17.5 mg
cyclosporine	SOTYKTU (deucravacitinib)

methotrexate	
OTEZLA (apremilast)	

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- Acitretin 17.5 mg Only: See [Preferred Dosage Form](#) Criteria
- Sotyktu Only: The member must have failed a 30-day trial of Otezla, as evidenced by paid claims or pharmacy print outs

**Topical**

*Foams, Solution, Suspension*

<b>PREFERRED AGENTS (NO PA REQUIRED)</b>	<b>NON-PREFERRED AGENTS (PA REQUIRED)</b>
calcipotriene solution	calcipotriene foam
ENSTILAR (calcipotriene/betamethasone) FOAM	calcipotriene/betamethasone suspension
SORILUX (calcipotriene) FOAM – <i>Brand Required</i>	
TACLONEX (calcipotriene/betamethasone) SUSPENSION – <i>Brand Required</i>	

*Cream, Lotion*

<b>PREFERRED AGENTS (NO PA REQUIRED)</b>	<b>NON-PREFERRED AGENTS (PA REQUIRED)</b>
calcipotriene cream	DUOBRII (halobetasol/tazarotene) LOTION
	DOVONEX (calcipotriene) CREAM
	tazarotene 0.1% cream
	VTAMA (tapinarof) 1% CREAM
	ZORYVE (roflumilast) 0.3% CREAM

*Ointment*

<b>PREFERRED AGENTS (NO PA REQUIRED)</b>	<b>NON-PREFERRED AGENTS (PA REQUIRED)</b>
calcipotriene ointment	calcipotriene/betamethasone ointment
TACLONEX (calcipotriene/betamethasone) OINTMENT – <i>Brand Required</i>	calcitriol ointment
VECTICAL (calcitriol) OINTMENT – <i>Brand Required</i>	

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of each preferred agent of an unique active ingredient, as evidenced by paid claims or pharmacy print outs

**Prurigo Nodularis**

<b>PREFERRED AGENTS (CLINICAL PA REQUIRED)</b>
DUPIXENT (dupilumab)

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, a dermatologist

- The member is experiencing nodular lesions that produce itch for greater than 6 weeks that has significantly diminished quality of life, including sleep disturbances.
- The member has failed each of the following trials, as evidenced by paid claims or pharmacy printouts:
  - A 2-week trial of a topical corticosteroid of medium or higher potency
  - A 3-month trial of an immunologic systemic therapy (e.g., azathioprine, cyclosporine, methotrexate)

## Steroids – Topical

### Super-High Potency (Group 1)

Dosage Form	PREFERRED AGENTS (NO PA REQUIRED)		NON-PREFERRED AGENTS (PA REQUIRED)	
Cream	clobetasol emollient	0.05%		
	clobetasol propionate	0.05%		
	fluocinonide	0.10%		
	halobetasol propionate	0.05%		
Lotion	clobetasol propionate	0.05%	betamethasone dipropionate, augmented	0.05%
			STEP 2* IMPEKLO (clobetasol)	0.05%
			STEP 2* ULTRAVATE (halobetasol) MDP	0.05%
Ointment	betamethasone dipropionate, augmented	0.05%	halobetasol propionate	0.05%
	clobetasol propionate	0.05%		
	clobetasol propionate foam	0.05%		
Foam, Gel, Shampoo, Solution, Spray	clobetasol propionate shampoo	0.05%	betamethasone dipropionate, augmented gel	0.05%
	clobetasol propionate solution	0.05%	STEP 2* clobetasol emulsion foam	0.05%
	clobetasol propionate spray	0.05%	STEP 2* halobetasol propionate foam	0.05%
	clobetasol propionate gel	0.05%		

### Electronic Duration Verification

Group 1 topical steroids are covered for 30 days every 90 days. Group 1 steroids are covered with group 2 steroids to facilitate an alternating schedule.

- If the following conditions apply, please call for an override by calling provider relations at 1-800-755-2604:
  - Location of application: palms and soles
  - Indication: psoriasis
  - Close monitoring for side effects

### Reference:

Joint AAD-NFP guidelines for management and treatment of psoriasis recommend limiting the use of Group 1 topical steroids to no more than twice daily up to 4 weeks. Transitions to lower potent agents, intermittent therapy, and combination treatment with non-steroids are recommended to minimize side effects.

### High Potency (Group 2)

Dosage Form	PREFERRED AGENTS (NO PA REQUIRED)		NON-PREFERRED AGENTS (PA REQUIRED)	
Cream	betamethasone dipropionate, augmented	0.05%	STEP 2* APEXICON E (diflorasone emollient)	0.05%



	fluocinonide	0.05%	desoximetasone	0.25%
	HALOG (halcinonide)– <i>Brand Required</i>	0.10%		
Lotion			BRYHALI (halobetasol) LOTION	0.01%
Ointment	betamethasone dipropionate	0.05%	STEP 2* diflorasone diacetate	0.05%
	desoximetasone	0.25%		
	fluocinonide	0.05%		
	fluticasone propionate	0.01%		
	HALOG (halcinonide)	0.10%		
Gel, Solution, Spray	desoximetasone spray	0.25%	desoximetasone gel	0.05%
	fluocinonide gel	0.05%	HALOG (halcinonide) SOLUTION	0.10%
	fluocinonide solution	0.05%		

### High Potency (Group 3)

Dosage Form	PREFERRED AGENTS (NO PA REQUIRED)		NON-PREFERRED AGENTS (PA REQUIRED)	
Cream	betamethasone dipropionate	0.05%	STEP2* amcinonide	0.10%
	triamcinolone acetonide	0.50%	desoximetasone	0.05%
			STEP2* diflorasone diacetate	0.05%
			fluocinonide-E	0.05%
Lotion			amcinonide	0.10%
Ointment	betamethasone valerate	0.10%	desoximetasone	0.05%
	fluticasone propionate	0.01%		
	mometasone furoate	0.10%		
	triamcinolone acetonide	0.50%		
Foam	betamethasone valerate foam	0.12%		

### Medium Potency (Group 4)

Dosage Form	PREFERRED AGENTS (NO PA REQUIRED)		NON-PREFERRED AGENTS (PA REQUIRED)	
Cream	fluticasone propionate	0.05%	STEP2* clocortolone pivalate	0.10%
	mometasone furoate	0.10%		
	triamcinolone acetonide	0.10%		
Ointment	fluocinolone acetonide	0.025%	hydrocortisone valerate	0.20%
	triamcinolone acetonide	0.10%	STEP2* flurandrenolide	0.05%
	triamcinolone acetonide	0.05%		
Aerosol, Paste Solution	mometasone furoate solution	0.10%	triamcinolone acetonide aerosol	0.147 MG/G
	triamcinolone acetonide paste	0.10%		

### Lower-Mid Potency (Group 5)

Dosage Form	PREFERRED AGENTS (NO PA REQUIRED)		NON-PREFERRED AGENTS (PA REQUIRED)	
-------------	-----------------------------------	--	------------------------------------	--

Cream	betamethasone valerate	0.10%	fluocinolone acetonide	0.03%
	hydrocortisone valerate	0.20%	prednicarbate	0.10%
			STEP2*flurandrenolide	0.05%
			hydrocortisone butyrate	0.10%
			hydrocortisone butyrate emollient	0.10%
Lotion	betamethasone dipropionate	0.05%	STEP2*flurandrenolide	0.05%
	LOCOID (hydrocortisone butyrate) – Brand Required	0.10%	fluticasone propionate	0.05%
	triamcinolone acetonide	0.10%		
Ointment	desonide	0.05%	hydrocortisone butyrate	0.10%
	triamcinolone acetonide	0.025%	prednicarbate	0.10%
Gel, Solution	hydrocortisone butyrate solution	0.10%	desonide gel	0.05%

### Low Potency (Group 6)

Dosage Form	PREFERRED AGENTS (NO PA REQUIRED)		NON-PREFERRED AGENTS (PA REQUIRED)	
Cream	alclometasone dipropionate	0.05%	fluocinolone acetonide	0.01%
	desonide	0.05%		
	triamcinolone acetonide	0.03%		
Lotion	betamethasone valerate lotion	0.10%		
	desonide lotion	0.05%		
	triamcinolone acetonide lotion	0.025%		
Ointment	alclometasone dipropionate	0.05%		
Oil, Solution	fluocinolone acetonide oil	0.01%		
	fluocinolone acetonide solution	0.01%		

### Least Potent (Group 7)

Dosage Form	PREFERRED AGENTS (NO PA REQUIRED)		NON-PREFERRED AGENTS (PA REQUIRED)	
Cream	hydrocortisone	1.00%		
	hydrocortisone	2.50%		
Lotion	hydrocortisone	2.50%		
Ointment	hydrocortisone	1.00%		
	hydrocortisone	2.50%		
Solution			TEXACORT (hydrocortisone) SOLUTION	2.50%

### Prior Authorization

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 2-week trial of all preferred drug entities within the same potency category and dosage form group within the last 3 months, as evidenced by paid claims or pharmacy printouts

#### Agents labeled as "STEP 2"

- The member must have failed a 2-week trial of all preferred and non-preferred drug entities not labeled "STEP 2" within the same potency category and dosage form group within the last 3 months.

# Endocrinology

## Androgens

### Injectable

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
testosterone cypionate injection	AVEED (testosterone undecanoate)
testosterone enanthate injection	DEPO-TESTOSTERONE (testosterone cypionate)
	XYOSTED (testosterone enanthate)

### Oral

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
JATENZO (testosterone undecanoate)	methyltestosterone
	METHITEST (methyltestosterone)
	TLANDO (testosterone undecanoate)

### Topical

#### Gel Packet

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ANDROGEL (testosterone) GEL PACKET – <i>Brand Co-Preferred</i>	testosterone 1.62% (20.25mg/1.25g) gel packet
testosterone 1% (50mg/5g) gel packet	testosterone 1.62% (40.5mg/2.5g) gel packet
testosterone 1% (25mg/2.5g) gel packet	

#### Gel Pump

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ANDROGEL (testosterone) GEL MD PUMP – <i>Brand Co-Preferred</i>	testosterone 2% (10mg/0.5g) gel MD PMP bottle
FORTESTA (testosterone) 2% (10mg/0.5g) GEL MD PMP – <i>Brand Required</i>	
testosterone 1% (12.5mg/1.25g) gel MD PMP bottle	
testosterone 1.62% (20.25mg/1.25g) gel MD PMP bottle	
testosterone 2% (30mg/1.5g) solution MD PMP	

#### Gel Tube

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TESTIM (testosterone) GEL TUBE – <i>Brand Co-Preferred</i>	
testosterone 1% (50mg/5g) gel tube	

#### Nasal Gel

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	NATESTO (testosterone) GEL MD PMP

Patch

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ANDRODERM (testosterone) PATCH	

Solution MDP

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	testosterone (30mg/1.5mL)

Pellet

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TESTOPEL (testosterone) PELLET – Medical Billing Only	

Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

Prior Authorization

Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of each preferred agent with a comparable route of administration, as evidenced by paid claims or pharmacy printouts.
- Clinical justification must be provided explaining why the member is unable to use the preferred products (subject to clinical review).

## Cushing Syndrome

### Adrenal Enzyme Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ketoconazole	ISTURISA (osilodrostat)
LYSODREN (mitotane)	RECORLEV (levoketoconazole)
METOPIRONE (metyrapone)	

Electronic Diagnosis Verification

- Isturisa and Recorlev: Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

Prior Authorization

Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, an endocrinologist or specialist in the treatment of endogenous Cushing’s syndrome.
- The member must have failed a 3-month trial of combination treatment with ketoconazole tablets and metyrapone.
- The member is not a candidate for surgery or surgery has not been curative; or is waiting for surgery or effect of pituitary radiation.
- The member must have a mean (at least two measurements) 24-hour urine free cortisol (UFC) level that is 3 x above the normal range per the reporting laboratory reference range.

Renewal Criteria - Approval Duration: 12 months

- The member has normalization of 24-hour urine free cortisol (UFC) level per the reporting laboratory reference range.

## Glucocorticoid Receptor Antagonist

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
mifepristone	KORLYM (mifepristone)

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### Prior Authorization

#### Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, an endocrinologist or specialist in the treatment of endogenous Cushing's syndrome.
- The member must have failed a 3-month trial of combination treatment with ketoconazole tablets and metyrapone.
- The member is not a candidate for surgery or surgery has not been curative; or is waiting for surgery or effect of pituitary radiation.
- The member has uncontrolled hyperglycemia (type 2 diabetes or glucose intolerance) as defined by a hemoglobin A1c > 7%, despite adherence to an anti-diabetes regimen.
- See [Preferred Dosage Form](#) Criteria

#### Renewal Criteria - Approval Duration: 12 months

- The member must have experienced and maintained an improvement in cushingoid appearance, acne, hirsutism, striae, psychiatric symptoms, or excess total body weight.
- The member has improved hyperglycemia as a hemoglobin A1c decrease of 1% or greater not attributed to an increase in medications, dosages, or adherence to an anti-diabetes regimen.

## Diabetes

### References:

1. American Diabetes Association Diabetes Care 2020 Jan; 43(Supplement 1): S98-S110.  
<https://doi.org/10.2337/dc20-S009>

### Covered options in combination with Insulin therapy:

GLP-1 Agonists, SGLT-2 inhibitors, TZDs, and metformin

- GLP-1 Agonist and SGLT-2 inhibitors are recommended first line treatments for every pathway indicated in the guidelines (ASCVD, HF, CKD, hypoglycemia risk, and to minimize weight gain)
- TZDs increase insulin sensitivity and hypoglycemia risk should be monitored
- Metformin is recommended throughout treatment escalation.

### Therapeutic Duplication

- One Strength of one medication is allowed at a time
- Medication classes not payable together:
  - DPP4-Inhibitors and GLP-1 Agonists
    - GLP-1 and DPP4-Inhibitors should not be used concurrently due to similar mechanisms of action
  - DPP4-Inhibitors and Insulins
    - GLP-1 should be considered in most members prior to insulin

- When initiating injectable therapy, sulfonylureas and DPP-4 inhibitors are typically discontinued
- Sulfonylureas and Insulins
  - When initiating injectable therapy, sulfonylureas and DPP-4 inhibitors are typically discontinued
- Humulin R U-500 is not allowed with any other insulin (basal or prandial)
  - Humulin R U-500 is indicated for monotherapy. It acts differently than regular insulin (U-100). It provides both basal and prandial coverage. Injections can be increased to 3 times per day for prandial coverage.

### Underutilization

- Toujeo, Tresiba, and Metformin 1000mg must be used adherently and will reject on point of sale for late fill

## DPP4-Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
JANUMET (sitagliptin/metformin)	++alogliptan/pioglitazone
JANUMET XR (sitagliptin/metformin)	++alogliptin
JANUVIA (sitagliptin)	++alogliptin/metformin
JENTADUETO (linagliptin/metformin)	++KAZANO (alogliptin/metformin)
JENTADUETO XR (linagliptin/metformin)	++KOMBIGLYZE XR (saxagliptin/metformin)
TRADJENTA (linagliptin)	++NESINA (alogliptin)
	++ONGLYZA (saxagliptin)
	++OSENII (alogliptin/pioglitazone)

++Clinically Non-Preferred: Alogliptin and Saxagliptan have a potentially higher risk for heart failure

### Electronic Age Verification

- The member must be 18 years or older for Januvia, Janumet, or Janumet XR

### Electronic Step Care and Concurrent Medications

- A total of 28-day supply of metformin must be paid within 100 days prior to the DPP4-Inhibitor's date of service. Members with GI intolerances to high dose IR metformin must trial at minimum a dose of 500mg ER.
  - Metformin is recommended to be continued with therapy with DPP4-Inhibitors. If metformin is not tolerated, SGLT2 inhibitor and GLP-1 Agonists are recommended as part of the glucose-lowering regimen independent of A1C and are first line alternatives.

### References:

1. American Diabetes Association Diabetes Care 2020 Jan; 43(Supplement 1): S98-S110.  
<https://doi.org/10.2337/dc20-S009>

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial with EACH of the following agents, as evidenced by paid claims or pharmacy printouts:
  - A preferred sitagliptin product (Janumet, Janumet XR, or Januvia)
  - A preferred linagliptin preferred product (Jentadueto or Tradjenta)
  - A preferred SGLT2 inhibitor

## DPP4-Inhibitors / SGLT2 Inhibitors Combination

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TRIJARDY XR (empagliflozin/linagliptan/metformin)	GLYXAMBI (empagliflozin/linagliptin)
	STEGLUJAN (ertugliflozin/sitagliptin)
	++QTERN (dapagliflozin/saxagliptin)

++Clinically Non-Preferred: Saxagliptan has a potentially higher risk for heart failure

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided explaining why the member cannot use individual preferred products separately or preferred agent

## GLP-1 Agonists

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (STEP 1 – PA REQUIRED)	NON-PREFERRED AGENTS (STEP 2 – PA REQUIRED)
VICTOZA (liraglutide)	TRULICITY (dulaglutide)	BYDUREON BCISE (exenatide microspheres)
		++BYETTA (exenatide)
		OZEMPIC (semaglutide)
		RYBELSUS (semaglutide)

++Clinically Non-Preferred: Byetta is less effective than other available agents

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Step 1: Trulicity: One of the following apply:
  - The member must have failed a 90-day trial of a combination of a SGLT-2 Inhibitor and Victoza, as evidenced by paid claims or pharmacy printouts.
    - If failure is due to inability to meet A1c goal with good adherence, documentation of A1c level and goal must be provided.
  - The member must have failed a 90-day trial of a combination of a SGLT-2 inhibitor and a DPP-4 inhibitor, as evidenced by paid claims or pharmacy printouts, if the following apply:
    - Member has previously failed a trial of Victoza due to intolerance
    - A GLP-1 has not been previously used in combination therapy with an SGLT-2 inhibitor or insulin
- Step 2: The member must have failed 90-day trial of a combination of a SGLT-2 Inhibitor and each of the following, titrated to max tolerated dose, as evidenced by paid claims or pharmacy printouts:
  - Victoza
  - Trulicity

## GIP/GLP-1 Agonists

CLINICAL PA REQUIRED
MOUNJARO (tirzepatide)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed 90-day trial of a combination of a SGLT-2 Inhibitor and each of the following, titrated to max tolerated dose, as evidenced by paid claims or pharmacy printouts:
  - Victoza



- Trulicity

## Gastroparesis

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
metoclopramide tablet	GIMOTI (metoclopramide nasal spray)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 3 months

- Clinical justification must be provided explaining why the member is unable to use an oral dosage formulation (including ODT and solution formulations) with relevant medical documentation (e.g., swallow study) attached to the request, subject to clinical review.

## Glucose Rescue Medications

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BAQSIMI (glucagon) SPRAY	glucagon kit – 00548, 63323
glucagon kit – Labeler 00002	
GLUCOGEN (glucagon) HYPOKIT – <i>Brand Co-Preferred</i>	
GVOKE (glucagon) INJECTION	
ZEGALOGUE (dasiglucagon) AUTOINJECTOR	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided explaining why the member is unable to use the preferred products (subject to clinical review).

### Electronic Duration Verification

- 2 doses (initial and replacement doses) are covered every 180 days without prior authorization.
  - The following information will need to be submitted as a follow up for the override by either emailing [medicaidpharmacy@nd.gov](mailto:medicaidpharmacy@nd.gov) or documenting on [General Prior Authorization Form](#):
    - The provider must attest if it is known that the previous dose was taken by the member (and not diverted or given to another person)
    - One of the following criteria must be met (A, B, or C)
      - A. The previous dose has expired
      - B. The dose was used by member for a hypoglycemic episode
      - C. The member is currently taking insulins or sulfonylureas and meets one of the following criteria:
        - The diabetes treatment has been adjusted to prevent future instances of hypoglycemia
        - The provider has provided medical justification why the diabetes treatment has not been adjusted at this time to prevent future instances of hypoglycemia.

## Insulin/GLP-1 Agonist Combination

CLINICAL PA REQUIRED
SOLIQUA (Insulin glargine/lixisenatide)
XULTOPHY (insulin degludec/liraglutide)



## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided explaining why the member is unable to use the preferred products (subject to clinical review).

## Insulin

### Rapid Acting Insulin

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
APIDRA (insulin glulisine) VIAL	ADMELOG (insulin lispro) VIAL
APIDRA SOLOSTAR (insulin glulisine) INSULIN PEN	ADMELOG SOLOSTAR (insulin lispro) INSULIN PEN
HUMALOG (insulin lispro) CARTRIDGE	++AFREZZA (insulin regular, human)
HUMALOG U-100 (insulin lispro) KWIKPEN – <i>Brand Co-Preferred</i>	FIASP (insulin aspart) CARTRIDGE***
HUMALOG (insulin lispro) VIAL– <i>Brand Co-Preferred</i>	FIASP (insulin aspart) SYRINGE***
HUMALOG JUNIOR KWIKPEN (insulin lispro) – <i>Brand Co-Preferred</i>	FIASP (insulin aspart) VIAL***
Insulin aspart cartridge	HUMALOG U-200 (insulin lispro) KWIKPEN
Insulin aspart syringe	++HUMULIN R (insulin regular, human) VIAL
Insulin aspart vial	LYUMJEV (Insulin lispro-aabc) KWIKPEN
Insulin lispro junior syringe	LYUMJEV (Insulin lispro-aabc) VIAL
Insulin lispro cartridge	++NOVOLIN R (insulin regular, human) FLEXPEN
Insulin lispro syringe	++NOVOLIN R (insulin regular, human) VIAL
Insulin lispro vial	
NOVOLOG (insulin aspart) CARTRIDGE – <i>Brand Co-Preferred</i>	
NOVOLOG (insulin aspart) FLEXPEN – <i>Brand Co-Preferred</i>	
NOVOLOG (insulin aspart) VIAL– <i>Brand Co-Preferred</i>	

++Clinically Non-Preferred: ACOG (American College of Obstetricians and Gynecologists) guidelines prefer insulin analogues (insulin aspart and lispro) over regular insulin due to better compliance, better glycemic control, and overall fewer hypoglycemic episodes

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months

- Fiasp: The member must have failed a one 3-month trial of Novolog, Humalog, or Apidra, as evidenced by paid claims or pharmacy printouts.
- Humalog U-200: Request must not be for use in an insulin pump: [HUMALOG® \(insulin lispro\) 200 Units/mL: Do Not Use in a Pump \(lillymedical.com\)](http://HUMALOG®(insulin%20lispro)%20200%20Units/mL%3A%20Do%20Not%20Use%20in%20a%20Pump%20(lillymedical.com))
  - Doses ≤ 200 units/day: Clinical justification must be provided why member cannot tolerate the volume of insulin required to use Humalog U-100 or tolerate two injections per dose.
  - Doses > 200 units/day: Clinical justification must be provided why member is not a candidate for Humulin R U-500.
- Lyumjev: The member must have failed a one 3-month trial of Fiasp, as evidenced by paid claims or pharmacy printouts.
- Regular Insulin (Humulin R / Novolin R / Afrezza): The member must have failed a 3-month trial of two of the following agents, as evidenced by paid claims or pharmacy printouts:

- Novolog, Humalog, or Apidra

## Intermediate Acting Insulin

PREFERRED AGENTS (NO PA REQUIRED)	PREFERRED AGENTS (PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
HUMULIN R U-500 (insulin regular, human) KWIKPEN	++ NOVOLIN N (insulin NPH human isophane) FLEXPEN	++ HUMULIN N (insulin NPH human isophane) VIAL
HUMULIN R U-500 (insulin regular, human) VIAL		++ HUMULIN N (insulin NPH human isophane) KWIKPEN
		++ NOVOLIN N (insulin NPH human isophane) VIAL

++ Clinically non-preferred: Lantus and Levemir have been demonstrated to reduce the risk of symptomatic and nocturnal hypoglycemia compared with NPH insulin.

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- One of the following must be met:
  - Member must be pregnant or breastfeeding
  - Member must be on tube feedings
  - Member must be post-solid organ transplant
    - For kidney transplant - Medicare eligibility must be ruled out
  - Clinical justification explaining why the member is unable to use Lantus or Levemir (subject to clinical review)

#### Non-Preferred Agent Criteria

- See [Preferred Dosage Form](#) Criteria

## Long-Acting Insulin

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
LANTUS (insulin glargine) SOLOSTAR – <i>Brand Required</i>	BASAGLAR KWIKPEN U-100 (insulin glargine)
LANTUS (insulin glargine) VIAL – <i>Brand Required</i>	insulin degludec
LEVEMIR (insulin detemir) VIAL	insulin glargine solostar
LEVEMIR (insulin detemir) FLEXTOUCH	insulin glargine-yfgn vial
TOUJEO MAX SOLOSTAR (insulin glargine) *No PA required for doses 100 unit/day to 200 unit/day	SEMGLEE (insulin glargine)
TRESIBA (insulin degludec) FLEXTOUCH U-200 *No PA required for doses 100 unit/day to 200 unit/day - <i>Brand Required</i>	TOUJEO SOLOSTAR (insulin glargine)
	TRESIBA (insulin degludec) FLEXTOUCH U-100 - <i>Brand Required</i>
	TRESIBA (insulin degludec) VIAL - <i>Brand Required</i>

### Quantity Override Request

- Toujeo Max Solostar 300 unit/mL and Tresiba 200 unit/mL:
  - Doses > 200 units/day:
    - Clinical justification must be provided explaining why the member is not a candidate for U-500R

- Toujeo and Tresiba are not intended as replacements for U-500R insulin
- Doses >100 units/day to ≤ 200 units/day
  - No prior authorization required.  
Please call for an override by calling provider relations at 1-800-755-2604 if the day supply is less than 30 days and dose is between 100 units/day and 200 units/day (e.g., short-cycle filling).
- Doses ≤ 100 units/day:
  - Must meeting Prior Authorization Criteria below

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- The requested medication must be prescribed by, or in consult with, an endocrinologist or diabetes specialist
- The member has had a 90-day trial with good compliance, as evidenced by paid claims or pharmacy printouts, of each of the following:
  - Lantus
  - Levemir
- One of the following must be met, as evidenced by provided clinical notes or labs:
  - The member experiences recurrent episodes of hypoglycemia despite adjustments to current regimen (prandial insulin, interacting drugs, meal, and exercise timing).
  - The member must be experiencing inconsistent blood sugars

Renewal Criteria - Approval Duration: 12 months

- The member must have experienced at least one of the following, as evidenced by provided clinical notes or labs:
  - Reduction in frequency and/or severity of hypoglycemia
  - Improved glycemic control (A1C)

**Mixed Insulin**

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
HUMALOG MIX 50/50 (insulin NPL/insulin lispro) KWIKPEN	HUMULIN 70/30 (insulin NPH human/regular insulin human) VIAL
HUMALOG MIX 75/25 (insulin NPL/insulin lispro) KWIKPEN – <i>Brand required</i>	HUMULIN 70/30 (insulin NPH human/regular insulin human) KWIKPEN
HUMALOG MIX 50/50 (insulin NPL/insulin lispro) VIAL	insulin lispro mix 75/25 kwikpen
HUMALOG MIX 75/25 (insulin NPL/insulin lispro) VIAL	NOVOLIN 70-30 (insulin NPH human/regular insulin human) VIAL
insulin aspart protamine/insulin aspart 70/30 pen	NOVOLIN 70-30 (insulin NPH human/regular insulin human) FLEXPEN
Insulin aspart protamine/insulin aspart 70//30 vial	NOVOLOG MIX 70/30 (insulin aspart protamine/insulin aspart) FLEXPEN
	NOVOLOG MIX 70/30 (insulin aspart protamine/insulin aspart) VIAL

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided explaining why the member is unable to use the preferred products or a long acting plus short acting regimen (subject to clinical review).
- Humulin 70/30 and Novolin 70/30 only:
  - One of the following must be met:

- Member must be pregnant or breastfeeding
- Member must be on tube feedings
- Member must be post-solid organ transplant
  - For kidney transplant - Medicare eligibility must be ruled out

## SGLT2 Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
FARXIGA (dapagliflozin)	INVOKAMET XR (canagliflozin/metformin)
INVOKANA (canagliflozin)	STEGLATRO (ertugliflozin)
INVOKAMET (canagliflozin/metformin)	STEGLATROMET (ertugliflozin/metformin)
JARDIANCE (empagliflozin)	SYNJARDY XR (empagliflozin/metformin)
SYNJARDY (empagliflozin/metformin)	XIGDUO XR (dapagliflozin/metformin) 2.5 MG – 1000 MG
XIGDUO XR (dapagliflozin/metformin) 5 MG-500 MG, 5 MG-1000 MG, 10 MG-500 MG, 10 MG – 1000 MG	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of each preferred SGLT2 inhibitor of a unique active ingredient, as evidenced by paid claims or pharmacy printouts.
- Clinical justification must be provided explaining why the member is unable to use the preferred agents and other classes of medication (subject to clinical review).

## Sulfonylureas

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
glimepiride	++glyburide
glipizide	++glyburide/metformin
glipizide/metformin	++glyburide, micronized
glipizide ER	++GLYNASE (glyburide, micronized)

++Clinically Non-preferred: Glyburide is not recommended due to hypoglycemia

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of glipizide, as evidenced by paid claims or pharmacy printouts.
- Clinical justification must be provided explaining why the member is unable to use the preferred agents and other classes of medication (subject to clinical review).

## Graves' Disease

CLINICAL PA REQUIRED
TEPEZZA (teprotumumab-trbw) - Medical Billing Only

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months (8 infusions per lifetime)

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)

- The requested medication must be prescribed by, or in consult annually with, endocrinologist, ophthalmologist, or specialist in the treatment of Graves' disease associated with Thyroid Eye Disease (TED)
- The member must have a diagnosis of moderate to severe Graves' disease associated with Thyroid Eye Disease
- The onset of Thyroid Eye Disease symptoms is within 9 months of request for treatment
- The provider must submit documentation of each of the following:
  - Thyroxine (FT4) and free triiodothyronine (FT3) levels less than 50% above or below normal limits
  - Must have a Clinical Activity Score of greater than or equal to 4
- The member has had a one-month trial of a maximally tolerated indicated dose of systemic glucocorticoids.
- The member has not required prior surgical ophthalmologic intervention
- The member does not have any of the following:
  - A decrease in best corrected visual acuity (BVCA) due to optic neuropathy within the previous six months (i.e., decrease in vision of 2 lines on the Snellen chart, new visual field defect, or color defect secondary to optic nerve involvement)
  - Corneal decompensation that is unresponsive to medical management
  - Poorly controlled diabetes or diabetes must be maximally treated by, or in consult with, an endocrinologist with good adherence.

## Growth Hormone

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
NORDITROPIN FLEXPPO (somatropin)	GENOTROPIN (somatropin)
	GENOTROPIN MINIQUICK (somatropin)
	HUMATROPE (somatropin)
	NUTROPIN AQ (somatropin)
	OMNITROPE (somatropin)
	SAIZEN (somatropin)
	SKYTROFA (somatropin)
	ZOMACTON (somatropin)

### Prior Authorization Criteria

#### [Prior Authorization Form - Growth Hormone](#)

#### Initial Criteria - Approval Duration: 12 months

- Member must have one of the following covered diagnoses (listed below):
  - Multiple pituitary hormone deficiencies caused by a known hypothalamic-pituitary disease or its treatment (brain surgery and/or radiation)
  - Turner's syndrome
  - SHOX syndrome
  - Noonan syndrome
  - Chronic renal insufficiency
  - Prader-Willi syndrome
  - Endogenous growth hormone deficiency
- The requested medication must be prescribed by, or in consult annually with, an endocrinologist or nephrologist.
- The member must not have active malignancy
- The member must not have epiphyseal closure and must still be growing, unless one of the below exceptions is present:
  - The member has a diagnosis of Prader-Willi syndrome

- The member has a diagnosis of endogenous growth hormone deficiency and is experiencing hypoglycemic episodes without growth hormone and growth hormone is needed to maintain proper blood glucose.
- The requested medication is not Skytrofa

*Chronic Renal Insufficiency*

- The member must not have received a renal transplant.
- The member must consult with a dietitian annually to maintain a nutritious diet.

*Endogenous Growth Hormone Deficiency*

- ONE of below criteria must be met:
  - The member has multiple pituitary hormone deficiencies caused by a known hypothalamic-pituitary disease or its treatment (brain surgery and/or radiation) must have an IGF-1 or IGFBP-3 level of less than SDS -1.3.
  - The member has had GH stimulation testing by at least two different stimuli (e.g., insulin, levodopa, L-arginine, propranolol, clonidine, or glucagon) with a maximum peak of < 10ng/mL after stimulation no more than 6 months apart

*Prader-Willi Syndrome*

- If the member is obese, sleep apnea has been ruled out by sleep study
- The member must consult with a dietitian annually to maintain a nutritious diet.

Renewal Criteria - Approval Duration: 12 months

- The member must have been compliant with growth hormone (last 6 fills must have been on time).

*Prader-Willi Syndrome*

- If the member is obese, the BMI must have decreased
- If member is not obese, BMI must have maintained or decreased

**Serostim**

<b>CLINICAL PA REQUIRED</b>
SEROSTIM (somatropin)

*Prior Authorization Criteria*

[Prior Authorization Form - Growth Hormone](#)

Initial Criteria - Approval Duration: 3 months

- The member must not have an active malignancy
- The requested medication must be prescribed by, or in consult with, and infectious disease specialist or a specialist in the diagnosis and management of HIV infection
- The member must be on concomitant antiretroviral therapy
- The member must have failed a 3-month trial with megestrol, as evidenced by paid claims or pharmacy printouts
- Lean body mass and body weight must be provided
- Documentation of physical endurance must be provided.

Renewal Criteria - Approval Duration: 8 months (one time)

- Lean body mass and body weight must have increased from baseline
- Physical endurance must have increased from baseline

## Imcivree

### CLINICAL PA REQUIRED

IMCIVREE (setmelanotide)

#### *Prior Authorization Criteria*

##### Initial Criteria - Approval Duration: 4 months

- The member must have a diagnosis of obesity (BMI > 30 kg/m<sup>2</sup> for adults or > 95th percentile using growth chart assessments for pediatric members)
- The member's weight and body mass index (BMI) must be provided within the last 60 days
- The requested medication must be prescribed by, or in consult with, endocrinologist or medical geneticist
- The member's obesity must be due to one of the following:
  - Genetic testing confirms one of the following variants that is pathogenic, likely pathogenic, or of unknown significance:
    - Proopiomelanocortin (POMC)
    - Proprotein convertase subtilisin/kexin type 1 (PCSK1)
    - Leptin receptor (LEPR) deficiency
  - Bardet-Biedl syndrome as evidenced by three or more of the following:
    - Rod-cone dystrophy
    - Polydactyly
    - Genital anomalies
    - Renal anomalies
    - Intellectual impairment

##### Renewal Criteria - Approval Duration: 12 months

- One of the following must be met since starting treatment with Imcivree, as evidenced by medical documentation (e.g., chart notes) attached to the request:
  - Members ≥ 18 years old:
    - First renewal - a 5% weight reduction has been achieved or maintained
    - Subsequent renewal - a 10% weight reduction has been achieved or maintained
  - Members < 18 years old: a 5% reduction in BMI has been achieved or maintained

## Precocious Puberty

### NO PA REQUIRED

FENSOLVI (leuprolide) – *Medical Billing Only*

LUPRON DEPOT (leuprolide) – *Medical Billing Only*

SUPPRELIN LA (histrelin) – *Medical Billing Only*

SYNAREL (nafarelin) – *Medical Billing Only*

TRIPTODUR (triptorelin) – *Medical Billing Only*

## X-linked Hypophosphatemia (XLH) or Tumor-Induced Osteomalacia

### CLINICAL PA REQUIRED

CRYSVITA (burosumab) – *Medical Billing Only*



## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months (one-time 6-month approval for adult with planned orthopedic surgical)

- Documentation to confirm the diagnosis must be submitted, as evidenced by the following:
  - Genetic testing confirming phosphate regulating gene with homology to endopeptidases on the X chromosome (PHEX-gene) mutation
  - Increased (FGF23) level based on laboratory reference range with unresectable phosphaturic mesenchymal tumor
- The requested medication must be prescribed by, or in consult with, nephrologist, endocrinologist, geneticist, or specialist experienced in the treatment of metabolic bone disorders
- Documentation must be submitted confirming the member is experiencing the following:
  - Phosphate manifestations (*must have one*)
    - Fasting serum phosphate is below provided age adjusted reference range
    - Low tubular resorption of phosphate corrected for glomerular filtration rate (TmP/GFR) based on age
  - Bone manifestations (*must have one*)
    - Epiphyseal plate has not fused
    - Bone fractures
    - Planned orthopedic surgical procedure

### Renewal Criteria - Approval Duration: 12 months

- Documentation must be submitted demonstrating that the member has demonstrated a disease stability or beneficial response to therapy from baseline as shown by one or more of the following:
  - Normalization of phosphate levels as defined by laboratory
  - Decrease in serum alkaline phosphatase activity
  - Improvement of renal phosphate wasting
  - Normalization of growth velocity
  - Reduction or healing of fractures
  - Improvement of Thacher Rickets Severity Score (TRSS)

## GI – Gastroenterology

### Bowel Prep Agents

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CLENPIQ	PEG 3350/SOD SUL/NAACL/KCL/ASB/C
GAVILYTE-C	PLENVU
GAVILYTE-G	SUTAB
GAVILYTE-N	
GOLYTELY 236-22.74G – <i>Brand Co-Preferred</i>	
MOVIPREP – <i>Brand Required</i>	
OSMOPREP	
PEG-3350 AND ELECTROLYTES 236-22.74G	
PEG 3350-ELECTROLYTE 420 G	
PEG 3350-ELECTROLYTE SOLUTION	
SOD SOL-POTASS SUL-MAG SUL	
SUPREP – <i>Brand Co-Preferred</i>	



## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 1 month

- Clinical justification must be provided explaining why the member is unable to use the preferred agents, with medical documentation (e.g., chart notes) documenting the reason(s) preferred agents cannot be used (subject to clinical review).

## Clostridioides difficile-associated diarrhea (CDAD)

### Prevention

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
REBYOTA (fecal microbiota, live – jslm) SUSPENSION	

### Electronic Duration Verification:

- Rybyota is payable every 6 months.

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months

- The member has had at least two episodes of diarrhea with a positive stool test for *C.difficile* toxin within the last year

### Treatment

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
FIRVANQ (vancomycin) SOLUTION 25 mg/mL	DIFICID (fidaxomicin) 40 MG/ML SUSPENSION
vancomycin capsule	DIFICID (fidaxomicin) TABLET
vancomycin solution 50 mg/mL	FIRVANQ (vancomycin) SOLUTION 50 MG/ML
	VANCOGIN (vancomycin) CAPSULE

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 10-day trial with a preferred agent, as evidenced by paid claims or pharmacy printouts

## Crohn's Disease

### Interleukin (IL) 12/IL-23 Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	STELARA (ustekinumab)
	STELARA (ustekinumab) – IV Induction Medical Billing Only

### Interleukin (IL) - 23 Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	SKYRIZI (risankizumab-rzaa)
	SKYRIZI (risankizumab-rzaa)

	– IV Induction Medical Billing Only
--	-------------------------------------

### TNF inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AVSOLA (infliximab-axxq) – Medical Billing Only	INFLECTRA (infliximab-dyyb) – Medical Billing Only
CIMZIA (certolizumab pegol)	infliximab – Medical Billing Only
HUMIRA (adalimumab)	REMICADE (infliximab) – Medical Billing Only
RENFLEXIS (infliximab-abda) – Medical Billing Only	

### $\alpha 4$ Integrin Inhibitors

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	TYSABRI (natalizumab) – Medical Billing Only

### $\alpha 4\beta 7$ Integrin Inhibitors

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	ENTYVIO (vedolizumab) – Medical Billing Only

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Entyvio Only:
  - The member must meet one of the following:
    - The member must have failed a 3-month trial of a TNF Inhibitor, as evidenced by paid claims or pharmacy printouts.
    - The member has a high risk of infection or malignancy (e.g., age > 55, history of malignancy, history of serious infection)
- Remicade, Inflectra, infliximab Only:
  - See [Preferred Dosage Form](#) Criteria
- Skyrizi Only:
  - The member must have failed a 3-month trial of a TNF Inhibitor, as evidenced by paid claims or pharmacy printouts.
- Stelara Only:
  - The member has failed a 3-month trial of Entyvio or Skyrizi, as evidenced by paid claims or printouts
- Tysabri Only
  - The member has failed a 3-month trial of Entyvio, as evidenced by paid claims or printouts

## Constipation – Irritable Bowel Syndrome (IBS) / Opioid Induced

### Irritable Bowel Syndrome (IBS) / Idiopathic Constipation

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AMITIZA (lubiprostone) - Brand Required	IBSRELA (tenapanor)
LINZESS (linaclotide) 145 mcg, 290 mcg	LINZESS (linaclotide) 72 mcg
TRULANCE (plecanatide)	lubiprostone
	MOTEGRITY (prucalopride)

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months

- Linzess Only:
  - The member must be receiving good effect from the 145 mcg but experiencing adverse effects
- Motegrity and Ibsrela Only:
  - The member must also have had a 30-day trial with Trulance, as evidenced by paid claims or pharmacy printouts

## Therapeutic Duplication

- One medication is allowed at a time

## Opioid-Induced Constipation

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AMITIZA (lubiprostone) - <i>Brand Required</i>	lubiprostone
MOVANTIK (naloxegol)	RELISTOR (methylnaltrexone) TABLET
RELISTOR (methylnaltrexone) SYRINGE	SYMPROIC (naldemedine)
RELISTOR (methylnaltrexone) VIAL	

## Electronic Step Care and Concurrent Medications

- A total of 28 days of opioid analgesics must be paid within 40 days prior to requested Movantik, Symproic, or Relistor's date of service
  - Medications indicated for opioid-induced constipation should be discontinued when opioids are stopped.

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months

- The member must have failed 30-day trials of each of the oral preferred agents, as evidenced by paid claims or pharmacy printouts. Lubiprostone is required for females assigned at birth only.

## Diarrhea

## Irritable Bowel Syndrome

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
dicyclomine capsule	alosetron
dicyclomine tablet	dicyclomine oral syrup
diphenoxylate/atropine	LOMOTIL (diphenoxylate/atropine)
loperamide	VIBERZI (eluxadoline)
LOTROXEX (alosetron) - <i>Brand Required</i>	XIFAXAN (rifaximin) 550 mg tablet

## Electronic Diagnosis Verification

- Xifaxan: Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

## Electronic Step Care and Concurrent Medications

- **Xifaxan:** Xifaxan 550mg does not require prior authorization for hepatic encephalopathy if used concurrently with lactulose
  - A total of 30 days of lactulose must be paid within 65 days prior to Xifaxan's date of service
  - An override may be available after an adequate trial of lactulose where lactulose is not tolerated

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 3 months

- Documentation must be provided confirming that infectious and medication-induced etiologies of diarrhea have been ruled out
- The member must have failed a 30-day trial of each preferred unique active ingredient, as evidenced by paid claims or pharmacy printouts. Alestron is required for females assigned at birth only.

## HIV / AIDs

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
diphenoxylate/atropine	LOMOTIL (diphenoxylate/atropine)
loperamide	MYTESI (crofelemer)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 3 months

- Documentation must be provided confirming that infectious and medication-induced etiologies of diarrhea have been ruled out
- The member must have failed a 30-day trial of each preferred unique active ingredient, as evidenced by paid claims or pharmacy printouts.

## Digestive Enzymes

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CREON (lipase/protease/amylase)	PANCREAZE (lipase/protease/amylase)
ZENPEP (lipase/protease/amylase)	PERTZYE (lipase/protease/amylase)
	VIOKACE (lipase/protease/amylase)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- A 30-day trial of all preferred agents will be required before a non-preferred agent will be authorized unless member stable on a pancreatic enzyme written by a gastroenterologist or pancreas disease specialist

## Eosinophilic Esophagitis

CLINICAL PA REQUIRED
DUPIXENT (dupilumab)

### Prior Authorization Criteria

#### [Prior Authorization Form - Eosinophilic Esophagitis](#)

#### Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, a gastroenterologist
- The member must have  $\geq 15$  intraepithelial eosinophils per high-power field (eos/hpf).
- The member must have failed a 3-month trial of a swallowed inhaled respiratory corticosteroid (budesonide or fluticasone).

Renewal Criteria - Approval Duration: 12 months

- Documentation must be submitted that the member has achieved a significant reduction in dysphagia symptoms since treatment initiation.
- The member must have achieved an esophageal intraepithelial eosinophil count of  $\leq 6$  eos/hp.

## Familial Cholestasis Pruritis

### CLINICAL PA REQUIRED

BYLVAY (odevixibat)

LIVMARLI (maralixibat)

### Prior Authorization Criteria

Initial Criteria - Approval Duration: 6 months

- Documentation must be provided to support the presence of moderate to severe pruritis
- The requested medication must be prescribed by, or in consult with, a hepatologist or gastroenterologist
- The member must have cholestasis, as evidenced by  $\geq 1$  of the following:
  - Serum bile acid  $> 3x$  upper limit of normal as defined by the reporting laboratory
  - Conjugated bilirubin  $> 1\text{mg/dL}$
  - Fat soluble vitamin deficiency otherwise unexplainable
  - Gamma-glutamyl transferase  $> 3x$  the upper limit of normal
  - Intractable pruritus explainable only by liver disease
- The member must not have a history of liver transplant or decompensated cirrhosis.
- The member must not have history of biliary diversion surgery within the past 6 months.
- The member must have failed at least a 3-month trial of ursodiol, as evidenced by paid claims or pharmacy printouts.
- The member must have failed at least a 3-month trial of one of the following agents to treat pruritis: cholestyramine, rifampin, antihistamines, as evidenced by paid claims or pharmacy printouts.
- Bylvay Only:
  - Genetic testing confirms pathogenic variant (e.g., *ATP8B1*, *ABCB11*, *ABCB4*, *TJP2*, *NR1H4*, and *MYO5B*) indicating the presence and type of PFIC Type 1 or 2.
  - Genetic testing does not indicate PFIC Type 2 with *ABCB11* variants that predict complete absence of BSEP-3 protein.
- Livmarli Only:
  - Genetic testing confirms pathogenic variant of *JAG1* or *NOTCH1*

Renewal Criteria - Approval Duration: 12 months

- The member has experienced an improvement in pruritis, as evidenced by clinical documentation.
- The member must have experienced a reduction in serum bile acid as defined as a bile acid reduction  $\geq 70\%$  or reaching a bile acid level  $\leq 70 \mu\text{mol/L}$

## Acute Hepatic Porphyria (AHP)

### CLINICAL PA REQUIRED

GIVLAARI (givosiran) – Medical Billing Only

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a geneticist, hepatologist, hematologist, gastroenterologist, or specialist in acute hepatic porphyria (AHP)
- The member must have a diagnosis of AHP (i.e., acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), delta-aminolevulinic acid dehydratase deficient porphyria (ADP)) with the following as defined by laboratory reference range (evidenced with submitted documentation):
  - Elevated urine porphobilinogen (PBG)
  - Increased aminolevulinic acid (ALA)
  - Genetic testing confirming a mutation
- The member has addressed identifiable lifestyle triggers (e.g., [certain drugs](#), smoking, stress)
- The member has had two documented porphyria attacks within the past 6 months requiring hospitalization, urgent healthcare visit, or intravenous hemin administration (number of attacks and days of hemin are documented)
- The member has not had a liver transplant

### Renewal Criteria - Approval Duration: 12 months

- The member has had a meaningful reduction (e.g., 30%) in each of the following:
  - Number of porphyria attacks
  - Days of Hemin Use
  - Reduction in urinary ALA

## Proton Pump Inhibitor

### Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	PREFERRED STEP 1 AGENTS (ELECTRONIC STEP)	NON-PREFERRED STEP 2 AGENTS (PA REQUIRED)
DEXILANT (dexlansoprazole) – <i>Brand Required</i>	esomeprazole magnesium	ACIPHEX (rabeprazole)
lansoprazole	rabeprazole	dexlansoprazole
omeprazole		NEXIUM (esomeprazole)
pantoprazole		omeprazole-sodium bicarbonate
		PREVACID (lansoprazole)
		PRILOSEC (omeprazole)
		PROTONIX (pantoprazole)

### Electronic Step Care and Concurrent Medications

- Preferred Step 1 Agents: Member must have failed 14-day trial of at least 2 preferred agents at max dose within 365 days

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 6 months

- Non-Preferred Agents Criteria - Step 2 Agents:
  - Member must have failed a 30-day trial with all preferred agents (including Step 1 Agents), as evidenced by paid claims or pharmacy print outs

- Clinical justification must be provided explaining why the member is unable to use the other agents (subject to clinical review).

## Non-Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED (PA REQUIRED)
lansoprazole ODT	esomeprazole solution packet
NEXIUM (esomeprazole) PACKET- <i>Brand Required</i>	omeprazole-sodium bicarbonate packet
PROTONIX (pantoprazole) PACKET – <i>Brand Required</i>	pantoprazole packet
	PREVACID (lansoprazole) SOLUTAB
	PRILOSEC SUSPENSION (omeprazole)
	ZEGERID (omeprazole-sodium bicarbonate) PACKET

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months

- Member must have failed a 30-day trial with all preferred agents, as evidenced by paid claims or pharmacy print outs
- Clinical justification must be provided explaining why the member is unable to use the other agents (subject to clinical review).

### Electronic Age Verification

- Nexium 2.5 mg and 5 mg Packet: The member must be less than 1 years old (or less than 7.5 kg)

### Therapeutic Duplication

- One strength of one medication is allowed at a time
- Proton Pump Inhibitors is not allowed with:
  - Esomeprazole or omeprazole are not covered with clopidogrel.
    - Other PPIs such as pantoprazole are covered with clopidogrel. Clopidogrel is a substrate for 2C19 and esomeprazole and omeprazole are strong 2C19 inhibitors and can decrease effectiveness of Clopidogrel.
  - Dextroamphetamine/Amphetamine ER:
    - Proton Pump Inhibitors increase blood levels and potentiate the action of amphetamine. Co-administration of Adderall XR and gastrointestinal or urinary alkalizing agents should be avoided
  - H2 Blockers: If the following circumstances apply, please call for an override by calling provider relations at 1-800-755-2604:
    - Member is experiencing nocturnal symptoms after compliance with nighttime dose of proton pump inhibitor. A two-month override may be approved for concurrent H2 blocker use.
    - H2 blocker is being used concurrently with a H1 blocker for severe allergy prophylaxis, unrelated to PPI use for GI symptoms

### References

1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308-28.
2. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric breakthrough. Gastroenterology. 2002;122:625-632.



# Ulcerative Colitis

## Biologic Agents

### *α4β7 Integrin Inhibitors*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	ENTYVIO (vedolizumab) – <i>Medical Billing Only</i>

### *Interleukin (IL) 12/IL-23 Inhibitor*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	STELARA (ustekinumab) – <i>IV Induction Medical Billing Only</i>

### *TNF inhibitors*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AVSOLA (infliximab-axxq) – <i>Medical Billing Only</i>	INFLECTRA (infliximab-dyyb) – <i>Medical Billing Only</i>
HUMIRA (adalimumab)	infliximab – <i>Medical Billing Only</i>
RENFLEXIS (infliximab-abda) – <i>Medical Billing Only</i>	REMICADE (infliximab) – <i>Medical Billing Only</i>
	SIMPONI (golimumab)

### *Electronic Diagnosis Verification*

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### *Prior Authorization Criteria*

#### Initial Criteria - Approval Duration: 12 months

- Entyvio Only: The member must meet one of the following:
  - The member must have failed a 3-month trial of a TNF inhibitor, as evidenced by paid claims or pharmacy printouts.
  - The member has a high risk of infection or malignancy (e.g., age > 55, history of malignancy, history of serious infection)
- Remicade, Inflectra, infliximab Only: See [Preferred Dosage Form](#) Criteria
- Simponi Only: The member must have failed a 3-month trial of a TNF inhibitor, as evidenced by paid claims or pharmacy printouts.
- Stelara Only: The member must have failed a 3-month trial of Entyvio, as evidenced by paid claims or pharmacy printouts.

## 5-Aminosalicylic Acid (5-ASA)

### Oral

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
APRISO (mesalamine) CAPSULE – <i>Brand Required</i>	AZULFIDINE (sulfasalazine)
ASACOL HD (mesalamine) – <i>Brand Required</i>	AZULFIDINE DR (sulfasalazine)
balsalazide capsule	COLAZAL (balsalazide)
DELZICOL (mesalamine) CAPSULE– <i>Brand Required</i>	mesalamine DR



DIPENTUM (olsalazine)	mesalamine ER
LIALDA (mesalamine) TABLET– <i>Brand Required</i>	mesalamine HD
PENTASA (mesalamine) – <i>Brand Required</i>	
sulfasalazine DR tablet	
sulfasalazine tablet	

## Topical

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
hydrocortisone enema	CANASA (mesalamine) SUPPOSITORY
mesalamine enema	mesalamine enema kit
mesalamine rectal suppository	ROWASA (mesalamine) ENEMA KIT
	SF ROWASA (mesalamine) ENEMA
	UCERIS (budesonide) RECTAL FOAM

### *Prior Authorization Criteria*

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 3-month trial of mesalamine, as evidenced by paid claims or pharmacy printouts.

## Janus Kinase (JAK) Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
XELJANZ IR (tofacitinib) 5 mg, oral solution	RINVOQ ER (upadacitinib)
	XELJANZ IR (tofacitinib) 10 mg
	XELJANZ XR (tofacitinib)

### *Prior Authorization Criteria*

#### Initial Criteria - Approval Duration: 12 months

- Xeljanz IR 10 mg, Xeljanz XR Only: See [Preferred Dosage Form](#) Criteria
- Rinvoq ER Only:
  - The member must have failed a 3-month trial of Humira and Xeljanz IR, as evidenced by paid claims or pharmacy printouts.

## Sphingosine 1-Phosphate (S1P) Receptor Modulator

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	ZEPOSIA (ozanimod)

### *Prior Authorization Criteria*

#### Initial Criteria - Approval Duration: 12 months

- The member must have had a 30-day trial of a preferred agent, or a TNF inhibitor as evidenced by paid claims or pharmacy printouts.

## Wilson's Disease

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review)
- The member must have failed a 30-day trial of each preferred agent (listed in boxes below) within the past 2 years, as evidenced by paid claims or pharmacy printouts

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DEPEN (penicillamine) TITRATAB – <i>Brand Required</i>	CUPRIMINE (penicillamine) CAPSULE
trientine hydrochloride	penicillamine capsule
	penicillamine tablet
	SYPRINE (trientine hydrochloride)

## Genetic and Rare Disease

### Amyloidosis

#### RNA – targeted therapies

##### *TTR-specific small interfering RNA (siRNA)*

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ONPATTRO (patisiran) – <i>Medical Billing Only</i>	

##### *Transhyretin-directed small interfering RNA (siRNA)*

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AMVUTTRA (vutrisiran) – <i>Medical Billing Only</i>	

##### *Antisense Oligonucleotide (ASO)*

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TEGSEDI (inotersen)	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a neurologist, geneticist, or specialist in the treatment of amyloidosis
- Documentation of genetic testing confirming a pathogenic TTR mutation (e.g., V30M) must be provided
- Documentation of one of the following must be provided:
  - Baseline polyneuropathy disability (PND) score  $\leq$  IIIb
  - Baseline FAB Stage 1 or 2
  - Baseline neuropathy impairment (NIS) score  $\geq$  10 and  $\leq$  130
- The member has not had a liver transplant
- The member has clinical signs and symptoms of the disease (amyloid deposition in biopsy specimens, TTR protein variants in serum, weakness, sensory loss, decreased motor strength, decreased gait speed, etc.)
- The member is not receiving any other TTR reducing agent (i.e., vutrisiran, patisiran, tafamidis, inotersen).

Renewal Criteria - Approval Duration: 12 months

- Documentation of a therapeutic response as evidenced by stabilization or improvement (e.g., improved neurologic impairment, motor function, quality of life, slowing of disease progression, etc.) from baseline in one of the following:
  - Baseline polyneuropathy disability (PND) score  $\leq$  IIIb
  - Baseline FAB Stage 1 or 2
  - Baseline neuropathy impairment (NIS) score  $\geq$  10 and  $\leq$  130

## TTR Stabilizers

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
VYNDALCEL (tafamidis)	
VYNDAMAX (tafamidis)	

### Prior Authorization Criteria

Initial Criteria - Approval Duration: 12 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The member must have wild-type TTR mediated amyloidosis or documentation of genetic confirmation of hereditary TTR mediated amyloidosis as evidenced by a pathogenic TTR mutation (e.g., V30M)
- The requested medication must be prescribed by, or in consult with, a cardiologist, geneticist, or specialist in the treatment of amyloidosis
- The member has clinical signs and symptoms of the disease (heart failure, dyspnea, edema, hepatomegaly, ascites, angina, etc.)
- The member must not have any of the following:
  - NYHA class IV symptoms or severe aortic stenosis
  - Impaired renal function (i.e., GFR < 25)
  - Previous heart or liver transplant
- Documentation of baseline 6MWT > 100 meters must be submitted
- The member is not receiving any other TTR reducing agent (i.e., vutrisiran, patisiran, tafamidis, inotersen)

Renewal Criteria - Approval Duration: 12 months

- Documentation of a therapeutic response as evidenced by stabilization or improvement from baseline in both of the following:
  - 6MWT > 100 meters
  - NYHA class

## Late Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)

CLINICAL PA REQUIRED
BRINEURA (cerliponase alfa) – Medical Billing Only

### Prior Authorization Criteria

Initial Criteria - Approval Duration: 6 months

- The member must be between 3 and 8 years of age.
- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a metabolic specialist, geneticist, or pediatric neurologist

- Documentation of the diagnosis must be submitted, as evidenced by the following:
  - Molecular analysis that has detected two pathogenic variants/mutations in the TPP1/CLN2 gene
  - An enzyme assay confirming deficiency of tripeptidyl peptidase 1 (TPP1)
- The member must not have ventriculoperitoneal shunts
- Baseline results of motor and language domains of the Hamburg CLN2 Clinical Rating Scale must be submitted and meet the following parameters:
  - Results must show a combined score of less than 6 in the motor and language domains
  - Results must show a score of at least 1 in each of these domains

**Renewal Criteria - Approval Duration: 12 months**

- The member must not have acute, unresolved localized infection on or around the device insertion site or suspected or confirmed CNS infection
- The member maintains at a score of at least 1 in the motor domain on the Hamburg CLN2 Clinical Rating Scale
- The member has responded to therapy compared to pretreatment baseline with stability/lack of decline\* in motor function/milestones.

\* Decline is defined as having an unreversed (sustained) 2-category decline or an unreversed score of 0 in the Motor domain of the CLN2 Clinical Rating Scale

## Fabry Disease

### Alpha-Galactosidase A Pharmacological Chaperone

#### PREFERRED AGENTS (CLINICAL PA REQUIRED)

GALAFOLD (migalastat)

#### *Prior Authorization Criteria*

**Initial Criteria - Approval Duration: 6 months**

- The requested medication must be prescribed by, or in consult with, a metabolic specialist, geneticist, cardiologist, or specialist in Fabry disease
- The member must be assigned male at birth.
- Baseline value for plasma or urinary globotriosylceramide (GL-3) levels  $\geq 5$  ng/mcL or GL-3 inclusions  $\geq 0.3$  per kidney interstitial capillary (KIC) as measured in kidney biopsy
- The member's diagnosis must be confirmed to be caused by a pathologic galactosidase alpha gene (GLA) variant that is amenable to treatment with Galafold interpreted from a clinical geneticist professional, as evidenced by medical documentation attached to the request.
- The medication must not be used in conjunction with enzyme replacement therapy.
- The member must not have significant renal impairment (eGFR  $<30$  mL/minute/1.73 m<sup>2</sup>)

**Renewal Criteria - Approval Duration: 12 months**

- The member must have a decreased Gb3 level or Cb3 inclusion per KIC level and experienced and maintained improvement in one of the following symptoms since starting treatment with requested product, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review):
  - Acroparesthesias (burning pain in the extremities)
  - Angiokeratomas (cutaneous vascular lesions)
  - Hypo- or anhidrosis (diminished perspiration)
  - Corneal and lenticular opacities
  - Left ventricular hypertrophy (LVH), hypertrophic cardiomyopathy, or arrhythmia of unknown etiology

- Chronic kidney disease (CKD), multiple renal cysts, and/or proteinuria of unknown etiology

## Enzyme Replacement Therapy

### PREFERRED AGENTS (CLINICAL PA REQUIRED)

Fabrazyme (agalsidase beta) – *Medical Billing Only*

#### Initial Criteria - Approval Duration: 6 months

- The member is 8 years of age or older
- The requested medication must be prescribed by, or in consult with, a metabolic specialist, geneticist, cardiologist, or specialist in Fabry disease
- The member will not be concurrently treated with Galafold (migalastat)
- The member must have a diagnosis of Fabry disease with the one of the following (as evidenced with submitted documentation):
  - In males assigned at birth:
    - Deficiency of less than 35% of mean normal alpha-galactosidase A ( $\alpha$ -Gal A) enzyme activity
    - Diagnosis is confirmed to be caused by a pathologic galactosidase alpha gene (GLA)
  - In females assigned at birth and males assigned at birth with  $\alpha$ -Gal A enzyme activity > 35 percent:
    - Diagnosis must be confirmed to be caused by a pathologic galactosidase alpha gene (GLA)
    - Baseline value for plasma or urinary globotriosylceramide (GL-3) levels  $\geq 5$  ng/mcL or GL-3 inclusions  $\geq 0.3$  per kidney interstitial capillary (KIC) as measured in kidney biopsy
    - The member is experiencing one of the following symptoms:
      - Acroparesthesias (burning pain in the extremities)
      - Angiokeratomas (cutaneous vascular lesions)
      - Hypo- or anhidrosis (diminished perspiration)
      - Corneal and lenticular opacities
      - Left ventricular hypertrophy (LVH), hypertrophic cardiomyopathy, or arrhythmia of unknown etiology
      - Chronic kidney disease (CKD), multiple renal cysts, and/or proteinuria of unknown etiology

#### Renewal Criteria - Approval Duration: 12 months

- The member must have a decreased Gb3 level or Cb3 inclusion per KIC level and experienced and maintained improvement in one of the following symptoms since starting treatment with requested product, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review):
  - Acroparesthesias (burning pain in the extremities)
  - Angiokeratomas (cutaneous vascular lesions)
  - Hypo- or anhidrosis (diminished perspiration)
  - Corneal and lenticular opacities
  - Left ventricular hypertrophy (LVH), hypertrophic cardiomyopathy, or arrhythmia of unknown etiology
  - Chronic kidney disease (CKD), multiple renal cysts, and/or proteinuria of unknown etiology

## Gaucher's Disease

### PREFERRED AGENTS (NO PA REQUIRED)

ELELYSO (taliglucerase alfa) – *Medical Billing Only*

### NON-PREFERRED AGENTS (PA REQUIRED)

CEREZYME (imiglucerase) – *Medical Billing Only*

VPRIV (velaglucerase alfa) – *Medical Billing Only*

#### *Prior Authorization Criteria*

#### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)

- The requested medication must be prescribed by, or in consult with, a geneticist, an endocrinologist, or a physician who specializes in the treatment of lysosomal storage disorders
- The member must have a diagnosis of Gaucher disease Type I or Type III with the one of the following (as evidenced with submitted documentation):
  - Deficiency in beta-glucocerebrosidase enzyme activity in peripheral leukocytes
  - Genetic testing confirming biallelic pathogenic variants in the GBA1 gene
- The member must be experiencing one or more of the following (as evidenced with submitted documentation):
  - Anemia with hemoglobin less than or equal to the laboratory reported low for patient age and gender
  - Thrombocytopenia with platelet count less than 100,000/mm<sup>3</sup>
  - Bone disease (T-score below -1.0 [DXA], height SDS <-2.25 with decreased growth velocity, bone crisis)
  - Hepatomegaly (liver size 1.25 or more times normal)
  - Splenomegaly (spleen size five (5) or more times normal)

*Non-Preferred Agent Criteria:*

- Please provide explanation with the request why the preferred agent cannot be used (subject to clinical review)

Renewal Criteria - Approval Duration: 12 months

- Documentation has been submitted that member has experienced a disease stability or beneficial response to therapy from baseline as shown by one or more of the following:
  - Reduction in liver volume to normal size or by 10%
  - Reduction in spleen volume by 15%
  - Increase in hemoglobin levels by 1 g/dl
  - Increase in platelet levels by 15%
  - Increased T-score [DXA] by 0.3, normalized growth velocity, or decrease in bone crisis

## Lysosomal Acid Lipase (LAL) deficiency

### CLINICAL PA REQUIRED

KANUMA (sebelipase alfa) – *Medical Billing Only*

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a specialist in the treatment of lysosomal acid lipase (LAL) such as a lipidologist, endocrinologist, cardiologist, or hepatologist
- Documentation of the member's diagnosis must be submitted, as evidenced by the following:
  - Genetic testing confirming 2 mutations in the LIPA gene
  - Deficiency of the LAL in peripheral blood leukocytes, fibroblasts, or dried blood spots

Renewal Criteria - Approval Duration: 12 months

- The member must have experienced and maintained clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including improvement in weight for age Z-scores for individuals with growth failure, improved LDL, HDL, AST, ALT and/or triglycerides

## Mucopolysaccharidosis I (MPS I)

### CLINICAL PA REQUIRED

ALDURAZYME (laronidase) – *Medical Billing Only*



## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, an expert in lysosomal storage diseases
- Documentation of the member's diagnosis must be submitted, as evidenced by the following:
  - Genetic testing confirming biallelic pathogenic mutations in the IDUA gene
  - Deficiency in activity of the lysosomal enzyme  $\alpha$ -L-iduronidase (IDUA) in fibroblast or leukocyte
- Documentation of the member's current motor function must be submitted, as evidenced by scores from the following assessments:
  - 6-minute walk test (6MWT)
  - Forced Vital Capacity (FVC) via Pulmonary Function Test

### Renewal Criteria - Approval Duration: 12 months

- The member must have experienced and maintained clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including improvement in the following scores and symptoms:
  - 6-minute walk test (6MWT)
  - Forced Vital Capacity (FVC) via Pulmonary Function Test

## Mucopolysaccharidosis II (MPS II) – Hunter Syndrome

### CLINICAL PA REQUIRED

ELAPRASE (idursulfase) – Medical Billing Only

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- Documentation of the member's diagnosis must be submitted, as evidenced by the following:
  - Deficiency in iduronate-2sulfatase (I2S) enzyme activity in white cells, fibroblasts, or plasma in the presence of normal activity of at least one other sulfatase
  - Genetic testing confirming pathogenic mutations in the IDS gene
- The member age must be 5 years of age or older
- The requested medication must be prescribed by, or in consult with, an expert in lysosomal storage diseases
- The member does not have severe cognitive or neurologic impairment (e.g., inability to swallow)
- Documentation of one of the following must be submitted:
  - The Forced Vital Capacity (FVC) via Pulmonary Function Test
  - Urinary glycosaminoglycan (uGAG) levels are elevated defined by laboratory reference range
  - 6-minute walk test (6MWT)
  - Hepatomegaly (liver size 1.25 or more times normal)
  - Splenomegaly (spleen size five (5) or more times normal)

### Renewal Criteria - Approval Duration: 12 months

- Documentation must be submitted confirming improvement of one of the following:
  - The Forced Vital Capacity (FVC) via Pulmonary Function Test relative improvement of 10% over baseline
  - Urinary glycosaminoglycan (uGAG) levels normalization defined by laboratory reference range
  - 6-minute walk test (6MWT) increase

- Reduction in liver volume to normal size or by 10%
- Reduction in spleen volume by 15%

## Mucopolysaccharidosis IVA (MPS IVA) - Morquio A syndrome

### CLINICAL PA REQUIRED

VIMIZIM (elosulfase alfa) – *Medical Billing Only*

#### *Prior Authorization Criteria*

##### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- Documentation of the member's diagnosis must be submitted, as evidenced by the following:
  - Genetic testing confirming biallelic pathogenic mutations in the GALNS gene
  - Deficiency in activity of the n N-acetylgalactosamine 6-sulfatase (GALNS) enzyme
- The requested medication must be prescribed by, or in consult with, a geneticist, metabolic specialist, or specialist in mucopolysaccharidoses (MPS)
- The member is experiencing musculoskeletal signs and symptoms of MSP-IVA such as knee deformity, kyphosis, hip dysplasia, arthralgia, etc.
- Documentation of one of the following must be submitted:
  - Forced Vital Capacity (FVC) via Pulmonary Function Test
  - 6-minute walk test (6MWT)
  - 3-minute stair claim test (3-MSCT)

##### Renewal Criteria - Approval Duration: 12 months

- The member must have experienced and maintained clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) by one of the following scores:
  - Forced Vital Capacity (FVC) via Pulmonary Function Test
  - 6-minute walk test (6MWT)
  - 3-minute stair claim test (3-MSCT)
  - Reduced Urine Keratan Sulfate (KS) levels

## Mucopolysaccharidosis VI (MPS VI) - Maroteaux-Lamy syndrome

### CLINICAL PA REQUIRED

NAGLAZYME (galsulfase) – *Medical Billing Only*

#### *Prior Authorization Criteria*

##### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- Documentation of the member's diagnosis must be submitted, as evidenced by the following:
  - Deficiency of N-acetylgalactosamine 4-sufatase (arylsulfatase B or ASB) enzyme activity of <10% of the lower limit of normal
  - Detection of pathogenic variants in the ARSB gene by molecular genetic testing
- The requested medication must be prescribed by, or in consult with, an expert in lysosomal storage diseases
- Documentation of both of the following must be submitted:
  - Elevated level of urinary excretion of glycosaminoglycans (GAGs) such as chondroitin sulfate and dermatan sulfate, as defined by being above the upper limit of normal by the laboratory reference range
  - Motor function as measured by one of the following:



- 6 or 12-minute walk test (6-MWT or 12-MWT)
- 3-minute stair claim test
- Forced Vital Capacity (FVC) via Pulmonary Function Test

**Renewal Criteria - Approval Duration: 12 months**

- The member must have experienced meaningful clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including improvement in the one of the following scores and symptoms:
  - Reduction in urinary excretion of glycosaminoglycans (GAGs)
  - Stability or improvement in 6 or 12-minute walk test (6-MWT or 12-MWT)
  - Stability or improvement in 3-minute stair claim test
  - Stability or improvement in Forced Vital Capacity (FVC) via Pulmonary Function Test

## Mucopolysaccharidosis VII (MPS VII) - Sly Syndrome

### CLINICAL PA REQUIRED

MEPSEVII (vestronidase alfa-vjbc) – *Medical Billing Only*

### *Prior Authorization Criteria*

**Initial Criteria - Approval Duration: 6 months**

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- Documentation of the member's diagnosis must be submitted, as evidenced by the following:
  - Deficiency of beta-glucuronidase enzyme
  - Detection of pathogenic variants in the GUSB gene by molecular genetic testing.
- The requested medication must be prescribed by, or in consult with, an expert in lysosomal storage diseases
- One or more of the following documentations must be submitted:
  - Skeletal abnormalities
  - Elevated level of urinary excretion of glycosaminoglycans (GAGs) such as chondroitin sulfate and dermatan sulfate, as defined by being above the upper limit of normal by the laboratory reference range
  - Liver and/or spleen volume
  - 6-minute walk test (6MWT)
  - Motor function test (e.g., Bruininks-Oseretsky Test of Motor Proficiency (BOT-2))
  - Forced Vital Capacity (FVC) via Pulmonary Function Test

**Renewal Criteria - Approval Duration: 12 months**

- The member must have experienced meaningful clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including improvement in the one of the following scores and symptoms:
  - Stability or improvement in skeletal abnormalities shown on x-ray, short stature, macrocephaly
  - Reduction in urinary excretion of glycosaminoglycans (GAGs)
  - Reduction in liver and/or spleen volume
  - Stability or improvement in 6-minute walk test (6MWT)
  - Stability or improvement in Forced Vital Capacity (FVC) via Pulmonary Function Test

## Phenylketonuria

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
sapropterin	JAVYGTOR (sapropterin)
	KUVAN (sapropterin)
	PALYNZIQ (pegvaliase-pqpz)

## Underutilization

- Sapropterin and Palynziq must be used adherently and will reject on point of sale for late fill

## Prior Authorization Criteria

### Prior Authorization Form - Phenylketonuria

#### Initial Criteria - Approval Duration: 2 months (sapropterin); 12 months (Palynziq)

- The member must have been compliant with a PHE restricted diet for past 6 months (documentation must be attached).
- The requested medication must be prescribed by, or in consult with, a geneticist or endocrinologist
- Baseline PHE levels must be attached
  - For members of childbearing potential and children  $\leq$  12 years old: PHE levels must be above 360  $\mu$ moles/liter (6 mg/dL)
  - For members without childbearing potential, and children  $>$  12 years old: PHE levels must be above 600  $\mu$ moles/liter 10 mg/dL)
- Sapropterin Only: The member's weight must be provided. Requested initial dose must be 10 mg/kg
- Palynziq Only: PHE levels must be attached documenting the member was unable to achieve a PHE level less than 600  $\mu$ moles/liter (10mg/dL) despite a 3-month trial of 20mg/kg dose of sapropterin with good compliance.

#### Renewal Criteria:

- Approval Duration: 12 months - if dose is the same or less than previous trial
  - PHE level must be between 60 and 600  $\mu$ moles per liter
  - Sapropterin Only: The member's weight must be provided
- Approval Duration: 4 months - for a dose increase from previous trial
  - PHE level must be attached that were taken after previous trial (1 month for Kuvan, 4 months for Palynziq)
  - For members of childbearing potential and children  $\leq$  12 years old: PHE levels must be above 360  $\mu$ moles/liter (6mg/dL)
  - For members without childbearing potential, and children  $>$  12 years old: PHE levels must be above 600  $\mu$ moles/liter 10mg/dL)
  - Sapropterin Only: The member's weight must be provided

## Pompe Disease

### **CLINICAL PA REQUIRED**

LUMIZYME (alglucosidase alpha) – *Medical Billing Only*

NEXVIAZYME (avalglucosidase alfa-ngpt) – *Medical Billing Only*

## Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- Documentation of the member's diagnosis must be submitted, as evidenced by the following:
  - Deficiency of acid alpha-glucosidase enzyme activity (2% to 40% partial deficiency of GAA non-classic infantile forms or late onset forms) of the lab specific normal mean value
  - Detection of pathogenic variants in the GAA gene by molecular genetic testing.
- The requested medication must be prescribed by, or in consult with, a cardiologist, neurologist or geneticist or specialist in the area of Pompe disease

- The member must not have permanent invasive ventilation
- Documentation must be submitted of the member’s current motor function such as motor function, respiratory function, cardiac involvement (infantile onset) and scores from at least two of the following assessments:
  - A. Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorder (CHOP-INTEND)
  - B. Hammersmith Infant Neurological Examination (HINE) Section 2 motor milestone score
  - C. Hammersmith Functional Motor Scale Expanded (HFMSE)
  - D. Motor Function Measure – 32 items (MFM-32)
  - E. Revised Upper Limb Module (RULM)
  - F. 6-minute walk test (6MWT)
  - G. Forced Vital Capacity (FVC) via Pulmonary Function Test

**Category Criteria (Renewal):** *Approval Duration: 12 months*

- The member must have experienced and maintained clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including stabilization or improvement of the following:
  - Motor function, respiratory function, cardiac involvement (infantile onset)
  - CHOP-INTEND, HINE, HFMSE, MFM-32, 6MWT, or RULM scores
  - Forced Vital Capacity (FVC) via Pulmonary Function Test (ages 5 and older)

## N-acetylglutamate synthase (NAGS) deficiency

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
carglumic acid	CARBAGLU (carglumic acid)

## Hematology/Oncology

### Anemia

PREFERRED AGENTS (CLINICAL PA REQUIRED)
REBLOZYL (luspatercept) – <i>Medical Billing Only</i>

**Initial Criteria - Approval Duration: 6 months**

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a hematologist or oncologist, or prescriber specializing in the treatment of beta thalassemia or myelodysplastic syndrome/myeloproliferative neoplasm
- The member must have a diagnosis of anemia due to beta thalassemia or myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts
- Documentation must be submitted of a pretreatment hemoglobin of less than 11 g/dL
- Other causes of anemia (e.g., hemolysis, bleeding, recent major surgery, vitamin deficiency, etc.) have been ruled out
- Member must not have any of the following:
  - Diagnosis of hemoglobin S/ $\beta$ -thalassemia or alpha-thalassemia
  - Deep vein thrombosis or stroke within the past 24 weeks
  - Platelet count greater than 1000 x 10<sup>9</sup> per liter

**For anemia due to myelodysplastic syndrome/myeloproliferative neoplasm:**

- Documentation must be submitted that the member requires 2 or more RBC units over an 8-week period as evidenced by the following:
  - One of the following:
    - Ring sideroblasts greater than or equal to 15%

- Ring sideroblasts greater than or equal to 5% and less than 15% with an SF3B1 mutation
- One of the following:
  - Serum erythropoietin greater than 500 mU/mL
  - Serum erythropoietin less than or equal to 500 mU/mL with inadequate response after a 3-month trial with a combination of an ESA (e.g., epoetin alfa) and granulocyte-colony stimulating factor (G-CSF)
- Member has very low to intermediate risk disease defined as one of the following:
  - Revised International Prognostic Scoring System (IPSS-R); very low, low, or intermediate (Score of 0 to 4.5);
  - IPSS: low/intermediate-1 (Score 0 to 1)
  - WHO-Based Prognostic Scoring System (WPSS): WPSS: very low, low, or intermediate (Score 0 to 2)

*For anemia due to beta thalassemia:*

- Documentation must be submitted confirming the following:
  - The member has required at least 6 red blood cell (RBC) transfusions in the previous 24 weeks
  - The member has not had a transfusion-free period for ≥ 35 days during the most recent 24 weeks

Renewal Criteria - Approval Duration: 12 months

- The member must have experienced stabilization, slowing of disease progression, or improvement of the condition since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including:
  - Reduction in transfusion requirements from pretreatment baseline achieving one of the following:
    - At least 2 units packed red blood cells
    - By one-half
    - Complete transfusions independence
- The member continues to have pretreatment hemoglobin of less than 11 g/dL
- Dose will be increased to 1.25 mg/kg daily

## Chelating Agents

### Iron Chelators

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
deferasirox tablet for suspension	EXJADE (deferasirox tablet for suspension)
deferasirox tablets	deferasirox sprinkle
deferoxamine mesylate vial – <i>Medical Billing Only</i>	DEFERAL MESYLATE VIAL – <i>Medical Billing Only</i>
	FERRIPROX (deferiprone)
	JADENU (deferasirox) SPRINKLE
	JADENU (deferasirox) TABLETS

### Prior Authorization Criteria

Initial Criteria - Approval Duration: 12 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review).
- The member must have failed a trial duration of 30 days (or less if duration is FDA approved) of each preferred agent (listed in boxes below) within the past 2 years, as evidenced by paid claims or pharmacy printouts.

## Cold Agglutinin Disease (CAD)

### Anti-B-cell Therapy

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
RITUXAN (rituximab)	

### Anti-Complement Therapy

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	ENJAYMO (sutimlimab-jome) – <i>Medical Billing Only</i>

### Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, a hematologist or specialist in cold agglutinin disease (CAD)
- The member must have all of the following:
  - Evidence of chronic hemolysis (e.g., high lactated dehydrogenase [LDH], low haptoglobin, high reticulocyte count)
  - Direct antiglobin (Coombs) test is positive for C3d
  - Cold agglutinin titer  $\geq 64$  at 4°C
- The member must have had at least one blood transfusion in the previous six months
- Cold agglutinin syndrome secondary to other factors has been ruled out (e.g., infection, rheumatologic disease, systemic lupus erythematosus, or overt hematologic malignancy)
- The member has a baseline hemoglobin level  $\leq 10$  g/dL
- The member has a baseline bilirubin level above normal reference range of the reporting laboratory
- The member has one or more of the following symptoms:
  - Symptomatic anemia
  - Acrocyanosis
  - Raynaud's phenomenon
  - Hemoglobinuria
  - Disabling circulatory symptoms
  - Major adverse vascular event
- The member must have been unresponsive to previous rituximab-based therapy or one of the following must be documented:
  - Member has a medical reason why rituximab-based therapy is not appropriate or is contraindicated
  - Member has severe anemia or acute exacerbations of hemolysis and needs a bridge therapy awaiting the effects of a rituximab-based therapy

### Renewal Criteria - Approval Duration: 12 months

- Documentation must be submitted that the member has had a beneficial response to therapy from baseline as shown by one or more of the following:
  - Decrease in transfusions from baseline
  - Increase in hemoglobin (Hgb) by  $\geq 2$  g/dL from baseline or Hgb level  $\geq 12$  g/dL
  - Normalization of bilirubin levels to less than 1.2mg/dL
- Therapy continues to be necessary due to ongoing cold agglutinin production and inability to use rituximab

## Cytokine Release Syndrome

### Interleukin (IL) -6 Receptor Inhibitors

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ACTEMRA (tocilizumab)	

ACTEMRA (tocilizumab) – Medical Billing Only

### Prior Authorization Criteria

Initial Criteria - Approval Duration: 12 months

- Actemra: See [Medications that cost over \\$3000/month](#) Criteria

## Hemophagocytic Lymphohistiocytosis (HLH)

### PREFERRED AGENTS (CLINICAL PA REQUIRED)

GAMIFANT (emapalumab-lzsg) – Medical Billing Only

Initial Criteria - Approval Duration: 3 months or up to the hematopoietic stem cell transplantation (HSCT) date

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a hematologist, oncologist, immunologist, or transplant specialist
- The member has refractory, recurrent or progressive disease or intolerance with conventional HLH therapy (i.e., etoposide + dexamethasone, cyclosporine A, or Anti-thymocyte globulin)
- The member must be a candidate for stem cell transplant
- Documentation must be submitted confirming the diagnosis, as evidenced by the following:
  - Confirmation of a gene mutation known to cause primary HLH (e.g., PRF1, UNC13D, STX11 RAB27A, STXBP2)
  - Confirmation of 5 of the following clinical characteristics:
    - Fever  $\geq 101.3^{\circ}\text{F}$  for over 7 days
    - Splenomegaly
    - Two of the following cytopenias in the peripheral blood:
      - Hemoglobin  $< 9$  g/dL (or  $< 10$  g/dL in infants less than 4 weeks of age)
      - Platelet count  $< 100,000/\text{microL}$
      - ANC  $< 1000/\text{microL}$
    - One of the following:
      - Hypertriglyceridemia defined as fasting triglycerides  $\geq 265$  mg/dL (2 mmol/L)
      - Hypofibrinogenemia defined as fibrinogen  $\leq 1.5$  g/L
    - Hemophagocytosis in bone marrow or spleen or lymph nodes with no evidence of malignancy
    - Low or absent natural killer cell activity
    - Ferritin  $\geq 500$  mg/L
    - Soluble CD25 (i.e., soluble IL-2 receptor)  $\geq 2,400$  U/mL
- The requested medication must be administered with dexamethasone as part of the induction or maintenance phase of stem cell transplant, which is to be discontinued at the initiation of conditioning for stem cell transplant

**Category Criteria (Renewal):** Approval Duration: 3 months or up to the HSCT date

- At least 3 HLH abnormalities must be improved by at least 50% from baseline.

## Hemophilia

### Factor VIIa

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
NOVOSEVEN RT (coagulation Factor VIIa recombinant)	
SEVENFACT (coagulation Factor VIIa recombinant)	



## Factor VIII – Hemophilia A

### Non-Extended Half Life

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AFSTYLA (factor VIII recombinant, single chain)	ADVATE (factor VIII recombinant)
HEMOPIL M (factor VIII plasma derived; mAb-purified)	KOGENATE FS (factor VIII recombinant)
KOATE (factor VIII plasma derived, chromatography purified)	KOVALTRY (factor VIII recombinant)
NOVOEIGHT (factor VIII Rrecombinant)	NUWIQ (factor VIII recombinant)
OBIZUR (recombinant, B domain-deleted porcine (pig) factor VIII)	RECOMBINATE (factor VIII recombinant)
XYNTHA (factor VIII recombinant)	
XYNTHA SOLOFUSE (factor VIII recombinant)	

### Extended Half Life

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ADYNOVATE (factor VIII recombinant, PEGylated)	ELOCTATE (factor VIII recombinant, Fc fusion protein)
JIVI (factor VIII recombinant, pegylated-aucl)	ESPEROCT (factor VIII recombinant, glycopegylated – exeI)

## Factor VIII; C-Hemophilia A

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
MONOCLATE-P (Antihemophilic Factor VIII:C (human))	

## Factor VIII – Hemophilia A/vWF

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ALPHANATE (Antihemophilic Factor/Von Willebrand Factor Complex (Human))	
HUMATE-P (Factor VIII/von Willebrand Factor (human))	
WILATE (Factor VIII/von Willebrand Factor (human))	

## Factor VIII – Von Willebrand Factor – Recombinant

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	VONVENDI (Recombinant human vWF)

## Factor IX – Hemophilia B

### Non-Extended Half Life

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ALPHANINE SD (factor IX, plasma-derived)	
BENEFIX (factor IX recombinant)	

IXINITY (factor IX recombinant)	
MONONINE (factor IX, plasma-derived mAb purified)	
PROFILNINE (factor IX complex)	
RIXUBIS (factor IX recombinant)	

## Extended Half Life

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ALPROLIX (factor IX recombinant, Fc fusion)	
IDELVION (factor IX recombinant, albumin fusion)	
REBINYN (factor IX recombinant, glycol-PEGylated)	

## Factor IXa/IX

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
HEMLIBRA (Emicizumab-kxwh)	

## Factor X

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
COAGADEX (Coagulation Factor X (Human))	

## Factor XIII

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CORIFACT (Factor XIII Concentrate (Human))	

## Factor XIII A – Subunit, Recombinant

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TRETTEN (Factor XIII A-Subunit, recombinant)	

## Anti-inhibitor Coagulant Complex

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
FEIBA NF (Anti-Inhibitor Coagulant Complex)	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The date of the member's last appointment with a Hemophilia Treatment Center must be within the past year.
- Contact information for treatment center must be provided

#### Non-Preferred Agents Criteria:

- Clinical justification must be provided explaining why the member is unable to use a preferred agent (subject to clinical review).
- The member may qualify for non-preferred product if they are stable on current therapy (have had a paid claim for requested therapy in the past 45 days)



## Hematopoietic, Colony Stimulating Factors

### Filgrastim

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
NEUPOGEN (filgrastim)	GRANIX (TBO-filgrastim)
	NIVESTYM (filgrastim-AAFI)
	RELEUKO (filgrastim-AYOW)
	ZARXIO (filgrastim-SNDZ)

### Pegfilgrastim

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
NYVEPRIA (pegfilgrastim – APGF)	FULPHILA (pegfilgrastim-JMDB)
ZIEXTENZO (pegfilgrastim-BMEZ)	FYLNETRA (pegfilgrastim-PBBK)
	NEULASTA (pegfilgrastim)
	STIMUFEND (pegfilgrastim-FPGK)
	UDENYCA (pegfligrastim-CBQV)

### Sargramostim

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
LEUKINE (sargramostim)	

#### Prior Authorization Criteria

##### Initial Criteria - Approval Duration: 12 months

- Clinical justification must be provided explaining why the member is unable to use the preferred product (subject to clinical review).

## Nausea/Vomiting

### Chemo-Induced

#### NK1 Receptor Antagonists

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AKYNZEO (netupitant/palonosetron) CAPSULE	aprepitant capsule
EMEND (aprepitant) CAPSULE 125 MG-80 MG TRIPACK – <i>Brand Required</i>	EMEND (aprepitant) CAPSULES 80 MG and 125 MG
	EMEND (aprepitant) SUSPENSION

#### 5-HT3 Receptor Antagonists

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AKYNZEO (netupitant/palonosetron)	SANCUSO (granisetron) PATCH
granisetron tablet	ZOFRAN (ondansetron) TABLET
ondansetron ODT	SUSTOL (granisetron) SYRINGE
ondansetron solution	
ondansetron tablet	

## Cannabinoids

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
dronabinol capsule	MARINOL (dronabinol) CAPSULE

### Electronic Diagnosis Verification

- Dronabinol Only: Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months or until last day of chemotherapy

- The requested medication must be prescribed by, or in consult with, an oncologist
- The member must be receiving a moderately or highly emetogenic chemotherapy
- The final date of chemotherapy treatment must be provided with the request
- The member must have failed a 3-day trial of each preferred product(s) in the same class within the last 6 months, as evidenced by paid claims or pharmacy print outs
- The member must not have failed preferred chemical entity with same active ingredient as requested product due to side effects

## Paroxysmal Nocturnal Hemoglobinuria (PNH)

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
EMPAVELI (pegcetacoplan)	SOLIRIS (eculizumab) – <i>Medical Billing Only</i>
ULTOMIRIS (ravulizumab)	
ULTOMIRIS (ravulizumab) – <i>Medical Billing Only</i>	

### Prior Authorization Criteria

#### [Prior Authorization Form - Empaveli](#)

#### Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, a hematologist, oncologist, or immunology specialist
- Diagnosis must be confirmed by flow cytometry with LDL level of 1.5 times the upper limit of normal (must include at least 2 different reagents tested on at least 2 cell lineages) demonstrating that individual's peripheral blood cells are deficient in glycosylphosphatidylinositol (GPI) – linked proteins (as evidenced by submitted documentation)
- One of the following criteria must be met (A or B):
  - The member is transfusion-dependent
  - The member has hemoglobin  $\leq 7$  g/dL or Hb  $\leq 9$  g/dL, and member has symptoms of thromboembolic complications (e.g., abdominal pain, shortness of breath, chest pain, end-organ damage, fatigue)

#### Non-Preferred Agent Criteria:

- The member must have failed a 3-month trial with Ultomiris, as evidenced by paid claims or printouts.

#### Renewal Criteria - Approval Duration: 12 months

- Documentation has been submitted that support one of the following positive responses to therapy:
  - Decrease in transfusions from baseline
  - Increase in hemoglobin by  $\geq 1$  g/dL from baseline

- Normalization in LDH levels  $\leq$  280 U/L

## Paroxysmal Nocturnal Hemoglobinuria (PNH)

### CLINICAL PA REQUIRED

RYPLAZIM (plasminogen, human-tvmh) – *Medical Billing Only*

#### Prior Authorization Criteria

##### Initial Criteria - Approval Duration: 3 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a hematologist or specialist in treated condition
- Documentation of the diagnosis must be submitted, as evidenced by the following:
  - Baseline plasminogen activity level  $\leq$  45% (*If the patient is receiving plasminogen supplementation with fresh frozen plasma, allow for a 7-day washout period before obtaining baseline plasminogen activity level.*)
  - Documented history of lesions (e.g., ligneous conjunctivitis, ligneous gingivitis, occlusive hydrocephalus, abnormal wound healing)
  - Genetic testing to confirm biallelic pathogenic PLG mutation

##### Renewal Criteria - Approval Duration: 12 months, a one-time 6-month approval for dose adjustment allowed for members not meeting renewal criteria upon request

- The member must have experienced meaningful clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including the following:
  - Member has demonstrated a 50% resolution of lesions, with no active or recurrent lesions
  - Trough plasminogen activity levels are  $>10\%$  above baseline

## Sickle Cell Disease

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ADAKVEO (crizanlizumab-tmca) – <i>Medical Billing Only</i>	ENDARI (glutamine)
DROXIA (hydroxyurea capsule)	OXBRYTA (voxelotor)
hydroxyurea capsule	SIKLOS (hydroxyurea tablet)

#### Prior Authorization Criteria

##### Initial Criteria - Approval Duration: 12 months

- The requested medication must be prescribed by, or in consult with, a hematologist, oncologist, or immunology specialist
- The member must have had a 30-day trial of a preferred agent at the maximum (35 mg/kg/day) or maximally tolerated dose, as evidenced by paid claims or pharmacy printouts
- The member has experienced at least one sickle cell-related vaso-occlusive crisis within past 12 months (documentation required)
- Oxbryta Only:
  - Baseline hemoglobin (Hb)  $\leq$  10.5 g/dL
- Siklos Only:
  - Baseline hemoglobin (Hb)  $\leq$  10.5 g/dL

- See [Preferred Dosage Form](#) Criteria

**Renewal Criteria - Approval Duration: 12 months**

- The member must have experienced and/or maintained clinical benefit since starting treatment with the requested product, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) by one of the following:
  - Increase in hemoglobin (Hb) by  $\geq 1$  g/dL from baseline
  - Decrease in indirect bilirubin from baseline
  - Decrease in percent reticulocyte count from baseline
  - Reduction in sickle cell-related vaso-occlusive crisis

## Thrombocytopenia

### Immune Thrombocytopenic Purpura (ITP)

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
NPLATE (romiplostim)	DOPTELET (avatrombopag)
PROMACTA (eltrombopag)	TAVALISSE (fostamatinib)
PROMACTA (eltrombopag) POWDER PACK	

*Prior Authorization Criteria*

**Initial Criteria - Approval Duration: 4 months**

- The member has diagnosis of immune thrombocytopenic purpura (ITP) lasting >6 months
- Documentation of platelet count of less than  $30 \times 10^9/L$
- The member must have experienced an inadequate response after one of the following (A, B or C):
  - A. The member must have failed a trial of appropriate duration of a corticosteroid or immunoglobulins, as evidenced by paid claims or pharmacy print outs
  - B. Rituximab
  - C. The member must have undergone a splenectomy

***Non-Preferred Agents Criteria:***

- The member must have failed trials with each preferred agent (at the recommended dose and duration) with each preferred agent, as evidenced by paid claims or pharmacy printouts.

**Renewal Criteria - Approval Duration: 12 months**

- Platelet counts must have achieved greater than or equal to  $50 \times 10^9/L$  in response to therapy (supported by documentation)

### Chronic Liver Disease-Associated Thrombocytopenia

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DOPTELET (Avatrombopag)	MULPLETA (Lusutrombopag)

*Prior Authorization Criteria*

**Initial Criteria - Approval Duration: The 2 weeks prior to procedure**

- The member must have platelet count of less than  $50 \times 10^9/L$
- The member must be scheduled to undergo a procedure that puts the member at risk of bleeding (documentation must include name and scheduled date of procedure)
- Documentation must include the date therapy will be initiated and discontinued:
  - Doptelet: Member must undergo procedure 5-8 days after last dose

- Mulpleta: Member must undergo procedure 2-8 days after last dose

## Chronic Hepatitis C Infection-Associated Thrombocytopenia

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
PROMACTA (eltrombopag)	
PROMACTA (eltrombopag) POWDER PACK	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 4 months

- The member is unable to receive direct acting antivirals for hepatitis C
- The member's degree of thrombocytopenia must prevent initiation or continuation of interferon-based therapy

#### Renewal Criteria - Approval Duration: 12 months

- Platelet counts must have achieved greater than or equal to  $50 \times 10^9/L$  in response to therapy (supported by documentation)
- The member is currently receiving interferon-based therapy

## Aplastic Anemia

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
PROMACTA (eltrombopag)	
PROMACTA (eltrombopag) POWDER PACK	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 4 months

- The member must have platelet count of less than  $30 \times 10^9/L$
- The member must have failed therapy or be receiving concurrent therapy with immunosuppressive therapy (e.g., corticosteroid, Atgam, cyclosporine, cyclosporine)

#### Renewal Criteria - Approval Duration: 12 months

- Platelet counts must have achieved greater than or equal to  $50 \times 10^9/L$  in response to therapy (supported by documentation)

## Infectious Disease

### Anti-infectives - Resistance Prevention

#### Antifungals – Aspergillus and Candidiasis Infections

##### Solid Dosage Form

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
clotrimazole	CRESEMBA (isavuconazonium)
clotrimazole troche	DIFLUCAN (fluconazole)
fluconazole	NOXAFIL (posaconazole)
itraconazole	SPORANOX (itraconazole)
nystatin	VFEND (voriconazole)
ORAVIG (miconazole)	

posaconazole	
terbinafine	
voriconazole	

### Non-Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
fluconazole suspension	DIFLUCAN (fluconazole) SUSPENSION
itraconazole solution	NOXAFIL (posaconazole) POWDERMIX SUSPENSION
NOXAFIL (posaconazole) SUSPENSION	SPORANOX (itraconazole) SOLUTION
VFEND (voriconazole) SUSPENSION – <i>Brand Required</i>	TOLSURA (itraconazole) DISPERSE CAPSULE
	voriconazole suspension

### Community-Acquired Pneumonia

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
amoxicillin	BAXDELA (delafloxacin)
amoxicillin-clavulanate	FACTIVE (gemifloxacin)
azithromycin	XENLETA (lefamulin)
cefepodoxime	
cefuroxime	
clarithromycin	
doxycycline	
levofloxacin	
linezolid	
moxifloxacin	

### Cytomegalovirus infection

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
valganciclovir	LIVTENCITY (maribavir)

### Methicillin-Resistant *Staphylococcus aureus* (MRSA):

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
clindamycin	BAXDELA (delafloxacin)
doxycycline	NUZYRA (omadacycline)
linezolid	SIVEXTRO (tedizolid)
minocycline	
trimethoprim-sulfamethoxazole	

### *Helicobacter pylori*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
lansoprazole/amoxicillin/clarithromycin	OMECLAMOX-PAK (omeprazole/clarithromycin/amoxicillin)
PYLERA (bismuth subcitrate potassium/metronidazole/tetracycline)	TALICIA (omeprazole/amoxicillin/rifabutin)
	VOQENZA DUAL PAK (vonoprazan/amoxicillin)

VOQENZA TRIPLE PAK (vonoprazan/amoxicillin/clarithromycin)
---

## Tuberculosis

PREFERRED AGENTS (NO PA REQUIRED)	PREFERRED AGENTS (PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ethambutol	isoniazid	cycloserine
PRIFTIN (rifapentine)		MYCOBUTIN (rifabutin)
pyrazinamide		RIFADIN (rifampin)
rifabutin		SIRTURO (bedaquiline)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 5 days

- Diagnosis must be proven to be caused by a susceptible microorganism by culture and susceptibility testing
- The requested medication must be prescribed by, or in consult with, an infection disease specialist, an antibiotic stewardship program, or protocol.
- One of the following criteria must be met (A or B):
  - A. The member is continuing treatment upon discharge from an acute care facility
  - B. Clinical justification must be provided explaining why the preferred antibiotics are not an option due to susceptibility, previous failed trials, or other contraindications (subject to clinical review)

#### *Aspergillus and Candidiasis Infections Only:*

- The request must be for use as prophylaxis of invasive Aspergillus and Candida infections or Oropharyngeal Candidiasis

#### *Tuberculosis Only:*

- Isoniazid: The ND Division of Disease Control Tuberculosis Prevention and Control program provides isoniazid for no cost through the UND Center for Family Medicine Pharmacy. Please contact 701-328-2378 to obtain supply.

#### Renewal Criteria - Approval Duration: 5 days

- It is medically necessary to continue treatment course after re-evaluation of the member's condition.
- The total requested duration of use must not be greater than manufacturer labeling or treatment guideline recommendations (whichever is greater).

## Human Immunodeficiency Virus (HIV)

### Antiretrovirals – Pre-exposure Prophylaxis (PrEP)

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
APRETUDE (cabtegravir)	TRUVADA (emtricitabine/tenofovir)
DESCOVY (emtricitabine/tenofovir)	
emtricitabine/tenofovir	

### Antiretrovirals – Treatment

#### References:



1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf> Accessed (October 9, 2020)

## Integrase Strand Transfer Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BIKTARVY (bictegravir/emtricitabine/tenofovir)	
CABENUVA (cabotegravir/rilpivirine)	
DOVATO (dolutegravir/lamivudine)	
GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir)	
ISENTRESS (raltegravir)	
JULUCA (dolutegravir/rilpivirine)	
STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir)	
TIVICAY (dolutegravir)	
TRIUMEQ (abacavir/dolutegravir/lamivudine)	
TRIUMEQ PD (abacavir/dolutegravir/lamivudine)	

## Non-Nucleoside Reverse Transcriptase Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
COMPLERA (emtricitabine/rilpivirine/tenofovir)	ATRIPLA (efavirenz/emtricitabine/tenofovir)
EDURANT (rilpivirine)	efavirenz/lamivudine/tenofovir
efavirenz	SUSTIVA (efavirenz)
efavirenz/emtricitabine/tenofovir	
JULUCA (dolutegravir/rilpivirine)	
ODEFSEY (emtricitabine/rilpivirine/tenofovir)	
PIFELTRO (doravirine)	
rilpivirine	
SYMFI (efavirenz/lamivudine/tenofovir) – <i>Brand Required</i>	
SYMFI LO (efavirenz/lamivudine/tenofovir) – <i>Brand Required</i>	
<b>Not Recommended for First Line Use</b>	
INTELENCE (etravirine) – <i>Brand Required</i>	etravirine
nevirapine	
nevirapine ER	

- Etravirine - Guidelines do not recommend for treatment-naïve members due to insufficient data. FDA indication is for treatment experienced members and so should be reserved for salvage therapy, pretreated members with NNRTI resistance and PI exposure or who have ongoing adverse effects with first line therapies.
- Nevirapine - Guidelines no longer recommend nevirapine for initial treatment of HIV infection in treatment-naïve members. In resource limited settings, it can be considered as a third agent. Nevirapine demonstrated inferiority relative to efavirenz and is associated with serious and fatal hepatic and rash events.

## Nucleoside Reverse Transcriptase Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
abacavir	ATRIPLA (efavirenz/emtricitabine/tenofovir)
abacavir/lamivudine	efavirenz/lamivudine/tenofovir
BIKTARVY (bictegravir/Emtricitabine/tenofovir)	emtricitabine capsule
CIMDUO (lamivudine/tenofovir)	EPIVIR (lamivudine)
COMPLERA (emtricitabine/rilpivirine/tenofovir)	EPZICOM (abacavir)
DELSTRIGO (doravirine/lamivudine/tenofovir)	TRIZIVIR (abacavir/lamivudine)
DESCOVY (emtricitabine/tenofovir)	TRUVADA (emtricitabine/tenofovir)
EMTRIVA (emtricitabine) CAPSULE – <i>Brand Required</i>	VIREAD (tenofovir)
efavirenz/emtricitabine/tenofovir	ZERIT (stavudine) CAPSULE
emtricitabine solution	ZIAGEN (abacavir)
emtricitabine/tenofovir	
GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir)	
lamivudine	
ODEFSEY (emtricitabine/rilpivirine/tenofovir)	
SYMFI (efavirenz/lamivudine/tenofovir) – <i>Brand Required</i>	
SYMFI LO (efavirenz/lamivudine/tenofovir) – <i>Brand Required</i>	
STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir)	
SYMTUZA (darumavir/cobicistat/emtricitabine/tenofovir)	
tenofovir	
TEMIXYS (lamivudine/tenofovir)	
TRIUMEQ (abacavir/dolutegravir/lamivudine)	
TRIUMEQ PD (abacavir/dolutegravir/lamivudine)	
<b>Not Recommended for First Line Use</b>	
abacavir/lamivudine/zidovudine	COMBIVIR (lamivudine/zidovudine)
didanosine	RETROVIR (zidovudine)
lamivudine/zidovudine	VIDEX EC (didanosine)
stavudine	ZERIT (stavudine) CAPSULE
VIDEX (didanosine)	
zidovudine	

- abacavir/lamivudine/zidovudine – Guidelines do not recommend ABC/3TC/ZDU (as either a triple-NRTI combination regimen or in combination with tenofovir (TDF) as a quadruple-NRTI combination regimen) due to inferior virologic efficacy.
- didanosine – Guidelines do not recommend ddl/3TC or ddl/FTC regimens due to inferior virologic efficacy, limited trial experience in ART-naïve members, and ddl toxicities (including pancreatitis and peripheral neuropathy). ddl/TDF regimens are not recommended due to high rate of early virologic failure, rapid selection of resistance mutations, potential for immunologic nonresponse/CD4 cell decline, and increased ddl drug exposure and toxicities.

- lamivudine/zidovudine – Guidelines do not recommend ZDV/3TC due to greater toxicities than recommended NRTIs (including bone marrow suppression, GI toxicities, skeletal muscle myopathy, cardiomyopathy, and mitochondrial toxicities such as lipoatrophy, lactic acidosis and hepatic steatosis).
- stavudine – Guidelines do not recommend d4T/3TC due to significant toxicities (including lipoatrophy, peripheral neuropathy) and hyperlactatemia (including symptomatic and life-threatening lactic acidosis, hepatic steatosis, and pancreatitis)

## Post-Attachment Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TROGARZO (Ibalizumab-uiyk)	

## Protease Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
atazanavir	NORVIR (ritonavir) TABLET
EVOTAZ (atazanavir/cobicistat)	REYATAZ (atazanavir) CAPSULE
NORVIR (ritonavir) POWDER	
NORVIR (ritonavir) SOLUTION	
PREZCOBIX (darunavir/cobicistat)	
PREZISTA (darunavir)	
REYATAZ (atazanavir) POWDER PACK	
ritonavir	
SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir)	
<b>Not Recommended for First Line Use</b>	
APTIVUS (tipranavir)	KALETRA (lopinavir/ritonavir) SOLUTION
fosamprenavir	KALETRA (lopinavir/ritonavir) TABLET
INVIRASE (saquinavir)	LEXIVA (fosamprenavir)
lopinavir/ritonavir tablet	
lopinavir/ritonavir solution	
VIRACEPT (nelfinavir)	

- Fosamprenavir – Guidelines do not recommend use of unboosted FPV or FPV/r due to virologic failure with unboosted FPV-based regimens that may result in selection of mutations that confer resistance to FPV and DRV. There is also less clinical trial data for FPV/r than other RTV-boosted PIs.
- Lopinavir/ritonavir – Guidelines do not recommend LPV/r due to GI intolerance, higher pill burden and higher RTV dose than other PI-based regimens
- Nelfinavir – Guidelines do not recommend use of NFV due to inferior virologic efficacy and diarrhea.
- Saquinavir – Guidelines do not recommend use of unboosted SQV due to inadequate bioavailability and inferior virologic efficacy or SQV/r due to high pill burden and QT and PR prolongation.
- Tipranavir – Guidelines do not recommend TPV/r due to inferior virologic efficacy, higher dose of RTV and higher rate of adverse events than other RTV-boosted PIs.

## Capsid Function Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
<b>Not Recommended for First Line Use</b>	
SUNLENCA (lenacapavir) INJECTION – <i>Medical Billing Only</i>	
SUNLENCA (lenacapavir) TABLET	

- **lenacapavir** - SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
<b>Not Recommended for First Line Use</b>	
FUZEON (enfuvirtide)	
SELZENTRY (maraviroc)	

- **Enfuvirtide** (Fusion Inhibitor)– Guidelines do not recommend T20 for initial therapy due to twice daily injections, high rate of injection site reactions, and it has only been studied in members with virologic failure
- **Maraviroc** (CCR5 Antagonist) – Guidelines do not recommend MVC for initial therapy due to twice daily dosing, no virologic benefit compared to recommended regimens, and required CCR5 tropism testing.

## Diarrhea

Mytesi: [Jump to Criteria](#)

## Loss of Appetite

Dronabinol: [Jump to Criteria](#)

## Wasting Cachexia

Serostim: [Jump to Criteria](#)

## Hepatitis C Antiviral Treatments

### Direct Acting Antivirals

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
HARVONI (ledipasvir/sofosbuvir) 45 mg/200 mg tablet	EPCLUSA (sofosbuvir/velpatasvir)
MAVYRET (glecaprevir/pibrentasvir)*** sofosbuvir/velpatasvir	HARVONI (ledipasvir/sofosbuvir) 90mg/400mg tablet HARVONI (ledipasvir/sofosbuvir) ORAL PALLET
SOVALDI (sofosbuvir) 200 MG TABLET	ledipasvir/sofosbuvir 90mg/400mg tablet
VOSEVI (sofosbuvir/velpatasvir/voxilaprevir)	SOVALDI (sofosbuvir) 400MG TABLET SOVALDI (sofosbuvir) ORAL PALLET
	VIEKIRA PAK (dasabuvir/ombitasvir/paritaprevir/ritonavir)
	ZEPATIER (elbasvir/grazoprevir)

### Electronic Step Care and Concurrent Medications

- Epclusa (and its generic): A total of 28 days of ribavirin must be billed within the previous 14 days of a sofosbuvir/velpatasvir claim if member has decompensated cirrhosis (Child Pugh B or C).

### Prior Authorization Criteria

#### [Prior Authorization Form – Hepatitis C](#)

Initial Criteria - Approval Duration: Based on label recommendations

- The member must not be receiving a known recreationally used high risk combination of drugs (e.g., “the holy trinity”) for the past 6 months.
- The member must have established compliant behavior including attending scheduled provider visits (defined as 1 or less no-shows) and filling all maintenance medications on time for the past 90 days, as evidenced by pharmacy claims history.
- The member must not have life expectancy of less than 12 months.
- The member and prescriber attestation forms must be attached to request
- Chronic Hepatitis C must be documented by one of the following:
  - Liver fibrosis F1 and below: 2 positive HCV RNA levels at least 6 months apart
  - Liver fibrosis F2 and above: 1 positive HCV RNA test within the last 12 months
- Epclusa pellet packs: Members that weigh 30 kg or greater must meet [Non-Solid Dosage Preparations](#) criteria in addition to Hepatitis C criteria
- Mavyret pellet packs: Members that weigh 45 kg or greater must meet [Non-Solid Dosage Preparations](#) criteria in addition to Hepatitis C criteria

*Non-Preferred Agents Criteria:*

- Clinical justification must be provided explaining why the member is unable to use the preferred product (subject to clinical review).

Prescriber may be primary care provider or family practice with the following exceptions:	
<b>Prescriber must be a hepatology, gastroenterology, or infectious disease specialist</b>	• Decompensated cirrhosis (Child’s Pugh B or C)
	• Status post solid organ transplantation
	• Known or suspected hepatocellular carcinoma
	• Evidence/suspicion of acute liver injury while on HCV treatment
	• HIV or HBsAg positive
<b>Prescriber must be, or in consult with, a hepatology, gastroenterology, or infectious disease specialist (including via Project ECHO)</b>	• Current pregnancy or breastfeeding
	• Compensated cirrhosis (Child’s Pugh A) • For Hep C retreatment after Direct Acting Antivirals

**For FIRST TIME treatments with Direct Acting Antivirals:**

Must be drug (drugs of abuse by injection) and alcohol free as documented by:	
<b>No history of alcohol use disorder or history of using drugs of abuse by injection</b>	• 1 drug and alcohol test completed within 30 days of the request date
<b>History of alcohol use disorder or history of drugs</b>	Currently enrolled or <u>has completed</u> a substance use treatment program within the past 12 months
	• 1 negative IV drug and/or alcohol test within 30 days of the request date (if history of use within past 5 years) • The member is receiving treatment or must have received treatment for substance use disorder since initial Hepatitis C treatment with Direct Acting Antivirals,

of abuse by injection		<p>and the provider/facility name must be provided with the request.</p> <ul style="list-style-type: none"> <li>• Chart notes must be attached regarding assessment of member's readiness for treatment including readiness for abstinence from alcohol and IV drug use during and after treatment</li> </ul>
	<p><u>Has not completed</u> a substance use treatment program within the past 12 months</p>	<ul style="list-style-type: none"> <li>• 2 negative IV drug and/or alcohol tests, dated at least 3 months apart, with the most current test completed within 30 days of the request date (if history of use within past 5 years)</li> <li>• Provider must submit chart notes documenting that the member has maintained sobriety for the past year or since last substance use treatment program completion</li> </ul>

**For RE-TREATMENT after Direct Acting Antivirals:**

Reason for retreatment:		
Due to drugs of abuse by injection	<ul style="list-style-type: none"> <li>• The member is receiving treatment or must have received treatment for substance use disorder since initial Hepatitis C treatment with Direct Acting Antivirals, and the provider/facility name must be provided with the request.</li> </ul>	
	<ul style="list-style-type: none"> <li>• The member must not be at high risk of relapse from illicit drug use by injection during and after treatment as evidenced by treatment provider notes or risk assessment</li> </ul>	
	Liver fibrosis F2 and below	Liver fibrosis F3 and above
	<ul style="list-style-type: none"> <li>• The provider must submit chart notes documenting that the member has abstained from drugs of abuse for the past year</li> </ul>	<ul style="list-style-type: none"> <li>• Two drug tests: 1 test completed 3 months prior to request and 1 test within 30 days of the request date</li> </ul>
	<ul style="list-style-type: none"> <li>• Two drug tests: 1 test completed 6 months (+/- 1 months) prior to request and 1 test within 30 days of the request date</li> </ul>	
Due to non-compliance (defined as a medication possession ratio (MPR) of less than 80%)	Liver fibrosis F2 and below	Liver fibrosis F3 and above
	<ul style="list-style-type: none"> <li>• The member must have established compliant behavior including attending scheduled provider visits (defined as 1 or less no-shows) and filling all maintenance medications on time for the past 180 days, as evidenced by pharmacy claims history.</li> </ul>	<ul style="list-style-type: none"> <li>• The member must have established compliant behavior including attending scheduled provider visits (defined as 1 or less no-shows) and filling all maintenance medications on time for the past 90 days, as evidenced by pharmacy claims history.</li> </ul>
Resistance	<ul style="list-style-type: none"> <li>• <b>FIRST TIME treatment with Direct Acting Antivirals</b> criteria must be met</li> </ul>	

## Malaria

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
hydroxychloroquine	atovaquone/proguanil
quinine	chloroquine
	COARTEM (artemether/lumefantrine)
	KRINTAFEL (tafenoquine)
	MALARONE (atovaquone/proguanil)
	mefloquine
	primaquine
	QUALAQUIN (quinine)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 7 days

- The member must have had a trial of a generic quinine in the last 30 days, as evidenced by paid claims or pharmacy print outs
- The request must be for treatment of malaria (NOT covered for prophylaxis)

## Respiratory Syncytial Virus (RSV) Prophylaxis

### CLINICAL PA REQUIRED

SYNAGIS (palivizumab) – *Medical Billing Only*

### Prior Authorization Criteria

#### [Prior Authorization Form - Synagis](#)

Initial Criteria - Approval Duration: Up to 5 weight-based doses within 6 months of season onset. No further prior authorization requests will be approved following season offset

Respiratory Syncytial Virus (RSV) Season defined as onset (1<sup>st</sup> of 2 consecutive weeks when percentage of PCR tests positive for RSV is > 3% and offset (Last of 2 consecutive weeks when percentage of PCR tests positive for RSV is < 3%) as reported by The National Respiratory and Enteric Virus Surveillance System (NREVSS) Midwest Region [RSV Regional Trends - NREVSS | CDC](#)

- The member must have one of the following diagnoses and the additional criteria outlined for diagnosis:
  - **Prematurity:**
    - < 29 weeks, 0 days gestational age
      - ≤ 12 months of age at start of RSV season
    - ≥ 29 weeks, 0 days gestational age to ≤ 35 weeks, 0 days gestational age
      - ≤ 6 months of age at start of RSV season
      - One of the following:
        - Neuromuscular disease or pulmonary abnormality that impairs ability to clear secretions from the upper airway because of ineffective cough
        - Profoundly immunocompromised receiving chemotherapy, solid organ transplantation, hematopoietic stem cell transplantation, or require colony stimulating factors
  - **Chronic Lung Disease of Prematurity (CLD)**
    - < 32 weeks, 0 days gestational age
      - ≤12 months of age at start of RSV season
      - Requires supplemental oxygen > 21% for at least the first 28 days after birth



- < 32 weeks, 0 days gestational age
  - 13-24 months of age at start of RSV season
  - Requires supplemental oxygen > 21% for at least the first 28 days after birth
  - Continues to receive medical support within six months before the start of RSV season with supplemental oxygen, diuretic, or chronic corticosteroid therapy
- **Congenital Heart Disease**
  - ≤12 months of age at start of RSV season
    - Hemodynamically significant cyanotic or acyanotic congenital heart disease with medical therapy required

**References:**

1. American Academy of Pediatrics. Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2022-2023 RSV Season. American Academy of Pediatrics; July 2022. Available at: <https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/>
2. Midgley CM, Haynes AK, Baumgardner JL, et al. Determining the seasonality of respiratory syncytial virus in the United States: the impact of increased molecular testing. J Infect Dis 2017;216:345–55
3. Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory Syncytial Virus Seasonality — United States, 2014–2017. MMWR Morb Mortal Wkly Rep 2018;67:71–76. DOI: [http://dx.doi.org/10.15585/mmwr.mm6702a4external icon](http://dx.doi.org/10.15585/mmwr.mm6702a4external%20icon)

## Nephrology/Urology

### Complement-mediated Thrombotic Microangiopathy (TMA) /

### Complement-mediated Hemolytic Uremic Syndrome

<b>CLINICAL PA REQUIRED</b>
SOLIRIS (eculizumab) – <i>Medical Billing Only</i>
ULTOMIRIS (ravulizumab-cwvz)
ULTOMIRIS (ravulizumab-cwvz) – <i>Medical Billing Only</i>

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a hematologist or nephrologist
- The member has all the following (as evidenced by submitted documentation):
  - Low platelet count, as defined by laboratory reference range or member requires dialysis
  - Evidence of hemolysis such as an elevation in serum lactate dehydrogenase (LDH), elevated indirect bilirubin, reduced haptoglobin, or increased reticulocyte, as defined by laboratory reference range or member requires dialysis
  - Serum creatinine above the upper limits of normal, as defined by laboratory reference range or member requires dialysis
- The member does not have bloody diarrhea

Renewal Criteria - Approval Duration: 12 months

- The member must have experienced meaningful clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including one of the following scores and symptoms:
  - Normalization of platelet count, as defined by laboratory reference range

- Normalization of lactate dehydrogenase (LDH), as defined by laboratory reference range
- ≥ 25% improvement in serum creatinine from baseline or ability to discontinue dialysis

## Benign Prostatic Hyperplasia

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
alfuzosin ER	AVODART (dutasteride)
CARDURA XL (doxazosin)	CARDURA (doxazosin)
doxazosin	ENTADFI (finasteride/tadalafil)
dutasteride	FLOMAX (tamsulosin)
finasteride	MINIPRESS (prazosin)
prazosin	PROSCAR (finasteride)
silodosin	RAPAFLO (silodosin)
tamsulosin	sildenafil
terazosin	tadalafil

### Electronic Diagnosis Verification

- Finasteride: Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of each preferred agent, as evidenced by paid claims or pharmacy printouts
- Sildenafil/tadalafil: Documentation (e.g., chart notes) must be provided confirming the diagnosis

## Chronic Kidney Disease

### Non-steroidal selective mineralocorticoid receptor antagonist (MRA)

CLINICAL PA REQUIRED
KERENDIA (finerenone)

### Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

NO PA REQUIRED
ACE (angiotensin-converting enzyme) inhibitors - <i>all oral agents preferred</i>
ARBs (angiotensin receptor blockers) - <i>all oral agents preferred</i>
TEKTURNA (aliskiren)

### SGLT-2 Inhibitor

NO PA REQUIRED
FARXIGA (dapagliflozin)
INVOKANA (canagliflozin)

### Systemic Corticosteroids

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
methylprednisolone	TARPEYO (budesonide EC)

prednisone	
------------	--

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- If member is on renal dialysis, Medicare eligibility must be ruled out.
- The member must be on the following at the target or maximally tolerated dose, as evidenced by paid claims or pharmacy printouts:
  - An ACE-inhibitor or an ARB
  - A SGLT-2 inhibitor

*Kerendia Only*

- The member must have history of diabetes
- Estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m<sup>2</sup> AND urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g (≥3 mg/mmol)

*Tarpeyo Only*

- The member must have eGFR ≥ 30.
- The member must be experiencing proteinuria > 1 gram/day or UPCR ≥ 0.8 g/g (documentation must be attached) despite 6-month trials with good compliance of the following at the target or maximally tolerated dose, as evidenced by paid claims or pharmacy printouts:
  - ACE inhibitor or an ARB
  - A SGLT-2 inhibitor
  - Prednisone or methylprednisolone

**References:**

1. Rossing, Peter, et al. "KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease." *Kidney international* 102.5 (2022): S1-S127.
2. de Boer, Ian H., et al. "Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)." *Diabetes care* 45.12 (2022): 3075-3090.

**Hematopoietic, Erythropoiesis Stimulating Agents**

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ARANESP (darbepoetin alfa)	EPOGEN (epoetin alfa)
PROCRIT (epoetin alfa)	MIRCERA (methoxy polyethylene glycol-epoetin beta)
	RETACRIT (epoetin alfa - epbx)

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- The member must have had a 4-week trial of each preferred agent, as evidenced by paid claims or pharmacy printouts.
- If member is on renal dialysis, Medicare eligibility must be ruled out.

**Hematopoietic Syndrome of Acute Radiation Syndrome (NPlate)**

PREFERRED AGENTS (CLINICAL PA REQUIRED)
NPLATE (romiplostim)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: treatment plan must be documented in request

- The requested medication must be prescribed by, or in consult with, a hematologist or oncologist.
- The member meets one of the following:
  - The member has had a  $\geq 2$  gray exposure to radiation
  - The member has had exposure to radiation and experiencing one of the following:
    - Gross blood loss
    - $> 10\%$  decrease in hemoglobin
    - Platelet count  $< 50,000/\text{microL}$
    - Absolute neutrophil count  $< 1000$  cells/ $\text{microL}$
    - Absolute lymphocyte count  $< 1000$  cells/ $\text{microL}$

## Hyperkalemia (Chronic)

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
LOKELMA (sodium zirconium cyclosilicate)	VELTASSA (patiromer)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 3 months

- The requested medication must be prescribed by, or in consult with, a nephrologist
- If member is on renal dialysis, Medicare eligibility must be ruled out.
- The member's current serum potassium level must be exceeding the upper limit of normal, as evidenced by documentation from at least two separate lab values, submitted with the request
- One of the following criteria must be met:
  - The member must have failed 30-day trials with at least two of the following products
    - bumetanide, chlorothiazide, fludrocortisone, furosemide, hydrochlorothiazide, indapamide, metolazone, torsemide
- The member must not be receiving the medications known to cause hyperkalemia listed below, OR medical justification must be provided explaining why discontinuation of these agents would be clinically inappropriate in this member:
  - angiotensin-converting enzyme inhibitor
  - angiotensin II receptor blocker
  - aldosterone antagonist
  - nonsteroidal anti-inflammatory drugs (NSAIDs)

#### Non-Preferred Agent Criteria:

- The member must have failed a 30-day trial with Lokelma, as evidenced with paid claims or pharmacy print outs

#### Renewal Criteria - Approval Duration: 12 months

- The member's current serum potassium level is within normal limits or has been significantly reduced from baseline, as evidenced by lab documentation submitted with the request

## Primary Hyperoxaluria Type 1 (PH1)

CLINICAL PA REQUIRED
OXLUMO (lumasiran) – Medical Billing Only

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a nephrologist, urologist, geneticist or other provider experience in treating primary hyperoxaluria type 1 (PH1)
- Documentation of the member's diagnosis must be submitted, as evidenced by the following:
  - Mutation in the alanine: glyoxylate aminotransferase (AGXT) gene confirmed by genetic testing
  - Liver enzyme analysis confirming absent or significant deficiency in alanine: glyoxylate aminotransferase (AGT) activity
- The member does not have secondary causes of hyperoxaluria (e.g., diet with excessive intake of oxalate, gastric bypass surgery, IBD, other intestinal disorders, etc.)
- The member has had at least a 90-day trial of pyridoxine (vitamin B6) of maximally tolerated doses (maximum dose, 20 mg/kg per day) that failed to achieve at least a 30% reduction in urinary oxalate excretion
- The member has not received a liver transplant
- Documentation of the one of the following must be submitted:
  - Elevated urinary oxalate excretion (i.e., > 1 mmol/1.73 m<sup>2</sup> per day [90 mg/1.73 m<sup>2</sup> per day])
  - Elevated urinary oxalate: creatinine ratio as defined by age defined laboratory reference range
  - Elevated urinary excretion of glycolate (i.e., > 0.5 mmol/1.73 m<sup>2</sup> per day [45 mg/1.73 m<sup>2</sup> per day])

### Renewal Criteria - Approval Duration: 12 months

- The member must have experienced meaningful clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including one of the following scores and symptoms:
  - Reduced signs and symptoms of PH1 (e.g., nephrocalcinosis, formation of renal stones, renal impairment)
  - Decreased or normalized urinary oxalate excretion
  - Decreased or normalized urinary oxalate: creatinine ratio relative to normative values for age
  - Decreased or normalized plasma oxalate and glyoxylate concentrations

## Lupus Nephritis

### First Line Agents

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
cyclophosphamide	
mycophenolate	
systemic oral corticosteroids	

### Anti-CD20 Monoclonal Antibodies

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
RITUXAN (rituximab) – Medical Billing Only	

### B-Lymphocyte Stimulator (BLyS) – Specific Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BENLYSTA (belimumab) – Medical Billing Only	

### Calcineurin Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
cyclosporine	LUPKYNIS (voclosporin)

tacrolimus	
------------	--

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, a nephrologist or rheumatologist
- If member is on renal dialysis, Medicare eligibility must be ruled out.
- The member has an eGFR > 45
- The member must be using concurrently with mycophenolate and a systemic corticosteroid for 3 months, as evidenced by paid claims or pharmacy printouts.
- The member has had clinical progression (e.g., worsening of proteinuria or serum creatinine) despite a 3-month trial with Benlysta (belimumab)

Renewal Criteria - Approval Duration: 12 months

- The provider must submit documentation showing that the member has experienced clinical benefit since starting treatment, as evidenced by documentation of one of the following:
  - Improvement of proteinuria (UPCR decreased by 50% and/or below 0.5 to 0.7 g/day)
  - Improvement of serum creatinine (SCr ≤ 1.4 mg/dl)
  - Chronic steroid use to ≤ 7.5 mg/day

**Overactive Bladder**

*Topical Formulations*

<b>PREFERRED AGENTS (NO PA REQUIRED)</b>
GELNIQUE (oxybutynin)
OXYTROL (oxybutynin) PATCH

*Oral Solid Dosage Formulations*

<b>PREFERRED AGENTS (NO PA REQUIRED)</b>	<b>PREFERRED STEP 1 AGENTS (ELECTRONIC STEP)</b>	<b>NON-PREFERRED STEP 2 AGENTS (PA REQUIRED)</b>
oxybutynin ER	MYRBETRIQ (mirabegron)	darifenacin ER
oxybutynin tablet	tolterodine	DETROL (tolterodine)
solifenacin	tolterodine ER	DETROL LA (tolterodine)
tamsulosin		DITROPAN XL (oxybutynin)
TOVIAZ (fesoterodine) – <i>Brand Required</i>		dutasteride/tamsulosin
trospium		fesoterodine
		flavoxate
		FLOMAX (tamsulosin)
		GEMTESA (vibegron)
		JALYN (dutasteride/tamsulosin)
		trospium ER
		VESICARE (solifenacin)

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- The member must have had a 30-day trial of three preferred agents including Myrbetriq, as evidenced by paid claims or pharmacy printouts.

## Step Care and Concurrent Medications

- Preferred Step 1 Agents: A total of 30 days of a preferred agent at max dose must be paid within 100 days prior to step 1 agents date of service.

### Therapeutic Duplication

- One strength of one of the following medications is allowed at a time: dutasteride, Jalyn, or finasteride
- Alpha 1 blockers (alfuzosin ER, doxazosin, dutasteride-tamsulosin, prazosin, terazosin, tamsulosin) are not allowed with carvedilol or labetalol
  - Carvedilol and labetalol are nonselective beta blockers with alpha 1 blocking activity
- Anticholinergic medications (tolterodine, oxybutynin, trospium, solifenacin) are not covered with Acetylcholinesterase Inhibitors. [Click here](#) for a full listing of medications included.
  - The effects of an anticholinergic (blocks the effect of acetylcholine) and acetylcholinesterase inhibitors (prevents breakdown of acetylcholine) oppose each other, and the therapeutic effect of both products is diminished

### Non-Solid Dosage Form

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
oxybutynin syrup	MYRBETRIQ (mirabegron) SUSPENSION
	VESICARE (solifenacin) LS SUSPENSION

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have had a 30-day trial of a preferred agent, as evidenced by paid claims or pharmacy printouts.
- Must meet [Non-Solid Dosage Forms](#) criteria

### Therapeutic Duplication

- Anticholinergic medications (tolterodine, oxybutynin, trospium, solifenacin) are not covered with Acetylcholinesterase Inhibitors. [Click here](#) for a full listing of medications included.
  - The effects of an anticholinergic (blocks the effect of acetylcholine) and acetylcholinesterase inhibitors (prevents breakdown of acetylcholine) oppose each other, and the therapeutic effect of both products is diminished

## Phosphate Binders

### Solid Dosage Form

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
calcium acetate	AURYXIA (ferric citrate) TABLET
sevelamer carbonate tablet	RENAGEL (sevelamer HCl) TABLET
	REVELA (sevelamer carbonate) TABLET
	sevelamer HCl
	VELPHORO (sucroferric oxyhydroxide)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- If member is on renal dialysis, Medicare eligibility must be ruled out.



- The member must have failed a 30-day trial of sevelamer carbonate, as evidenced by paid claims or pharmacy printouts.

### Non-Solid Dosage Form

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
FOSRENOL (lanthanum) CHEWABLE TABLET – <i>Brand Required</i>	FOSRENOL (lanthanum) POWDER PACK
PHOSLYRA (calcium acetate) ORAL SOLUTION	lanthanum chew tab
RENVELA (sevelamer carbonate) POWDER PACK – <i>Brand Required</i>	sevelamer carbonate powder pack

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- If member is on renal dialysis, Medicare eligibility must be ruled out.

## Neurology

### Alzheimer's Disease

#### Cholinesterase Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
donepezil 5 mg, 10 mg tablet	ADLARITY (donepezil) PATCH
EXELON (rivastigmine) PATCH – <i>Brand Required</i>	ARICEPT (donepezil)
galantamine tablet	donepezil 23 mg tablet
galantamine ER	donepezil ODT
rivastigmine capsule	galantamine oral solution
	RAZADYNE (galantamine)
	RAZADYNE ER (galantamine)
	rivastigmine patch

#### NMDA Receptor Antagonists

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
memantine	memantine oral solution
	memantine ER capsule sprinkle
	NAMENDA (memantine)
	NAMENDA XR (memantine) CAPSULE SPRINKLE

#### Cholinesterase Inhibitors / NMDA Receptor Antagonist Combinations

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	NAMZARIC (memantine/donepezil)

### Therapeutic Duplication

- One memantine medication is allowed at a time
- Anticholinergic medications are not covered with acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine, pyridostigmine). [Click here](#) for a full listing of medications included.

- The effects of an anticholinergic (blocks the effect of acetylcholine) and acetylcholinesterase inhibitors (prevents breakdown of acetylcholine) oppose each other, and the therapeutic effect of both products is diminished

### *Electronic Diagnosis Verification*

- Memantine: Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### *Electronic Age Verification*

- Submit chart notes to verify diagnosis for members less than 30 years old

### *Prior Authorization Criteria*

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of a pharmaceutically equivalent preferred agent, as evidenced by paid claims or pharmacy printouts.
- The member must not reside in facility where medications are managed such as skilled nursing care.
- Donepezil 23 mg: Clinical justification must be provided explaining why the member is unable to use the preferred products (subject to clinical review).

## **Amyloid Beta-Directed Monoclonal Antibody**

### **CLINICAL PA REQUIRED**

ADUHELM (aducanumab-avwa) – *Medical Billing Only*

### *Prior Authorization Criteria*

#### Initial Criteria - Approval Duration: 12 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a specialist in neurology or gerontology
- The member has mild cognitive impairment (MCI) or mild Alzheimer's dementia due to Alzheimer's disease (Stage 3 or 4) as evidenced by all the following with the past 6 months:
  - objective evidence of cognitive impairment at screening
  - Positron Emission Tomography (PET) scan or Cerebral Spinal Fluid (CSF) is positive for amyloid beta plaques
- Other conditions of non-Alzheimer's dementia etiology have been ruled out (e.g., vascular dementia, dementia with Lewy bodies [DLB], frontotemporal dementia [FTD], Parkinson's Disease dementia)
- The member has received a baseline brain magnetic resonance imaging (MRI) within past year prior to initiating treatment verifying the member does not have the following:
  - acute or subacute hemorrhage
  - macrohemorrhage
  - > 4 brain microhemorrhages
  - any areas of superficial siderosis
- Documentation must be submitted including baseline disease severity utilizing one of the following scores (within the past 6 months):
  - Mini-Mental Status Exam (MMSE) score  $\geq 21$
  - Clinical Dementia Rating - Global Score (CDR-GS)  $\leq 1.0$
  - Montreal Cognitive Assessment (MoCA)  $\geq 17$

#### Renewal Criteria - Approval Duration: 12 months

- The member must have experienced meaningful clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including one of the following scores and symptoms (within the past 6 months):
  - CDR-GS of  $\leq 1.0$
  - MMSE score  $\geq 21$
  - MoCA  $\geq 17$
- Prior to the 5<sup>th</sup>, 7<sup>th</sup>, 12<sup>th</sup> infusion, documentation of recent (within the previous month) brain MRI showing one of the following:
  - $\leq 4$  new incident microhemorrhages and 1 focal area of superficial siderosis
  - radiographic stabilization since baseline (i.e., no increase in size or number of amyloid-related imaging abnormalities – hemosiderin deposition (ARIA-H))

## Amyotrophic Lateral Sclerosis (ALS)

PREFERRED AGENTS (NO PA REQUIRED)	PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
riluzole tablet	EXSERVAN (riluzole) FILM	RADICAVA (edaravone) – <i>Medical Billing Only</i>
	TIGLUTIK (riluzole) ORAL SUSPENSION	RADICAVA ORS (edaravone)
		RELYVRIO (sodium phenylbutyrate/taurursodiol) ORAL POWDER FOR SUSPENSION
		RILUTEK (riluzole) TABLET

### Prior Authorization Criteria

*Preferred Agents:* Must meet [Non-Solid Dosage Forms](#) criteria

*Non-Preferred Agents:*

Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a neurologist
- The member has had ALS symptoms present for less than 2 years
- Documentation has been submitted that the member has a forced vital capacity (FVC)  $> 80$  percent of predicted
- Documentation of one of the following has been submitted:
  - ALS Function Rating Scale-Revised (ALSFRS-R) with a score of 2 or greater on each individual item of the scale
  - Japanese ALS Severity Scale with a grade of 1 or 2
- The member must not have permanent invasive ventilation

Renewal Criteria - Approval Duration: 12 months

- Documentation of Forced Vital Capacity (FVC)  $> 60$  percent of predicted
- Documentation of a therapeutic response as evidenced by stabilization or improvement (e.g., improved neurologic impairment, motor function, quality of life, slowing of disease progression, etc.) from baseline as evidenced by one of the following:
  - ALS Function Rating Scale-Revised (ALSFRS-R)
  - Japanese ALS Severity Scale

## Anticonvulsants

### Anticonvulsant Prevention

#### Narrow Spectrum:

##### *Carbamazepine*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
carbamazepine chewable tablet	carbamazepine ER capsule
carbamazepine oral suspension	carbamazepine XR tablet
carbamazepine tablet	EPITOL (carbamazepine)
CARBATROL (carbamazepine) – <i>Brand Required</i>	TEGRETOL (carbamazepine oral suspension)
EQUETRO (carbamazepine)	TEGRETOL (carbamazepine)
TEGRETOL XR (carbamazepine) – <i>Brand Required</i>	

##### *Ethosuximide*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ethosuximide capsule	ZARONTIN (ethosuximide)
ethosuximide oral solution	ZARONTIN (ethosuximide) ORAL SOLUTION

##### *Gabapentin*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
gabapentin capsule	NEURONTIN (gabapentin) CAPSULE
gabapentin oral solution	NEURONTIN (gabapentin) ORAL SOLUTION
gabapentin tablet	NEURONTIN (gabapentin) TABLET

##### *Lacosamine*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
lacosamide oral solution	VIMPAT (lacosamide) ORAL SOLUTION
lacosamide tablet	VIMPAT (lacosamide) TABLET

##### *Oxcarbazepine*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
oxcarbazepine tablet	oxcarbazepine oral solution
OXTELLAR XR (oxcarbazepine)	TRILEPTAL (oxcarbazepine)
TRILEPTAL (oxcarbazepine) ORAL SUSPENSION – Brand Required	

##### *Pregabalin*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
pregabalin	LYRICA (pregabalin)
pregabalin oral solution	LYRICA (pregabalin) ORAL SOLUTION
	LYRICA CR (pregabalin)
	pregabalin ER

##### *Phenytoin*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
phenytoin chewable tablet	DILANTIN (phenytoin) CHEWABLE TABLET

phenytoin ER capsule	DILANTIN (phenytoin) ORAL SUSPENSION
phenytoin suspension	DILANTIN ER (phenytoin)
phenytoin sodium ER	PHENYTEK (phenytoin)

### Primidone

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
primidone	MYSOLINE (primidone)

### Tiagabine

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
GABITRIL (tiagabine) – <i>Brand Required</i>	tiagabine

### Vigabatrin

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
SABRIL (vigabatrin) TABLET – <i>Brand Required</i>	SABRIL (vigabatrin) POWDER PACK
vigabatrin powder pack	vigabatrin tablet
	VIGADRONE (vigabatrin)

### Other

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
APTIOM (eslicarbazepine)	
CELONTIN (methsuximide)	
DIACOMIT (stiripentol)	
EPIDIOLEX (cannabidiol)	
FINTEPLA (fenfluramine) ORAL SOLUTION	
phenobarbital elixir	
phenobarbital tablet	
XCOPRI (cenobamate)	
ZTALMY (ganaxolone) SUSPENSION	

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale for Diacomit, Epidiolex, and Fentepla

### Electronic Step Care and Concurrent Medications

- A total of 28 days of clobazam must be paid within 45 days prior to Diacomit.
  - Diacomit is FDA approved to be used in combination with clobazam.

### Prior Authorization Criteria:

- Pregabalin CR: See [Preferred Dosage Form](#) Criteria

### Therapeutic Duplication

- One Vimpat strength is allowed at a time
- Lyrica and gabapentin are not allowed together.

- Lyrica and gabapentin oral solutions are not allowed with benzodiazepines, muscle relaxants (except baclofen), or narcotic solid dosage forms. If a member can swallow, they should be transitioned to a solid dosage form.

Please call for an override by calling provider relations at 1-800-755-2604 if the member's medications are dispensed in solid formulations are being crushed or opened to administer because member is unable to swallow

## Broad Spectrum:

### *Clobazam*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
clobazam	ONFI (clobazam)
clobazam oral solution	ONFI (clobazam) ORAL SOLUTION
	SYMPAZAN (clobazam)

### *Divalproex/Valproic Acid*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DEPAKOTE SPRINKLE (divalproex sodium) – <i>Brand Co-Preferred</i>	DEPAKENE (valproic acid) CAPSULE
divalproex sodium ER	DEPAKENE (valproic acid) ORAL SOLUTION
divalproex sodium sprinkle	DEPAKOTE (divalproex sodium) TABLET
divalproex sodium tablet	DEPAKOTE ER (divalproex sodium)
valproic acid capsule	
valproic acid oral solution	

### *Felbamate*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
FELBATOL (felbamate) ORAL SUSPENSION - <i>Brand Required</i>	felbamate oral suspension
FELBATOL (felbamate) TABLET– <i>Brand Required</i>	felbamate tablet

### *Lamotrigine*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
lamotrigine chewable tablet	LAMICTAL (lamotrigine) CHEWABLE TABLET
lamotrigine ER	LAMICTAL (lamotrigine) DOSE PACK
lamotrigine ODT	LAMICTAL (lamotrigine) TABLET
lamotrigine ODT dose pack	lamotrigine dose pack
lamotrigine tablet	LAMICTAL ODT (lamotrigine)
SUBVENITE (lamotrigine)	LAMICTAL ODT (lamotrigine) DOSE PACK
	LAMICTAL XR (lamotrigine)
	LAMICTAL XR (lamotrigine) DOSE PACK
	SUBVENITE (lamotrigine) DOSE PACK

### *Levetiracetam*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
levetiracetam ER	ELEPSIA XR (levetiracetam)
levetiracetam oral solution	KEPPRA (levetiracetam)
levetiracetam tablet	KEPPRA (levetiracetam) ORAL SOLUTION

	KEPPRA XR (levetiracetam)
	SPRITAM (levetiracetam)

### Rufinamide

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BANZEL (rufinamide) ORAL SUSPENSION – <i>Brand Co-Preferred</i>	
BANZEL (rufinamide) TABLET – <i>Brand Co-Preferred</i>	
rufinamide suspension	
rufinamide tablet	

### Topiramate

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
EPRONTIA (topiramate) SOLUTION	TOPAMAX (topiramate)
QUDEXY XR (topiramate) SPRINKLE CAPSULE – <i>Brand Required</i>	TOPAMAX (topiramate) SPRINKLE CAPSULE
topiramate sprinkle capsule	topiramate ER sprinkle cap
topiramate tablet	
TROKENDI XR (topiramate)	

### Other

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BRIVIACT (brivaracetam)	
FYCOMPA (perampanel)	
FYCOMPA (perampanel) ORAL SUSPENSION	
zonisamide	

## Anticonvulsant Rescue Therapies

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DIASTAT PEDIATRIC (diazepam) RECTAL GEL – <i>Brand Required</i>	diazepam pediatric rectal gel
DIASTAT ACUDIAL (diazepam) RECTAL GEL – <i>Brand Required</i>	diazepam rectal gel
NAYZILAM (midazolam) NASAL SPRAY	
VALTOCO (diazepam) NASAL SPRAY	

## Duchenne Muscular Dystrophy

### Corticosteroids

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
prednisone	EMFLAZA (deflazacort)

### Prior Authorization Criteria

#### [Prior Authorization Form - Emflaza](#)

- In the FOR-DMD trial:



- Slowing of growth was greater with daily deflazacort compared with daily prednisone. The difference in height at three years for daily prednisone compared with daily deflazacort was 2.3 cm (98.3% CI 0.7-3.9 cm)
- Weight gain was greater with daily prednisone compared with daily deflazacort. The difference in weight gain for daily prednisone compared with daily deflazacort was 2.6 kg (98.3% CI 0.2-5.0 kg)

Initial Criteria - Approval Duration: 6 months

- Diagnosis must be confirmed by the documented presence of abnormal dystrophin or a confirmed mutation of the dystrophin gene
- The requested medication must be prescribed by, or in consult with, a physician who specializes in the treatment of Duchenne Muscular Dystrophy (DMD) and/or neuromuscular disorders
- Onset of weakness must have occurred before 2 years of age
- The member must have serum creatinine kinase activity of at least 10 times the upper limit of normal (ULN) prior to initiating treatment
- The member must have failed a 6-month trial of prednisone, as evidenced by paid claims or pharmacy printouts
- The provider must submit baseline motor milestone score results from at least ONE the following assessments:
  - 6-minute walk test (6MWT)
  - North Star Ambulatory Assessment (NSAA)
  - Motor Function Measure (MFM)
  - Hammersmith Functional Motor Scale (HFMS)
- The member must have ONE of the following significant intolerable adverse effects supported by documentation:
  - Cushingoid appearance
  - Central (truncal) obesity
  - Undesirable weight gain (>10% of body weight gain increase over 6-month period)
  - Diabetes and/or hypertension that is difficult to manage
  - Severe behavioral adverse effect

Renewal Criteria - Approval Duration: 12 months

- The member must have improvement in motor milestone score from baseline from ONE the following assessments:
  - 6MWT – improvement of 20 meters from baseline
  - NSAA – improvement of 2 points from baseline
  - MFM – improvement of 2 points from baseline
  - HFMS – improvement of 2 points from baseline
- The member must have had improvement of adverse effects experienced on prednisone supported by documentation:
  - Cushingoid appearance
  - Central (truncal) obesity
  - Undesirable weight gain (>10% of body weight gain increase over 6-month period)
  - Diabetes and/or hypertension that is difficult to manage
  - Severe behavioral adverse effect

## Genetic Therapies

### Exon 45 Skipping

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AMONDYS 45 (casimersen) – <i>Medical Billing Only</i>	

### Exon 51 Skipping

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
EXONDYS 51 (eteplirsen) – Medical Billing Only	

### Exon 53 Skipping

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
VILTEPSO (viltolarsen) – Medical Billing Only	VYONDYS 53 (golodirsen) – Medical Billing Only

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 8 weeks

- The member must be assigned male at birth between ages of 4 and 19 years old
- Diagnosis must be confirmed by the documented presence of abnormal dystrophin or a confirmed mutation of the dystrophin gene
- The requested medication must be prescribed by, or in consult with, a physician who specializes in the treatment of Duchenne Muscular Dystrophy (DMD) and/or neuromuscular disorders
- The member has had an inadequate treatment response with standard corticosteroid therapy for a minimum of 6 months with adherence, as evidenced by paid claims or pharmacy printouts
- Medical records must be provided confirming the member has:
  - A baseline 6-Minute Walk Time (6MWT)  $\geq$  300 meters while walking independently (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)
  - Stable respiratory function – FVC predicted  $>$  50%, not requiring ventilatory assistance
  - Stable cardiac function – LVEF  $>$  40 % by ECHO
- Weight and calculated dose must be provided consistent with approved FDA dose
- The member must not be taking any other RNA antisense agent or any other gene therapy

#### Non-Preferred Agent Criteria (Initial)

- Please provide explanation with the request why the preferred agent cannot be used (subject to clinical review)

#### Renewal Criteria - Approval Duration: 12 months

- Medical records must be provided confirming the member has maintained:
  - A 6MWT  $\geq$  300 meters while walking independently (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)
  - Stable respiratory function – FVC predicted  $>$  50%, not requiring ventilatory assistance
  - Stable cardiac function – LVEF  $>$  40 % by ECHO

## Huntington's Disease

CLINICAL PA REQUIRED
AUSTEDO (deutetrabenazine)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The requested medication must be prescribed by, or in consult with, a neurologist or psychiatrist
- The member must have failed a 3-month trial of tetrabenazine, as evidenced by paid claims or pharmacy printouts

## Hypersomnolence (Narcolepsy and Idiopathic Hypersomnia)

PREFERRED AGENTS (NO PA REQUIRED)	PREFERRED STEP 1 AGENTS (ELECTRONIC STEP)	NON-PREFERRED AGENTS (PA REQUIRED)
armodafinil	SUNOSI (solriamfetol)	NUVIGIL (armodafinil)
modafinil	XYREM (sodium oxybate)	PROVIGIL (modafinil)
		sodium oxybate
		WAKIX (pitolisant)
		XYWAV (sodium, calcium, magnesium, potassium oxybate)

### Electronic Step Care and Concurrent Medications

- Sunosi and Xyrem requires a 30-day trial of armodafinil to be paid within 60 days of submitted claim
- Wakix requires titration to 17.8 mg dose with 4.45 mg tablets.

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed 30-day trials of each preferred agent (except Sunosi for idiopathic hypersomnia) and at least 1 additional CNS stimulant indicated for treatment of narcolepsy, as evidenced by paid claims or pharmacy printouts
- Documentation of each treatment failure must be provided, as evidenced by one of the following:
  - Multiple Sleep Latency Test (MSLT) <8 minutes
  - EPWORTH sleepiness scale score ≥10
- Xywav Only:
  - The member must have failed a 30-day trial with Wakix
  - Clinical justification must be provided explaining why the member is unable to Xyrem due to sodium content (subject to clinical review).

#### Renewal Criteria - Approval Duration: 12 months

- Provider must submit documentation of symptom improvement, as evidenced by documentation of one of the following, while on prior treatments:
  - Multiple Sleep Latency Test (MSLT) <8 minutes
  - EPWORTH sleepiness scale score ≥10

### Therapeutic Duplication

- Sunosi and Wakix are not allowed together
- Provigil and Nuvigil are not allowed together
- Xyrem, Xywav is not allowed with sleeping medication or benzodiazepines

### Underutilization

- Wakix, Sunosi, and Xywav must be used adherently and will reject on point of sale for late fill

## Prophylaxis of Migraine

### Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AIMOVIG (erenumab-oooe) INJECTION	NURTEC ODT (rimegepant) TABLETS
AJOVY (fremanezumab-vfrm) INJECTION	QULIPTA (atogepant) TABLETS
EMGALITY (galcanzumab-gnlm) INJECTION	VYEPTI (eptinezumab-jjmr) – <i>Medical Billing Only</i>

#### *Prior Authorization Criteria*

#### [Prior Authorization Form – Migraine Prophylaxis/Treatment](#)

#### Initial Criteria - Approval Duration: 6 months

- The member must experience 3 or more migraine days per month
- The member must have failed 2-month trials of at least two of the following agents from different therapeutic classes, as evidenced by paid claims or pharmacy printouts:
  - amitriptyline, atenolol, divalproex sodium, metoprolol, nadolol, propranolol, timolol, topiramate, venlafaxine
- Documentation must include clinical notes regarding failure of prior treatments to reduce migraine frequency after each 2-month trial.

#### *Non-Preferred Agents Criteria:*

- The member must have failed a 3-month trial of each preferred agent, as evidenced by paid claims or pharmacy printouts.
- Vyepti Only:
  - The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
  - The prescriber is, or is in consult with a neurologist, or specialist in migraine treatment and prevention
  - The member must have failed a 3-month trial of each self-administered CGRP (Ajovy, Emgality, and Aimovig), as evidenced by paid claims or pharmacy printouts.

#### Renewal Criteria - Approval Duration: 12 months

- The member must have experienced at least a 50% reduction in migraines from baseline

## Treatment of Migraine

### Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
NURTEC ODT (rimegepant)	UBRELVY (ubrogepant)

#### *Prior Authorization Criteria*

#### [Prior Authorization Form – Migraine Prophylaxis/Treatment](#)

#### Initial Criteria - Approval Duration: 3 months

- The member must have failed a 30-day trial of two triptans (5HT-1 Agonists) of unique ingredients, as evidenced by paid claims or pharmacy printouts.

### Non-Preferred Agents Criteria:

- The member must have failed a 30-day trial of the preferred agent, as evidenced by paid claims or pharmacy printouts.

### Therapeutic Duplication

- One strength of one medication for treatment of migraine is allowed at a time

## Serotonin (5-HT) 1F Receptor Agonist

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	REYVOW (lasmiditan)

### Prior Authorization Criteria

#### [Prior Authorization Form – Migraine Prophylaxis/Treatment](#)

#### Initial Criteria - Approval Duration: 3 months

- The member must have failed a 30-day trial of two triptans (5HT-1 Agonists) of unique ingredients, as evidenced by paid claims or pharmacy printouts.
- The member must have failed a 30-day trial of Nurtec ODT, as evidenced by paid claims or pharmacy printouts.

### Therapeutic Duplication

- One strength of one medication for treatment of migraine is allowed at a time

### Therapeutic Duplication

- One strength of one medication for treatment of migraine is allowed at a time

## Ergot Alkaloids

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	D.H.E.45 (dihydroergotamine) INJECTION
	dihydroergotamine injection
	dihydroergotamine nasal spray
	ERGOMAR (ergotamine) SL TABLET
	MIGERGOT (ergotamine/caffeine) RECTAL SUPPOSITORY
	TRUDHESA (dihydroergotamine)

### Prior Authorization Criteria

#### [Prior Authorization Form – Migraine Prophylaxis/Treatment](#)

#### Initial Criteria - Approval Duration: 3 months

- The member must have failed a 30-day trial of two triptans (5HT-1 Agonists) of unique ingredients, as evidenced by paid claims or pharmacy printouts.

- The member must have failed a 30-day trial of Nurtec ODT, as evidenced by paid claims or pharmacy printouts.

### Therapeutic Duplication

- One strength of one medication for treatment of migraine is allowed at a time

## Triptans (5HT-1 Agonists)

### Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED STEP 1 AGENTS (PA REQUIRED)	NON-PREFERRED STEP 2 AGENTS (PA REQUIRED)
RELPAK (eletriptan) TABLET – <i>Brand Required</i>	FROVA (frovatriptan) TABLET – <i>Brand Required</i>	almotriptan tablet
rizatriptan tablet	naratriptan tablet	AMERGE (naratriptan) TABLET
sumatriptan tablet	zolmitriptan tablet	eletriptan tablet
		frovatriptan tablet
		IMITREX (sumatriptan) TABLET
		MAXALT (rizatriptan) TABLET
		sumatriptan/naproxen tablet
		TREXIMET (sumatriptan/naproxen) TABLET
		ZOMIG (zolmitriptan) TABLET

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

#### Non-Preferred Step 1 Agents:

- The member must have failed a 30-day trial of rizatriptan, as evidenced by paid claims or pharmacy printouts.
- Members over 18 years old: The member must also have failed a 30-day trial of Relpax (eletriptan), as evidenced by paid claims or pharmacy printouts.

#### Non-Preferred Step 2 Agents:

- The member must have failed a 30-day trial of each available preferred triptan agent, as evidenced by paid claims or pharmacy printouts

### Therapeutic Duplication

- One strength of one medication for treatment of migraine is allowed at a time

### Non-Solid Oral Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
rizatriptan ODT	MAXALT MLT (rizatriptan)
	zolmitriptan ODT

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of rizatriptan ODT, as evidenced by paid claims or pharmacy printouts.

### Therapeutic Duplication

- One strength of one medication for treatment of migraine is allowed at a time

### Nasal Spray

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
IMITREX (sumatriptan) NASAL SPRAY – <i>Brand Required</i>	ONZETRA XSAIL (sumatriptan) NASAL SPRAY
ZOMIG (zolmitriptan) NASAL SPRAY – <i>Brand Required</i>	sumatriptan spray
	TOSYMRA (sumatriptan) NASAL SPRAY
	zolmitriptan spray

### Injectable

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
IMITREX (sumatriptan) 0.6 MG/0.5 ML CARTRIDGE – <i>Brand Required</i>	IMITREX (sumatriptan) 0.4 MG/0.5 ML CARTRIDGE
	IMITREX (sumatriptan) 0.4 MG/0.5 ML SYRINGE
	IMITREX (sumatriptan) PEN INJECTOR
	sumatriptan cartridge
	sumatriptan pen injector
	sumatriptan vial
	ZEMBRACE SYMTOUCH (sumatriptan)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must be unable to take oral medications (subject to clinical review).
- The member must have had a 30-day trial of a preferred injectable and preferred nasal spray, as evidenced by paid claims and pharmacy printouts.

### Therapeutic Duplication

- One strength of one medication for treatment of migraine is allowed at a time

## Cluster Headache

### Cluster Headache Prevention

#### CLINICAL PA REQUIRED

EMGALITY (galcanazumab-gnlm)

- Emgality is to be used as preventative treatment during episodic cluster headache episodes (cluster periods usually last between 2 weeks and 3 months with pain-free periods lasting at least 3 months), as it is not indicated for chronic use



## Prior Authorization Criteria

### [Prior Authorization Form – Migraine Prophylaxis/Treatment](#)

#### Initial Criteria - Approval Duration: 3 months

- The member has had at least five attacks fulfilling criteria A-C
  - A. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting at least 15 minutes
  - B. Occurring with a frequency of at least every other day
  - C. The member must have at least one of the following:
    - A sense of restlessness or agitation
    - Any of the following symptoms or signs, ipsilateral to the headache:
      - Conjunctival injection and/or lacrimation
      - Nasal congestion and/or rhinorrhea
      - Eyelid edema
      - Forehead and facial swelling
      - Miosis and/or ptosis
- The member must have had a 2-month trial with verapamil

## Myasthenia Gravis

### *Acetylcholinesterase inhibitor*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
neostigmine	
pyridostigmine	

### *Immunotherapy*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
RITUXAN (rituximab) – <i>Medical Billing Only</i>	SOLIRIS (eculizumab) – <i>Medical Billing Only</i>
ULTOMIRIS (ravulizumab) – <i>Medical Billing Only</i>	
VYVGART (ergatigimod alfa) – <i>Medical Billing Only</i>	

## Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational).
- The requested medication must be prescribed by, or in consult with, a neurologist
- The following documentation must be submitted:
  - The member has a Myasthenia Gravis Foundation of America (MGFA) clinical classification class of II, III, or IV
  - The member has a Myasthenia Gravis-specific Activities of Daily Living (MG-ADL) total score  $\geq 6$
  - Documented baseline Quantitative Myasthenia Gravis (QMG) score  $\geq 12$
  - The member has a positive serological test for anti-AChR antibodies (lab test must be submitted)
- The member has failed a 90-day trial of an acetylcholinesterase inhibitor

#### Non-Preferred Agent Criteria:

- The member has failed both of the following:
  - A 12-month trial (total duration) of at least two (2) immunosuppressive therapies (e.g., azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide)
  - The member required chronic intravenous immunoglobulin (IVIG) or chronic plasmapheresis/plasma exchange (i.e., at least every 3 months over 12 months without symptom control)

Renewal Criteria - Approval Duration: 12 months

- The member must have experienced meaningful clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including one of the following scores and symptoms:
  - Decreased rate of Myasthenia Gravis exacerbations
  - A 2-point improvement in the member's total MG-ADL score
  - A 3-point improvement in QMG total score

## Multiple Sclerosis

### Injectable Agents

#### B-cell and T-cell Therapies

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BRIUMVI (ublituximab-xiyy) – <i>Medical Billing Only</i>	MAVENCLAD (cladribine)
KESIMPTA (ofatumumab)	TYSABRI (natalizumab) – <i>Medical Billing Only</i>
LEMTRADA (alemtuzumab) – <i>Medical Billing Only</i>	
OCREVUS (ocrelizumab) – <i>Medical Billing Only</i>	

#### Interferons

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AVONEX (interferon beta-1A) PEN	EXTAVIA (interferon beta-1B)
AVONEX (interferon beta-1A) SYRINGE	PLEGRIDY (peginterferon beta-1A) PEN
AVONEX (interferon beta-1A) VIAL	PLEGRIDY (peginterferon beta-1A) SYRINGE
BETASERON (interferon beta-1B)	
REBIF (interferon beta-1A)	
REBIF REBIDOSE (interferon beta-1A)	

#### Non-Interferons

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
COPAXONE (glatiramer) 20 MG/ML – <i>Brand Required</i>	COPAXONE (glatiramer) 40 MG/ML
	glatiramer 20mg/ml
	glatiramer 40mg/ml
	GLATOPA (glatiramer)

#### Prior Authorization Criteria

Initial Criteria - Approval Duration: 12 months

- The member must have failed a 3-month trial of an agent from each available preferred multiple sclerosis class, as evidenced by paid claims
- Copaxone: See [Preferred Dosage Form](#) Criteria

### Oral Agents

#### Fumerates

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
dimethyl fumarate	BAFIERTAM (monomethyl fumarate)
	TECFIDERA (dimethyl fumarate)

	VUMERITY (diroximel fumarate)
--	-------------------------------

*Pyrimidine Synthesis Inhibitor*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AUBAGIO (teriflunomide)	

*Sphingosine 1-Phosphate (S1P) Receptor Modulators*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
GILENYA (fingolimod) – <i>Brand Required</i>	fingolimod
TASCENSO ODT (fingolimod)	MAYZENT (siponimod)
	PONVORY (ponesimod)
	ZEPOSIA (ozanimod)

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- The member must have failed a 3-month trial of an agent from each available preferred multiple sclerosis class, as evidenced by paid claims

**Neuromyelitis Optica Spectrum Disorder**

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
UPLIZNA (inebilizumab) – <i>Medical Billing Only</i>	SOLIRIS (eculizumab) – <i>Medical Billing Only</i>

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational).
- The requested medication must be prescribed by, or in consult with, a neurologist
- The member has positive serologic test for anti-AQP4 antibodies.
- The member has a history of  $\geq 1$  relapses that required rescue therapy within the past 12 months
- The member has an Expanded Disability Status Score (EDSS) of  $\leq 6.5$
- The member must have one of the core clinical characteristics from the following:
  - Optic neuritis
  - Acute myelitis
  - Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting
  - Acute brainstem syndrome
  - Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
  - Symptomatic cerebral syndrome with NMOSD-typical brain lesions

*Non-Preferred Agents Criteria*

- The member must have had a 3-month trial with Enspryng and/or Uplizna

Renewal Criteria - Approval Duration: 12 months

- The member must have experienced stabilization, slowing of disease progression, or improvement of the condition since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including:
  - Reduction in relapse rate
  - Reduction in symptoms (such as pain, fatigue, motor function)

## Pseudobulbar Affect (PBA)

### CLINICAL PA REQUIRED

NUDEXTA (dextromethorphan/quinidine)

#### *Prior Authorization Criteria*

#### [Prior Authorization Form - Nuedexta](#)

#### Initial Criteria - Approval Duration: 3 months

- The member must not have a diagnosis of any of the following: prolonged QT interval, heart failure, or complete atrioventricular (AV) block
- Documentation of the following must be provided:
  - Baseline Center for Neurological Studies lability (CNS-LS) score
  - Baseline weekly PBA episode count
- The member must have diagnosis of pseudobulbar affect (PBA) due to one of the following neurologic conditions and meet additional criteria for diagnosis:
  - Amyotrophic Lateral Sclerosis (ALS)
  - Multiple Sclerosis (MS)
  - Alzheimer's Disease
  - Stroke
- For diagnosis of PBA due to Alzheimer's disease or stroke only:
  - Neurologic condition must have been stable for at least 3 months
  - Member must have failed a 3-month trial of at least one medication from each of the following classes, as evidenced by paid claims or pharmacy print outs:
    - **SSRIs**: sertraline, fluoxetine, citalopram and paroxetine
    - **Tricyclic Antidepressants**: nortriptyline and amitriptyline
  - Documentation of each treatment failure of SSRI and tricyclic antidepressant must be provided, as evidenced by a PBA episode count and CNS-LS score before and after each trial showing one of the following:
    - PBA count has not decreased by more than 75 percent from baseline
    - CNS-LS score has not decreased by more than 7 points from baseline

#### Renewal Criteria - Approval Duration: 6 months

- Benefit of continued therapy must be assessed.
  - Spontaneous improvement of PBA occurs and should be ruled out periodically before continuing medication.
- Baseline and current PBA episode count must be included with request
  - Current PBA episode must be reduced by at least 75% from baseline
- For diagnosis of PBA due to Alzheimer's disease or stroke only:
  - Baseline and current Center for Neurological Studies lability (CNS-LS) must be included with request
  - Current CNS-LS score must be reduced by at least 30% from baseline

## Parkinson's disease

### Parkinson's Agents - Adenosine Receptor Agonist

### CLINICAL PA REQUIRED

NOURIANZ (Istradefylline)

#### *Prior Authorization Criteria*

#### Initial Criteria - Approval Duration: 12 months

- The requested medication must be prescribed by, or in consult with, a neurologist
- Documentation must be provided describing deterioration in quality of response to levodopa/carbidopa therapy, including currently experiencing intermittent hypomobility, or “off” episodes (number and frequency)
- The member must have had inadequate response to rasagiline and selegiline, as evidenced by paid claims or pharmacy printouts

### Parkinson’s Agents – Anticholinergics

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
benztropine	COGENTIN (benztropine)
trihexyphenidyl	

### Parkinson’s Agents – COMT inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
entacapone	COMTAN (entacapone)
TASMAR (tolcapone) – <i>Brand Required</i>	ONGENTYS (opicapone)
	tolcapone

#### Prior Authorization Criteria

##### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of preferred agents, as evidenced by paid claims or pharmacy printouts

### Parkinson’s Agents - Dopamine Precursor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
carbidopa-levodopa-entacapone 25 mg/100 mg, 37.5 mg/150 mg, 50 mg/200 mg	carbidopa-levodopa-entacapone 12.5 mg/50 mg, 18.75 mg/75 mg, 31.25 mg/125 mg
carbidopa-levodopa	SINEMET (carbidopa-levodopa) TABLET
carbidopa-levodopa ER	STALEVO (carbidopa-levodopa-entacapone)
carbidopa-levodopa ODT	
RYTARY (carbidopa-levodopa) ER CAPSULE	

#### Prior Authorization Criteria

- See [Preferred Dosage Form](#) Criteria

### Parkinson’s Agents - Dopaminergic Agents for Intermittent Treatment of Off Episode

#### Subcutaneous

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
APOKYN (apomorphine) – <i>Brand Required</i>	apomorphine

#### Enteral Suspension

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DUOPA (levodopa/carbidopa)	

## Inhalation

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
INBRIJA (levodopa)	

## Sublingual

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
KYNMOBI (apomorphine)	

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months

- The requested medication must be prescribed by, or in consult with, a neurologist
- The member must be currently taking carbidopa – levodopa, as evidenced by paid claims or pharmacy printouts, and will continue taking carbidopa – levodopa concurrently with requested agent
- Documentation must be provided of intermittent hypomobility or off episodes (number and frequency)
- At least one of the following criteria must be met:
  - The member is experiencing unpredictable off periods, morning off, delayed on, no on or failure of on response
  - The member is experiencing wearing off episodes or other levodopa dose cycle related dystonias or akathisias, and a treatment adjustment plan is attached (e.g., levodopa dose and interval adjustments, bedtime dose of CR or ER levodopa/ carbidopa, addition of adjunctive therapy)

## Parkinson's Agents – Ergot Dopamine Receptor Agonists

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
bromocriptine	PARLODEL (bromocriptine)
cabergoline	

## Parkinson's Agents – MAO-B Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
rasagiline	AZILECT (rasagiline)
selegiline	EMSAM (selegiline) PATCH
ZALAPAR ODT (selegiline)	XADAGO (safinamide)

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of selegiline, as evidenced by paid claims or pharmacy printouts
- Xadago Only:
  - The requested medication must be prescribed by, or in consult with, a psychiatrist or neurologist
  - The member must be currently experiencing intermittent hypomobility or “off” episodes
  - The member must be currently taking an extended-release formulation of carbidopa – levodopa, as evidenced by paid claims or pharmacy printouts, and will continue taking carbidopa – levodopa concurrently with requested agent
  - The member must be exhibiting deterioration in quality of response to during levodopa/carbidopa therapy for intermittent hypomobility, or “off” episodes
  - The member must have failed a 30-day trial of rasagiline and selegiline, as evidenced by paid claims or pharmacy printouts

## Parkinson's Agents - Non-ergot Dopamine Receptor Agonists Maintenance

### Oral

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
pramipexole IR	MIRAPEX (pramipexole)
ropinirole IR	MIRAPEX ER (pramipexole)
ropinirole ER	pramipexole ER
	REQUIP (ropinirole)

### Topical

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	NEUPRO (rotigotine) PATCH

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must not reside in facility where medications are managed such as skilled nursing care.
- Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review).
- Pramipexole ER: See [Preferred Dosage Form](#) Criteria

## Parkinson's Agents – Other

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
amantadine IR capsule	amantadine IR tablet
amantadine solution	GOCOVRI (amantadine ER)
	OSMOLEX ER (amantadine ER)

### Electronic Age Verification:

- Amantadine: Member must be 18 years old or older

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must not reside in facility where medications are managed such as skilled nursing care.
- See [Preferred Dosage Form](#) Criteria

## Spinal Muscular Atrophy (SMA)

### SMN2 Gene Splicing Modifiers

CLINICAL PA REQUIRED
EVRYSDI (risdiplam)
SPINRAZA (nusinersen) – <i>Medical Billing Only</i>

### Prior Authorization Criteria

#### [Prior Authorization Form - Evrysdi](#)

#### Initial Criteria - Approval Duration: 12 months



- The member must have a diagnosis of spinal muscular atrophy (SMA) with each of the following (as evidenced with submitted documentation):
  - Bi-allelic deletions or mutations of SMN1 as confirmed by genetic testing, reported as one of the following:
    - Homozygous deletions of exon 7
    - Compound heterozygous mutations
  - One of the following:
    - The member has number of SMN2 gene copies  $\geq 1$  but  $\leq 4$  as confirmed by genetic testing
    - The member is symptomatic (e.g., loss of reflexes, motor delay, motor weakness, abnormal EMG/neuromuscular ultrasound)
- The requested medication must be prescribed by, or in consult with, a neuromuscular neurologist or neuromuscular physiatrist
- The member must visit with a neuromuscular clinic once per year and clinic name, contact information, and date of last visit must be provided
- The member must not require continuous intubation > 3 weeks
- The member must not have received gene therapy (i.e., Zolgensma)
- The member's weight and prescribed dose must be provided and within dosing recommendations per the manufacturer label
- Documentation must be provided of the member's current motor function, as evidenced by scores from at least two of the following assessments
  - Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorder (CHOP-INTEND)
  - Hammersmith Infant Neurological Examination (HINE) Section 2 motor milestone score
  - Hammersmith Functional Motor Scale Expanded (HFMSSE)
  - Motor Function Measure – 32 items (MFM-32)
  - Revised Upper Limb Module (RULM)
  - 6-minute walk test (6MWT)
  - Forced Vital Capacity (FVC) via Pulmonary Function Test
- Spinraza Only: The member must not have severe contractures or severe scoliosis

Renewal Criteria - Approval Duration: 12 months

- The member's weight and prescribed dose must be provided and within dosing recommendations per the manufacturer label
- The member must visit with a neuromuscular clinic once per year and clinic name, contact information, and date of last visit must be provided
- The provider must submit documentation showing that the member has experienced clinical benefit (defined as maintenance of baseline motor function or significant slowed rate of decline vs expected natural course of the disease) since starting treatment, as evidenced by documentation of one of the following:
  - Current Forced Vital capacity (FVC and FEV1) via Pulmonary Function Test
  - CHOP-INTEND, HINE, HFMSSE, MFM-32, 6MWT, or RULM scores

## Gene Therapy

<b>CLINICAL PA REQUIRED</b>
ZOLGENSMA (onasemnogene abeparvovec) – <i>Medical Billing Only</i>

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 1 month (Approval is limited to a single intravenous infusion per lifetime)

- The member is less than 2 years of age
- The diagnosis is spinal muscular atrophy (SMA) with genetic testing confirming bi-allelic deletions or mutations in the *SMN1* gene
- The medication is prescribed per the dosing guidelines in the package insert (recommended dose is  $1.1 \times 10^{14}$  vector genomes per kilogram)

- Baseline Documentation has been provided confirming anti-adeno-associated virus serotype 9 (anti-AAV9) antibody titer is  $\leq 1:50$  measured by Enzyme-linked Immunosorbent Assay (ELISA) binding immunoassay
- Member must not have advanced SMA evidenced by one of the following
  - Complete paralysis of limbs
  - Permanent ventilator dependence (defined as requiring invasive ventilation (tracheostomy) or respiratory assistance for 16 or more hours per day (including noninvasive ventilatory support) continuously for 14 or more days in the absence of an acute reversible illness, excluding perioperative ventilation.

## Tardive Dyskinesia

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AUSTEDO (deutetrabenazine)	
INGREZZA (valbenazine)	
tetrabenazine	

### Electronic Step Care and Concurrent Medications

- If titrating Ingrezza, please use Initiation Pack before continuing therapy with 80 mg capsules
  - The 30-count 40 mg bottle is not packaged for titration to 80 mg. If therapy is expected to be continued at 40 mg at time of drug initiation, please call for override.

### Prior Authorization Criteria

#### [Prior Authorization Form – Tardive Dyskinesia](#)

#### Initial Criteria - Approval Duration: 12 months

- The requested medication must be prescribed by, or in consult with, a neurologist or psychiatrist
- The member must have a diagnosis of tardive dyskinesia, including the following:
  - Involuntary athetoid or choreiform movements
  - History of treatment with dopamine receptor blocking agent (DRBA)
  - Symptom duration lasting longer than 4-8 weeks

## Ophthalmology

### Antihistamines

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
azelastine	ALOCRI (nedocromil)
BEPREVE (bepotastine) – <i>Brand Required</i>	ALOMIDE (lodoxamide)
cromolyn	bepotastine
olopatadine 0.1%	epinastine
PAZEO (olopatadine)	olopatadine 0.2%
	ZERVIA (cetirizine)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed 30-day trials of at least 3 preferred agents, as evidenced by paid claims or pharmacy printouts.

## Anti-infectives

### Drops

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BESIVANCE (besifloxacin) DROPS	AZASITE (azithromycin) DROPS
ciprofloxacin drops	CILOXAN (ciprofloxacin) DROPS
gentamicin sulfate drops	gatifloxacin drops
moxifloxacin drops	levofloxacin drops
neomycin SU/polymyxin B/gramicidin drops	NATACYN (natamycin) DROPS
ofloxacin drops	OCUFLOX (ofloxacin) DROPS
polymyxin B/trimethoprim drops	POLYTRIM (polymyxin B/trimethoprim) DROPS
sulfacetamide drops	VIGAMOX (moxifloxacin) DROPS
tobramycin drops	ZYMAXID (gatifloxacin) DROPS

### Ointment

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
bacitracin/polymyxin B ointment	bacitracin ointment
CILOXAN (ciprofloxacin) OINTMENT	NEO-POLYCIN (neomycin SU/bacitracin/polymyxin B) OINTMENT
erythromycin ointment	POLYCIN (bacitracin/polymyxin B) OINTMENT
GENTAK (gentamicin sulfate) OINTMENT	sulfacetamide ointment
neomycin SU/bacitracin/polymyxin B ointment	
TOBREX (tobramycin) OINTMENT	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 5-day trial of a preferred agent in each unique therapeutic class, as evidenced by paid claims or pharmacy printouts.

## Anti-infectives/Anti-inflammatories

### Drops

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
neomycin/polymyxin b/dexamethasone drops	MAXITROL (neomycin/polymyxin b/dexamethasone) DROPS
PRED-G (gentamicin/prednisol ac) DROPS	neomycin/polymyxin b/hydrocortisone drops
sulfacetamide/prednisolone drops	tobramycin/dexamethasone drops
TOBRADEX (tobramycin/dexamethasone) DROPS – Brand Required	
TOBRADEX ST (tobramycin/dexamethasone) DROPS	
ZYLET (tobramycin/lotepred etab) DROPS	

### Ointment

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
neomycin/polymyxin b/dexamethasone ointment	BLEPHAMIDE S.O.P. (sulfacetamide/prednisolone) ointment
TOBRADEX (tobramycin/dexamethasone) OINTMENT	MAXITROL

	(neomycin/polymyxin b/dexamethasone) OINTMENT
	neomycin/bacitracin/polymyxin b/hydrocortisone ointment
	NEO-POLYCIN HC (neomycin SU/bacitracin/polymyxin B/hydrocortisone) OINTMENT
	PRED-G (gentamicin/prednisol ac) OINTMENT

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 5-day trial of a preferred agent in each unique therapeutic class, as evidenced by paid claims or pharmacy printouts.

## Anti-inflammatories

### Corticosteroids

#### Drops

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ALREX (loteprednol) DROPS	dexamethasone sodium phosphate drops
FLAREX (fluorometholone) DROPS	difluprednate drops
fluorometholone drops	DUREZOL (difluprednate) DROPS
FML FORTE (fluorometholone) DROPS	EYSUVIS (loteprednol) DROPS
LOTEMAX (loteprednol) DROPS – Brand Required	INVELTYS (loteprednol) DROPS
LOTEMAX (loteprednol) GEL DROPS – Brand Required	FML (fluorometholone) DROPS
MAXIDEX (dexamethasone) DROPS	LOTEMAX SM (loteprednol) DROPS
PRED MILD 0.12% (prednisolone acetate) DROPS	loteprednol eye drops
prednisolone acetate 1% drops	loteprednol gel eye drops
prednisolone sodium phosphate 1% drops	PRED FORTE 1% (prednisolone acetate) DROPS

#### Ointment

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
FML S.O.P. (fluorometholone) OINTMENT	
LOTEMAX (loteprednol) OINTMENT	

### Non-Steroidal Anti-inflammatory Drugs (NSAIDS)

#### Drops

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ACUVAIL (ketorolac) DROPS	ACULAR (ketorolac) DROPS
BROMSITE (bromfenac sodium) DROPS	ACULAR LS (ketorolac) DROPS
diclofenac sodium drops	bromfenac sodium drops
ILEVRO (nepafenac) DROPS	
ketorolac tromethamine 0.4% drops	
ketorolac tromethamine 0.5% drops	
NEVANAC (nepafenac) DROPS	

PROLENSA (bromfenac) DROPS	
----------------------------	--

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 5-day trial of each preferred agent in the respective therapeutic class, as evidenced by paid claims or pharmacy printouts.

## Dry Eye Syndrome

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED STEP 1 AGENTS (PA REQUIRED)	NON-PREFERRED STEP 2 AGENTS (PA REQUIRED)
RESTASIS (cyclosporine) DROPPERETTE	XIIDRA (lifitegrast)	CEQUA (cyclosporine)
		cyclosporine dropperette
		RESTASIS MULTIDOSE (cyclosporine)
		TYRVAYA (varenicline) NASAL SPRAY

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

#### *Non-Preferred Step 1 Agents:*

- The member must have failed a 14-day trial of the preferred agent, as evidenced by paid claims or pharmacy printouts.

#### *Non-Preferred Step 2 Agents:*

- The member must have failed a 14-day trial of the preferred agent, as evidenced by paid claims or pharmacy printouts.
- The member must have failed a 30-day trial of Xiidra, as evidenced by paid claims or pharmacy printouts.
- Clinical justification must be provided explaining why the member is unable to use all other products (subject to clinical review).

## Glaucoma

### Alpha Adrenergic

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ALPHAGAN P 0.1% (brimonidine) DROPS	brimonidine 0.15% drops
ALPHAGAN P 0.15% (brimonidine) DROPS – Brand Required	brimonidine-timolol 0.2%-0.5% drops
apraclonidine 0.5% drops	
brimonidine 0.2% drops	
COMBIGAN (brimonidine-timolol) DROPS – Brand Required	
IOPIDINE (apraclonidine) 1% DROPS	
LUMIFY (brimonidine) 0.03% DROPS	
SIMBRINZA (brinzolamide/brimonidine) DROPS	

## Beta Blockers

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BETOPTIC S (betaxolol) 0.25% DROPS	betaxolol 0.5% drops
carteolol drops	BETIMOL (timolol) DROPS
COMBIGAN (brimonidine/timolol) DROPS – <i>Brand Name Required</i>	brimonidine/timolol drops
dorzolamide/timolol drops	COSOPT (dorzolamide/timolol) PF DROPS
ISTALOL (timolol maleate) DROPS ONCE DAILY – <i>Brand Required</i>	timolol drops once daily
levobunolol drops	timolol gel forming solution
timolol maleate drops	TIMOPTIC (timolol maleate) DROPS
timolol maleate/PF drops 0.5%	TIMOPTIC OCUDOSE 0.5% (timolol) PF DROPS
TIMOPTIC OCUDOSE 0.25% (timolol) PF DROPS	TIMOPTIC-XE (timolol gel forming solution)

### Prior Authorization Criteria

- See [Preferred Dosage Form](#) Criteria

## Carbonic Anhydrase Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AZOPT (brinzolamide) – <i>Brand Required</i>	brinzolamide
dorzolamide	COSOPT (dorzolamide/timolol)
dorzolamide/timolol	TRUSOPT (dorzolamide)
SIMBRINZA (brinzolamide/brimonidine)	

## Prostaglandins

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
latanoprost	bimatoprost 0.03%
LUMIGAN (bimatoprost) 0.01%	tafluprost
ROCKLATAN (netarsudil/latanoprost)	travoprost
TRAVATAN Z (travoprost) - <i>Brand Required</i>	VYZULTA (latanoprostene)
	XALATAN (latanoprost)
	XELPROS (latanoprost)
	ZIOPTAN (tafluprost/pf) – <i>Brand Required</i>

### Prior Authorization Criteria

- See [Preferred Dosage Form](#) Criteria

## Rho Kinase Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
RHOPRESSA (netarsudil)	
ROCKLATAN (netarsudil/latanoprost)	

## Presbyopia

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
-----------------------------------	------------------------------------

pilocarpine	ISOPTO CARPINE (pilocarpine)
	VUITY (pilocarpine hydrochloride)

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: 12 months

- See [Preferred Dosage Form](#) Criteria
- The requested medication must be prescribed by, or in consult with, an optometrist or ophthalmologist.
- Documentation of medical necessity must be provided, including contraindication to the use of corrective lenses and how activities of daily living are adversely impacted due to inability to correct vision with corrective lenses.

Renewal Criteria - Approval Duration: 12 months

- Documentation must be provided including activities of daily living are positively impacted by drug therapy.

**Inherited Retinal Dystrophy**

**CLINICAL PA REQUIRED**

LUXTURNA (alglucosidase alfa) – *Medical Billing Only*

*Prior Authorization Criteria*

Initial Criteria - Approval Duration: Approval Duration: 1 month (once per lifetime per eye)

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational).
- The requested medication must be prescribed by, or in consult with, an ophthalmologist or retinal surgeon with experience providing subretinal injections
- The member must have a diagnosis of inherited retinal dystrophy (i.e., Leber’s congenital amaurosis [LCA], retinitis pigmentosa [RP]); confirmed by biallelic pathogenic variants in the RPE65 gene by molecular genetic testing (as evidenced with submitted documentation)
- The member has sufficient viable retinal cells as measured by OCT (optical coherence tomography) defined as one of the following:
  - retinal thickness greater than 100 microns within the posterior pole
  - ≥ 3-disc areas of the retina without atrophy or pigmentary degeneration within the posterior pole
  - remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent
- The member has remaining light perception in the eye(s) that will receive treatment.
- The member has not previously received RPE65 gene therapy in intended eye.

**Uveitis**

**PREFERRED AGENTS (NO PA REQUIRED)**

HUMIRA (adalimumab)

**NON-PREFERRED AGENTS (PA REQUIRED)**

**Vernal Keratoconjunctivitis**

**CLINICAL PA REQUIRED**

VERKAZIA (cyclosporine)



## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 6 months

- The requested medication must be prescribed by, or in consult with, an allergist or ophthalmologist.
- The member has failed\* a 3-month trial of combination of each of the following:
  - Topical dual-acting mast cell stabilizers/antihistamines (e.g., olopatadine, azelastine hydrochloride, epinastine, pemirolast potassium, or ketotifen fumarate)
  - Second- and third-generation oral antihistamines (e.g., fexofenadine, loratadine, desloratadine, cetirizine, or levocetirizine)
  - Cyclosporine ophthalmic emulsion 0.05%

\*Failure is defined as requiring frequent or prolonged courses of topical ophthalmic corticosteroids include prednisone acetate 1% and dexamethasone 0.1% for severe cases and prednisolone acetate 0.12%, fluorometholone, medrysone, loteprednol, etabonate 0.2 or 0.5%, and rimexolone 1% or compromised corneal epithelium

## VEGF Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ALYMSYS (bevacizumab-maly) – <i>Medical Billing Only</i>	BEOVU (brolucizumab-dbll) – <i>Medical Billing Only</i>
AVASTIN (bevacizumab) – <i>Medical Billing Only</i>	EYLEA (aflibercept) – <i>Medical Billing Only</i>
MVASI (bevacizumab-awwb) – <i>Medical Billing Only</i>	LUCENTIS (ranibizumab) – <i>Medical Billing Only</i>
ZIRABEV (bevacizumab-bvzr) – <i>Medical Billing Only</i>	SUSVIMO (ranibizumab) – <i>Medical Billing Only</i>
	VABYSMO (faricimab-svoa) – <i>Medical Billing Only</i>

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational).
- The requested medication must be prescribed by, or in consult with, an ophthalmologist or retina specialist with experience providing intraocular injections and implants
- The member must have a mean visual acuity letter score (VALS) of 70 or Best Corrected Visual Acuity of 20/40 or worse at baseline
- The member must have failed a trial consisting of at least 2 doses of a bevacizumab agent

### Renewal Criteria - Approval Duration: 12 months

- The member must have experienced meaningful clinical benefit since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review) including improvement or stabilization in VALS, defined as a loss of not more than 5 letters compared to baseline.
- The member must have at least a mean VALS of 20 or BCVA of 20/400

## Otic

### Anti-infectives/Anti-inflammatories – Fluoroquinolones

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CIPRO HC (ciprofloxacin/hydrocortisone)	ciprofloxacin/dexamethasone otic drops
CIPRODEX (ciprofloxacin/dexamethasone) – <i>Brand Required</i>	ciprofloxacin/fluocinolone

OTOVEL (ciprofloxacin/fluocinolone)
-------------------------------------

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 7-day trial of each of the preferred agent, as evidenced by paid claims or pharmacy printouts.

## Pain

### Lidocaine Patch

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
lidocaine 5% patch	LIDODERM (lidocaine) 5% PATCH
ZTLIDO (lidocaine) 1.8% PATCH	

### Lidocaine Topical Cream

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The request must be for injection pain from a medically necessary procedure

## NSAIDS

### Oral Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
celecoxib 50 mg, 100 mg, 200 mg	ARTHROTEC (diclofenac/misoprostol)
diclofenac potassium 50 mg tablet	celecoxib 400 mg
diclofenac sodium DR 50 mg, 75 mg	CELEBREX (celecoxib)
etodolac tablet	DAYPRO (oxaprozin)
flurbiprofen	diclofenac potassium 25 mg capsule
ibuprofen	diclofenac sodium 25 mg DR
indomethacin	diclofenac sodium 100 mg ER tablet
indomethacin ER	diclofenac/misoprostol
ketoprofen	DUEXIS (famotidine/ibuprofen)
ketorolac	etodolac capsule
meclofenamate	etodolac ER
mefenamic acid	famotidine/ibuprofen
meloxicam	FELDENE (piroxicam)
nabumetone	fenoprofen
naproxen	INDOCIN (indomethacin)
piroxicam	ketoprofen ER 200 mg
sulindac	meloxicam, submicronized
tolmetin	MOBIC (meloxicam)
VIMOVO (naproxen/esomeprazole) – <i>Brand Required</i>	NALFON (fenoprofen)
ZIPSOR (diclofenac) – <i>Brand Required</i>	NAPRELAN (naproxen)
	naproxen ER 375 mg, 500 mg

	naproxen/esomeprazole
	oxaprozin
	RELAFEN DS (nabumetone)
	SEGLENTIS (celecoxib/tramadol)
	VIVLODEX (meloxicam, submicronized)
	ZORVOLEX (diclofenac, submicronized)

### Electronic Diagnosis Verification

- Mefenamic acid and Meclofenamate: Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale for

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- *Non-preferred agents with no same active ingredient preferred:*
  - The member must have failed a 30-day trial of 3 different oral generic NSAIDs including a COX-2 inhibitor with GI intolerances, as evidenced by paid claims or pharmacy print outs
- *Non-preferred agents with same active ingredient preferred:*
  - See [Preferred Dosage Form](#) Criteria

### Therapeutic Duplication

- One strength of one medication is allowed at a time (topical and oral formulations are not allowed together)

If the following conditions apply, please call for an override by calling provider relations at 1-800-755-2604:

- The member is prescribed ketorolac and will stop regular NSAID therapy during course of ketorolac

## Oral Non-Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ibuprofen suspension	INDOCIN (indomethacin) SOLUTION
naproxen suspension	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of each preferred agent, as evidenced by paid claims or pharmacy print outs.

## Nasal Dosage Forms

CLINICAL PA REQUIRED
ketorolac nasal spray
SPRIX (ketorolac) NASAL SPRAY

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed 30-day trials of 2 oral and 1 topical preferred agent, as evidenced by paid claims or pharmacy printouts.

- Clinical justification must be provided explaining why the member is unable to use another dosage form (subject to clinical review).

## Topical Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
FLECTOR (diclofenac) PATCH - <i>Brand Required</i>	diclofenac patch
PENNSAID (diclofenac) 2% PUMP – <i>Brand Required</i>	diclofenac 2% pump
	LICART (diclofenac) PATCH 1.3%

### Prior Authorization Criteria

- See [Preferred Dosage Form](#) Criteria

## Opioid Analgesics

### Therapeutic Duplication

- One extended-release product/strength is allowed at a time
- One immediate release product is allowed (single ingredient or combination)
- 3A4 substrates (fentanyl, methadone, and oxycodone) are not allowed with strong 3A4 inhibitors.
- Opioid-acetaminophen combination products are not allowed with acetaminophen
- Carisoprodol: The “Holy Trinity” consists of an opioid, a benzodiazepine, and carisoprodol and is a highly abused dangerous combination that can lead to additive CNS depression, overdose, and death. It is not covered.
- Methadone is not allowed with opioids, benzodiazepines, or opioid use disorder medications
- Morphine is not covered with clopidogrel, prasugrel, ticagrelor, and ticlopidine (does not include other opioid analgesics)
  - Morphine may diminish the antiplatelet effect and serum concentrations of P2Y12 Inhibitor antiplatelet agents (clopidogrel, prasugrel, ticagrelor, and ticlopidine).
- Nucynta and Nucynta ER are not allowed with other narcotic medications
- Tramadol immediate release with tramadol extended release

### Opioids and Benzodiazepine Concurrent Use

#### [Opioid and Benzodiazepines Concurrent Use Form](#)

- Due to guidance in The SUPPORT for Members and Communities Act (H.R. 6) on CNS depression, this includes long-acting opioids over 90 MME/day or immediate release opioids over 15 MME/dose in combination with benzodiazepines

#### Initial Criteria - Approval Duration: 12 months

- The member has access to Narcan and has been counseled on overdose risk
- The member undergoes routine drug screens (blood and/or urine).
- The member has been counseled on the risks of utilizing opioids and benzodiazepines in combination with each other and other CNS depressing medications, including antipsychotics and sedatives.
- The member must currently be on long-acting opioid therapy or must not have achieved therapeutic goal with non-narcotic medication (NSAIDs, TCAs, SNRIs, corticosteroids, etc.) and non-medication alternatives (weight loss, physical therapy, cognitive behavioral therapy, etc.).
- One of the following criteria must be met:
  - The member resides in a facility with skilled nursing care
  - The member must have taper plan of one or both agents

- The opioid medication must be prescribed by, or in consult with, with an oncologist or pain management specialist with a pain management contract (with treatment plan including goals for pain and function, and urine and/or blood screens) if the cumulative daily dose of opioids exceeds 90 MME/day (specialist requirement not applicable to skilled nursing facility residents or tapering requests).
- The prescriber(s) of both agents have provided reasons why opioid analgesics and benzodiazepines cannot be avoided, or lower doses be used (subject to clinical review)
- The prescriber(s) of both agents routinely check the PDMP.
- The prescriber(s) of both agents routinely evaluated for medical necessity

### Greater than 90 Morphine Milligram Equivalents (MME) per Day

#### [Prior Authorization Form – Opioid Analgesics](#)

##### Initial Criteria - Approval Duration: 12 months

- See [Opioid Analgesics – Long-Acting Prior Authorization Criteria](#)
- A cumulative maximum of 90 MME will be allowed without authorization.
  - An MME calculator may be found at [Opioid Dose Calculator](#)

## Opioid Analgesics – Long Acting

### Partial Agonist/Antagonist Opioids

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BELBUCA (buprenorphine)	buprenorphine patches
Butorphanol	
BUTRANS (buprenorphine) PATCHES - <i>Brand Required</i>	

### Abuse Deterrent Formulations/Unique Mechanisms from Full Agonists Opioids

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
NUCYNTA ER (tapentadol)	CONZIP (tramadol ER) CAPSULES
OXYCONTIN (oxycodone) – <i>Brand Required</i>	hydrocodone ER tablets
tramadol ER Tablets	HYSINGLA ER (hydrocodone)
	levorphanol
	methadone
	MORPHABOND ER (morphine)
	tramadol ER Capsules
	XTAMPZA ER (oxycodone)

### Full Agonist Opioids Without Abuse Deterrent Formulations

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
fentanyl 12 mcg/hr	fentanyl patch 37.5 mcg/hr, 62.5 mcg/hr, 87.5 mcg/hr
fentanyl 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hr	hydrocodone ER capsules
morphine ER tablets	hydromorphone ER tablets
	morphine ER capsules
	MS CONTIN (morphine)
	oxycodone ER
	oxymorphone ER tablets

## Prior Authorization Criteria

### Prior Authorization Form – Opioid Analgesics

#### Initial Criteria - Approval Duration: 12 months

- The past 3 months of the member's North Dakota PDMP reports must have been reviewed.
- One of the following criteria must be met:
  - The member has access to Narcan and has been counseled on overdose risk
  - The member resides in a facility with skilled nursing care
- One of the following criteria must be met:
  - The member is currently on a long-acting opioid therapy
  - The member must have exceeded 90 MME during hospitalization requiring post discharge maintenance or tapering
  - Both of the following are met:
    - The member must have a diagnosis of cancer pain, palliative care, or sickle cell disease
    - The member must currently be on around-the-clock opioid therapy for at least a week, as evidenced by paid claims or pharmacy printouts
      - The around the clock opioid therapy must be equivalent to 60 mg oral morphine daily, 25 mcg transdermal fentanyl/hour, 30 mg oxycodone daily, 8 mg of oral hydromorphone daily, or equianalgesic dose of another opioid daily
  - Both of the following are met:
    - The member has established opioid tolerability by using short acting opioids daily for at least 90 days prior to request for long-acting opioid as evidenced by paid claims or pharmacy printouts
    - The member has not achieved therapeutic goal with non-narcotic medication (NSAIDs, TCAs, SNRIs, corticosteroids, etc.) and non-medication alternatives (weight loss, physical therapy, cognitive behavioral therapy, etc.).
- One of the following criteria must be met:
  - The member resides in a facility with skilled nursing care
  - The member must have taper plan of one or both agents
  - The opioid medication must be prescribed by, or in consult with, with an oncologist or pain management specialist with a pain management contract (with treatment plan including goals for pain and function, and urine and/or blood screens) if the cumulative daily dose of opioids exceeds 90 MME/day

#### *Fentanyl Patch:*

- The member must have a BMI  $\geq 17$
- The member must meet one of the following criteria:
  - The member has an indication of cancer pain or palliative care pain
  - The member requires a long-acting narcotic and cannot tolerate an oral dosage form
- Fentanyl Patch 12 mcg/hr Only:
  - Member must meet one of the following:
    - The member must be receiving a total daily opioid dose less than or equal to 60 Morphine Milligram equivalents (MME), as evidenced by paid claims or pharmacy printouts
    - The member must be continuously tapering off opioids from a higher strength fentanyl patch

#### *Non-Preferred Agents Criteria:*

- Clinical justification must be provided explaining why the member is unable to use other opioid and non-opioid analgesic agents (subject to clinical review).

#### Renewal Criteria - Approval Duration: 12 months

- One of the following must be met:
  - Documentation noting progress toward therapeutic goal must be included with request (e.g., improvement in pain level, quality in life, or function).

- The member must be stable on long-acting opioid medication for 2 years or longer

### Underutilization

- Long-acting opioid analgesics must be used adherently and will reject on point of sale for late fill

## Opioid Analgesic – Short Acting

### Fentanyl Products

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	ACTIQ (fentanyl) LOZENGE
	FENTORA (fentanyl) EFFERVESCENT TABLET
	fentanyl citrate effervescent tablet
	fentanyl lozenge

### Opioid Combination Solid Oral Products

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
acetaminophen-codeine tablets	ENDOCET (oxycodone-acetaminophen)
benzhydrocodone-acetaminophen	hydrocodone-acetaminophen 2.5-325 MG
hydrocodone-acetaminophen 5-325 MG	hydrocodone-acetaminophen 10 MG-300 MG
hydrocodone-acetaminophen 7.5-325 MG	hydrocodone-acetaminophen 5 MG-300 MG
hydrocodone-acetaminophen 10-325 MG	hydrocodone-acetaminophen 7.5-300 MG
oxycodone-acetaminophen 5-325 MG	hydrocodone-ibuprofen 5 mg-200 mg and 10 mg-200 mg
oxycodone-acetaminophen 10 -325 MG	LORCET (hydrocodone-acetaminophen)
tramadol-acetaminophen tablets	NALOCET (oxycodone-acetaminophen)
hydrocodone-ibuprofen 7.5 mg-200 mg	NORCO (hydrocodone-acetaminophen)
	oxycodone-acetaminophen 2.5-325 MG
	oxycodone-acetaminophen 7.5-325 MG
	PERCOCET (oxycodone/acetaminophen)
	PRIMLEV (oxycodone/acetaminophen)
	PROLATE (oxycodone/acetaminophen)
	SEGLENTIS (celecoxib/tramadol)
	ULTRACET (tramadol/acetaminophen)
	VICODIN (hydrocodone/acetaminophen)

### Opioid - Acetaminophen Combination Solid Oral Products

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
acetaminophen-codeine solution	hydrocodone-acetaminophen 5-163 mg/7.5 mL solution
hydrocodone-acetaminophen 7.5-325/15 ml solution	LORTAB (hydrocodone-acetaminophen) SOLUTION

### Opioid Single Agent Solid Oral Products

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
codeine tablets	butalbital-codeine tablet
hydromorphone tablet	DEMEROL (meperidine) TABLET
meperidine tablet	DILAUDID (hydromorphone) TABLET
morphine tablet	OXAYDO (oxycodone) TABLET
NUCYNTA (tapentadol) TABLET	oxycodone 15 mg, 20 mg, 30 mg tablet
oxycodone 5 mg, 10 mg tablet	ROXICODONE (oxycodone) TABLET



oxymorphone tablet	ROXYBOND (oxycodone) TABLET
tramadol 50 mg tablet	tramadol 100 mg tablet
	ULTRAM (tramadol) TABLET

*Opioid Single Agent Non-Solid Oral Products*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
hydromorphone liquid	
morphine solution	
oxycodone solution	

*First Fill*

- Short acting opioid analgesics must be filled with a 7-day supply if no previous fill within past 34 days
  - If member is filling prescription less than every 34 days due to decreased utilization, please get a new prescription for a lower quantity that reflects actual utilization within a 34-day window.

*Prior Authorization Criteria*

Prior Authorization Form – Opioid Analgesics

Initial Criteria - Approval Duration: 12 months

- The member has not achieved therapeutic goal with non-narcotic medication (NSAIDs, TCAs, SNRIs, corticosteroids, etc.) and non-medication alternatives (weight loss, physical therapy, cognitive behavioral therapy, etc.).
- The past 3 months of the member’s North Dakota PDMP reports must have been reviewed.
- The opioid medication must be prescribed by, or in consult with, with an oncologist or pain management specialist with a pain management contract (with treatment plan including goals for pain and function, and urine and/or blood screens) if the cumulative daily dose of opioids exceeds 90 MME/day

*Fentanyl Only:*

- The member’s age must be within label recommendations
- The member must have a diagnosis of cancer pain
- The member must currently be on around-the-clock opioid therapy for at least a week, as evidenced by paid claims or pharmacy printouts
  - The around the clock opioid therapy must be equivalent to 60 mg oral morphine daily, 25 mcg transdermal fentanyl/hour, 30 mg oxycodone daily, 8 mg of oral hydromorphone daily, or equianalgesic dose of another opioid daily

*Meperidine and Butalbital-Codeine Only:*

- Clinical justification must be provided explaining why the member is unable to use other opioid and non-opioid analgesic products (subject to clinical review).

*Oxycodone IR Only*

- The member must currently be on a long-acting opioid analgesic that provides a daily Morphine Milligram Equivalent (MME) which meets requirements below (based on requested strength), as evidenced by paid claims or pharmacy printouts (Please use an [Opioid Dose Calculator](#) to find the MME for specific products):
  - Oxycodone 15 mg tablet: long-acting opioid must provide  $\geq 150$  mg MME per day
  - Oxycodone 20 mg tablet: long-acting opioid must provide  $\geq 200$  mg MME per day
  - Oxycodone 30 mg tablet: long-acting opioid must provide  $\geq 300$  mg MME per day

*Member with a History of Opioid Use Disorder*

If 1 and 2 are met, please call for an override by calling provider relations at 1-800-755-2604 (chart notes will be required for requests beyond one fill):

1. The request is for one of the following:
  - A one-time fill request where pain cannot be reasonably treated with non-opioid therapy (e.g., surgery)
  - A request exceeding a one-time fill and a treatment plan has been provided with expected duration of use and why non-opioid therapy is not an option (subject to clinical review) or a taper plan is provided
2. One of the following is met:
  - Prescribers of both opioid prescription and MAT are aware of each other and agree to opioid therapy
  - MAT therapy has discontinued, and the prescriber of the opioid is aware of previous MAT treatment and confirms opioid therapy is required

Renewal Criteria - Approval Duration: 12 months

- Documentation noting progress toward therapeutic goal must be provided including pain level and function

## Qutenza (capsaicin patch)

### CLINICAL PA REQUIRED

QUTENZA (capsaicin patch) – *Medical Billing Only*

### Prior Authorization Criteria

Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a pain specialist
- The member must have failed a 3-month treatment of topical lidocaine patch

## Skeletal Muscle Relaxants

### Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
baclofen	AMRIX (cyclobenzaprine) TAB 24 HR
chlorzoxazone 500 mg	chlorzoxazone 375 mg and 750 mg
cyclobenzaprine 5 mg and 10 mg	cyclobenzaprine 7.5 mg
dantrolene	cyclobenzaprine ER
methocarbamol	carisoprodol
orphenadrine ER	carisoprodol-aspirin
tizanidine tablets	carisoprodol-aspirin-codeine
	DANTRIUM (dantrolene)
	LORZONE (chlorzoxazone)
	METAXALL (metaxalone)
	metaxalone
	NORGESIC FORTE (orphenadrine/aspirin/caffeine)
	ROBAXIN (methocarbamol)
	SKELAXIN (metaxalone)
	SOMA (carisoprodol)
	tizanidine capsules
	ZANAFLEX (tizanidine)

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months (carisoprodol = 1 week)

- Carisoprodol products only:
  - The member must be undergoing dose tapering
- Metaxalone
  - The member must have failed two 30-day trials of other skeletal muscle relaxants, including methocarbamol, as evidenced by paid claims or pharmacy printouts.
- All other products:
  - See [Preferred Dosage Form](#) Criteria

## Therapeutic Duplication

- One strength of one medication is allowed at a time
  - If the following conditions apply, please call for an override by calling provider relations at 1-800-755-2604:
    - The member has cerebral palsy or another chronic spastic disorder
    - The prescriber is a physiatrist
    - The requested combination is baclofen and tizanidine
- Carisoprodol is not allowed with opioids, benzodiazepines, or opioid use disorder medications
  - The “Holy Trinity” consists of an opioid, a benzodiazepine, and carisoprodol and is a highly abused dangerous combination that can lead to additive CNS depression, overdose, and death. It is not covered.
- Tizanidine is not allowed with other alpha 2 agonists (clonidine, clonidine/chlorthalidone, guanfacine, methyl dopa)
  - tizanidine is also an alpha 2 agonist

## Non-Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
baclofen solution 5 mg/5 mL	FLEQSUVY (baclofen) SUSPENSION
LYVISPAH (baclofen) GRANULE PACKET	OZOBAX (baclofen) SOLUTION

## Prior Authorization Criteria

- See [Preferred Dosage Form](#) Criteria

# Psychiatry

## ADHD

### Non-Stimulants

#### Alpha 2 Agonists

PREFERRED AGENTS (NO PA REQUIRED)	PREFERRED STEP 1 AGENTS (ELECTRONIC STEP)	NON-PREFERRED STEP 2 AGENTS (PA REQUIRED)
clonidine	clonidine ER 0.1 mg	clonidine ER 0.17 mg
guanfacine		INTUNIV (guanfacine ER)
guanfacine ER		KAPVAY (clonidine ER)

### First Fill

- Clonidine ER and guanfacine ER must be filled with a 14-day supply (or less) if no previous fill within past 99 days

### Therapeutic Duplication

Please see the [Psychotropic Monitoring Program](#) document for detailed information regarding clinical criteria for Therapeutic Duplication Requests.

- One strength of one medication is allowed at a time except guanfacine 4 mg IR and ER which may be combined guanfacine IR and ER, respectively, to form dosages up to 7 mg per day
- Clonidine and guanfacine are not allowed with each other or other alpha 2 agonists (clonidine/chlorthalidone, methyldopa, or tizanidine)

### Electronic Step Care and Concurrent Medication

- Clonidine ER: A total of 30 days of clonidine IR must be paid within 40 days prior to clonidine ER

## Norepinephrine Reuptake Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
atomoxetine	STRATTERA (atomoxetine)
PREFERRED AGENTS (CLINICAL PA REQUIRED)	
QELBREE (viloxazine)	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must meet one of the following:
  - The member has failed a 30-day trial of two stimulants at the maximally tolerated dose, as evidenced by paid claims or pharmacy printouts
  - The member has failed a 30-day trial of atomoxetine

### Therapeutic Duplication

- One strength of one medication is allowed at a time.

## Stimulants

### Amphetamines

#### Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ADDERALL XR (dextroamphetamine/amphetamine) – Brand Required	ADDERALL (dextroamphetamine/amphetamine)
amphetamine	DEXEDRINE ER (dextroamphetamine)
DESOXYN (methamphetamine) – Brand Required	dextroamphetamine/amphetamine ER

dextroamphetamine	EVEKEO (amphetamine)
dextroamphetamine ER	methamphetamine
dextroamphetamine/amphetamine	ZENZEDI (dextroamphetamine)
VYVANSE (lisdexamfetamine)	
<b>High-Cost Options</b>	
DYANAVEL XR (amphetamine)	
MYDAYIS (dextroamphetamine/amphetamine)	

### Non-Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DYANAVEL XR (amphetamine)	dextroamphetamine 5 mg/5 ml
EVEKEO ODT (amphetamine)	
PROCENTRA (dextroamphetamine) – Brand Required	
<b>High-Cost Options</b>	
ADZENYS XR - ODT (amphetamine)	
amphetamine ER suspension	
VYVANSE (lisdexamfetamine) CHEW TABLET	
XELSTRYM (dextroamphetamine) PATCH	

## Methylphenidate

### Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CONCERTA (methylphenidate) – Brand Required	FOCALIN (dexmethylphenidate)
dexmethylphenidate	FOCALIN XR (dexmethylphenidate)
dexmethylphenidate ER	METADATE ER (methylphenidate)
methylphenidate CD 30-70	methylphenidate ER tablet (generic Concerta)
methylphenidate tablet	RITALIN (methylphenidate)
methylphenidate ER tablet 10mg, 20mg	RITALIN LA (methylphenidate LA capsules - 50-50)
methylphenidate LA capsules - 50-50 (generic Ritalin LA)	
<b>High-Cost Options</b>	
ADHANSIA XR (methylphenidate)	methylphenidate ER 45 mg
AZSTARYS (serdexmethylphenidate/dexmethylphenidate)	methylphenidate ER 63 mg
JORNAY PM (methylphenidate)	methylphenidate ER 72 mg
	methylphenidate ER capsule

### Non-Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DAYTRANA (methylphenidate) PATCH – Brand Required	Methylphenidate patch
methylphenidate chew tablet	METHYLIN (methylphenidate) chew tablets
methylphenidate solution	METHYLIN (methylphenidate) solution
QUILLICHEW ER (methylphenidate)	
QUILLIVANT XR (methylphenidate)	
<b>High-Cost Options</b>	

APTENSIO XR (methylphenidate) – <i>Brand Required</i>	methylphenidate sprinkle capsules
COTEMPLA XR - ODT (methylphenidate)	

### Therapeutic Duplication

Please see the [Psychotropic Monitoring Program](#) document for detailed information regarding clinical criteria for Therapeutic Duplication Requests.

For all stimulants, the following are not payable:

- multiple strengths of a single medication
- amphetamine agent + methylphenidate agent
- multiple long-acting agents
- multiple short acting agents
- non-solid dosage + solid dosage forms

These long-acting products are not allowed with short-acting products:

- Aptensio XR (methylphenidate)
- Adhansia XR (methylphenidate)
- Cotempla XR-ODT (methylphenidate)
- Daytrana (methylphenidate)
- Adderall XR (mixed salts of a single-entity amphetamine product)
- Adzenys XR ODT (amphetamine suspension, extended release)
- Adzenys ER (amphetamine suspension, extended release)
- Dyanavel XR (amphetamine)
- Mydayis (mixed salts of a single-entity amphetamine product)
- Vyvanse (lisdexamfetamine)
- Vyvanse Chewable (lisdexamfetamine)

Amphetamines: One product will be allowed at a time. The following are not payable regimens:

- Dextroamphetamine/Amphetamine ER with Proton Pump Inhibitors
  - Proton pump inhibitors increase blood levels and potentiate the action of amphetamine. Co-administration of Adderall XR and gastrointestinal or urinary alkalizing agents should be avoided
- Concurrent use of Mydayis and Dyanavel XR with benzodiazepines or sedatives
  - Members reporting insomnia should use a shorter acting product that does not reach steady state

Methylphenidates: The following are not payable regimens:

- Concurrent use of dexamethylphenidate and methylphenidate
- Concurrent use of Adhansia XR and Azstarys with benzodiazepines or sedatives
  - Members reporting insomnia should use a shorter acting product that does not reach steady state

### First Fill

- Long-acting stimulants must be filled with a 14-day supply (or less) if no previous fill within past 99 days

## Antidepressants

### Electronic Step Care and Concurrent Medications

- Trintellix Only: Initiation with 10 mg must be used for 10 days prior to continuing therapy with 20 mg
  - Trintellix recommended starting dose is 10 mg once daily.
- Desvenlafaxine ER Only: 30 days of 50 mg must be paid within 40 days of 25 mg date of service
  - 25 mg is intended only for gradual titration before discontinuation. It is not a therapeutic dose.

## First Fill

- Viibryd and Trintellix must be filled with a 10-day supply if no previous fill within past 99 days

## Therapeutic Duplication

- One strength of one medication per therapeutic class is allowed at a time
  - Therapeutic classes:
    - SSRIs
    - SNRIs
    - Tricyclic Antidepressants
    - Bupropion
    - Mirtazapine
    - Selegiline
- Mirtazapine is not allowed with other alpha 2 agonists (clonidine, clonidine/chlorthalidone, guanfacine, methyl dopa)
  - Mirtazapine is also an alpha 2 agonist
- Fetzima, Viibryd, or Trintellix are not allowed with other antidepressant medications (exceptions: trazodone and mirtazapine)
- Fluvoxamine, a strong 1A2 inhibitor, is not covered with Ramelteon, a 1A2 Substrate.

## Atypical Antipsychotics

### Oral

#### Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
aripiprazole	ABILIFY (aripiprazole)
clozapine	CLOZARIL (clozapine)
FANAPT (iloperidone)	GEODON (ziprasidone)
LATUDA (lurasidone)	INVEGA ER (paliperidone)
olanzapine	RISPERDAL (risperidone)
quetiapine	SEROQUEL (quetiapine)
quetiapine ER	SEROQUEL XR (quetiapine)
paliperidone ER	ZYPREXA (olanzapine)
risperidone	
ziprasidone	
High-Cost Options	
CAPLYTA (lumateperone)	SYMBYAX (olanzapine/fluoxetine)
LYBALVI (olanzapine/samidorphan)	
olanzapine/fluoxetine	
REXULTI (brexpiprazole)	
VRAYLAR (cariprazine)	

#### Non-Solid Dosage Forms

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
clozapine ODT	asenapine
olanzapine ODT	RISPERDAL (risperidone) ORAL SOLUTION
risperidone ODT	RISPERDAL M-TAB (risperidone)



risperidone oral solution	ZYPREXA ZYDIS (olanzapine)
SAPHRIS (asenapine) – <i>Brand Required</i>	
<b>High-Cost Options</b>	
aripiprazole solution	ABILIFY DISCMELT (aripiprazole)
aripiprazole ODT	
SECUADO (asenapine)	

### *Electronic Step Care and Concurrent Medication*

Vraylar requires initiation titration:

- For 3 mg dose: Initiation pack or 1 day of the 1.5 mg tablet is required
- For 4.5 mg dose: Initiation pack or 1 day of the 1.5 mg tablet plus 6 days of 3 mg tablets is required

### *Therapeutic Duplication*

#### [Prior Authorization Form - Concurrent Antipsychotics](#)

Please see the [Psychotropic Monitoring Program](#) document for detailed information regarding clinical criteria for Therapeutic Duplication Requests.

- One strength of one medication is allowed at a time with the following exceptions:
  - risperidone 0.25 mg, 0.5 mg and 1 mg are allowed with other strengths of risperidone
  - quetiapine 25 mg and 50 mg are allowed with other strengths of quetiapine IR
  - quetiapine 50 mg ER is allowed with other strengths of quetiapine ER
  - olanzapine 2.5 mg is allowed with 10 mg, 15 mg, and 20 mg
  - olanzapine 5 mg is allowed with 7.5 mg and 20 mg

### *Underutilization*

- Caplyta, Fanapt, Latuda, Paliperidone ER, Rexulti, Saphris, Sacuado, and Vraylar must be used adherently and will reject on point of sale for late fill

### *First Fill*

- Caplyta, Fanapt, Latuda, Paliperidone ER, Rexulti, Saphris, Sacuado, and Vraylar must be filled with a 10-day supply if no previous fill within past 99 days

## **Long Acting Injectable (LAI)**

<b>PREFERRED AGENTS (NO PA REQUIRED)</b>	<b>NON-PREFERRED AGENTS (PA REQUIRED)</b>
ABILIFY MAINTENA (aripiprazole)	
ARISTADA (aripiprazole lauroxil)	
ARISTADA INITIO (aripiprazole lauroxil)	
INVEGA HAFYERA (paliperidone)	
INVEGA SUSTENNA (paliperidone)	
INVEGA TRINZA (paliperidone)	
PERSERIS (risperidone)	
RISPERDAL CONSTA (risperidone)	
ZYPREXA RELPREVV (olanzapine)	

## Electronic Step Care and Concurrent Medication

- Oral formulations must be used prior to injectable formulations to establish tolerability and achieve steady state.

If the following conditions apply, please call for an override by calling provider relations at 1-800-755-2604:

- There is a history of tolerability to active ingredient and no requirement for oral overlap for missed dose / initiation of long-acting injectable antipsychotic.

## Therapeutic Duplication

### [Prior Authorization Form - Concurrent Antipsychotics](#)

Please see the [Psychotropic Monitoring Program](#) document for detailed information regarding clinical criteria for Therapeutic Duplication Requests.

- One strength of one medication is allowed at a time

## Benzodiazepines

### Therapeutic Duplication

- One short acting medication is allowed at a time: alprazolam, lorazepam, oxazepam
- One long-acting medication is allowed at a time: chlordiazepoxide, clonazepam, diazepam, alprazolam ER
- Benzodiazepines are not covered with
  - Opioids: [Override Criteria Available](#)
  - Xyrem, Xywav
  - Mydayis
    - Insomnia has been reported in 25-56% of members receiving Mydayis. Members reporting insomnia should use a shorter acting product that does not reach steady state.
- 3A4 Substrates (alprazolam, clonazepam, midazolam,) are not allowed with strong 3A4 inhibitors
- For benzodiazepines only indicated for insomnia: see [Insomnia](#)

## Insomnia

### Non-addictive (Non-DEA scheduled) medications

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
hydroxyzine	doxepin
mirtazapine	ROZEREM (ramelteon)
ramelteon	SILENOR (doxepin)
trazodone	

### Addictive (DEA scheduled) medications

PREFERRED AGENTS (NO PA REQUIRED)	PREFERRED STEP 1 AGENTS (ELECTRONIC STEP)	NON-PREFERRED STEP 2 AGENTS (PA REQUIRED)
eszopiclone	BELSOMRA (suvorexant)	AMBIEN (zolpidem)
zaleplon	zolpidem 10 mg	AMBIEN CR (zolpidem)
zolpidem 5 mg		DAYVIGO (lemborexant)
zolpidem ER		EDLUAR (zolpidem)

		estazolam
		flurazepam
		LUNESTA (eszopiclone)
		QUVIVIQ (daridorexant)
		SECONAL SODIUM (secobarbital)
		temazepam
		triazolam
		zolpidem SL tab

### Electronic Step Care and Concurrent Medications

- Belsomra: The member must have had a 25-day trial of eszopiclone within the past 90 days
- Zolpidem: Initiation with trial of 5 mg must be used for 7 days within 90 days prior to 10 mg tablets
  - Zolpidem is recommended to be used at lowest dose possible.

### Prior Authorization Criteria

#### Prior Authorization Form – Sedative/Hypnotic

##### Initial Criteria - Approval Duration: 3 months

- Doxepin only
  - The member must have failed a 25-day trial with ramelteon with the most recent failure within the last 90 days, as evidenced by paid claims or pharmacy printouts
  - Clinical justification must be provided explaining why the member is unable to use mirtazapine, hydroxyzine, or trazodone (subject to clinical review)
- Edluar (zolpidem) only
  - The member's insomnia must be characterized by difficulty with sleep onset
  - The member must have failed a 25-day trial of each of the following with the most recent failure within the last 90 days, as evidenced by paid claims or pharmacy printouts
    - eszopiclone
    - zolpidem IR
    - zaleplon
- temazepam, zolpidem SL, Dayvigo, Quviviq only
  - The member's insomnia must be characterized by difficulty with sleep onset and maintenance
  - The member must have failed a 25-day trial of each of the following with the most recent failure within the last 90 days, as evidenced by paid claims or pharmacy printouts
    - eszopiclone
    - zolpidem ER
    - Belsomra
- triazolam, flurazepam, estazolam, seconal sodium only
  - Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review)

##### Renewal Criteria - Approval Duration: 6 months (2 weeks for benzodiazepines)

- Other conditions causing sleep issues have been ruled out
- benzodiazepines (temazepam, triazolam, flurazepam, estazolam) only:
  - The member must be undergoing dose tapering

### Therapeutic Duplication

- One strength of one medication is allowed at a time

- Benzodiazepines indicated only for insomnia are not covered with other non-barbiturate insomnia medications or other benzodiazepines
- Sedative/hypnotics are not covered with:
  - Xyrem
  - Mydayis
    - Insomnia has been reported in 25-56% of members receiving Mydayis. Members reporting insomnia should use a shorter acting product that does not reach steady state.
  - Long-acting benzodiazepines. Belsomra and Dayvigo are not covered with short or long-acting benzodiazepines.
    - Concomitant use can lead to CNS depression.
- Ramelteon, a 1A2 Substrate, is not covered with fluvoxamine, a strong 1A2 inhibitor
- Mirtazapine is not allowed with other alpha 2 agonists (clonidine, clonidine/chlorthalidone, guanfacine, methyldopa)
  - Mirtazapine is also an alpha 2 agonist
- Sedating benzodiazepines are not covered with opioids

## Non-24-hour Sleep-Wake Disorder

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ramelteon	HETLIOZ (tasimelteon) – <i>Brand Required</i>
	ROZEREM (ramelteon)
	tasimelteon

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a specialist in sleep disorders
- The member must have had a 30-day trial of ramelteon, as evidenced by paid claims or pharmacy printouts.
- One of the following must be met:
  - Member must be unable to perceive light in either eye
  - Sighted members must confirm diagnosis by documentation submitted of self-reported sleep diaries or actigraphy for at least 14 days demonstrating a gradual daily drift (typically later) in rest-activity patterns not better explained by sleep hygiene, substance or medication use, or other neurological or mental disorders.

### Underutilization

- Hetlioz/tasimelteon must be used compliantly and will reject on point of sale for late fill

## Smith-Magenis Syndrome

CLINICAL PA REQUIRED
HETLIOZ (tasimelteon) - <i>Brand Required</i>
tasimelteon

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a specialist in sleep disorders
- Documentation is submitted of genetic testing confirming deletion 17p11.2 (cytogenetic analysis or microarray) or RAI1 gene mutation
- Documentation of self-reported sleep diaries or actigraphy must be submitted for at least 14 days must be submitted.

### Underutilization

- Hetlioz/tasimelteon must be used compliantly and will reject on point of sale for late fill

## Pulmonary

### Asthma/COPD

#### Therapeutic Duplication

- One medication from each class is allowed at time
  - One inhaled steroid
  - Long-acting anticholinergic
  - Leukotriene pathway inhibitor
  - One short-acting beta agonist
  - One long-acting beta agonist

#### Electronic Step Care and Concurrent Medications

- Daliresp: A total of 90 days of an inhaled short or long-acting anticholinergic must be paid within 110 days prior to daliresp's date of service.
  - According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, daliresp is a recommended add-on therapy to members experiencing exacerbations while on antimuscarinic therapy.

### Albuterol/ Levalbuterol Rescue Inhalers

PREFERRED AGENTS (NO PA REQUIRED)	PREFERRED STEP 1 AGENTS (ELECTRONIC STEP REQUIRED)	NON-PREFERRED STEP 2 AGENTS (PA REQUIRED)
VENTOLIN (albuterol) HFA – Brand Required	levalbuterol HFA	albuterol HFA
	PROAIR RESPICLICK (albuterol)	PROAIR (albuterol) DIGIHALER
		PROVENTIL (albuterol) HFA
		XOPENEX (levalbuterol) HFA

#### Electronic Step Care and Concurrent Medications

- Levalbuterol HFA: A total of 30 days of albuterol HFA must be paid within 180 days prior to levalbuterol HFA's date of service
- ProAir Respiclick: A total of 30 days of steroid inhaler must be paid within 40 days prior to ProAir Respiclick's date of service.
  - The quantity limit for Ventolin HFA is set to 2 canisters per 6 months (2 puffs per day). If more is needed, member must switch to ProAir Respiclick HFA and be on a steroid inhaler to control asthma.

- According to the GINA guidelines:
  - A low dose ICS should be taken whenever SABA taken for step 1 control of asthma.
  - Dispensing  $\geq 3$  canisters per year is associated with higher risk of emergency department presentations
  - Dispensing  $\geq 12$  canisters per year is associated with higher risk of death

If the following conditions apply, please call for an override by calling provider relations at 1-800-755-2604:

- If primary insurance will only pay for ProAir Respiclick and member is well-controlled without steroid inhaler (i.e., uses less than 2 canisters per 6 months).

### Therapeutic Duplication

- Short acting beta agonist nebulizers and inhalers are not payable together
  - Inhalers and Nebulizers work equally well whether used at home, in school, or otherwise outside of the home. If member receives multiple forms of rescue medication, the risk of unidentified uncontrolled asthma and rescue inhaler dependence is increased.

If the following conditions apply, please call for an override by calling provider relations at 1-800-755-2604:

- Maximally treated members with end-stage COPD will be allowed an ongoing override (compliance with inhaled steroid, long-acting beta agonist, long-acting muscarinic antagonist, and Daliresp)
- Members with cystic fibrosis will be allowed an ongoing override
- Acutely ill children will be allowed a one-time override

### References:

1. [Albuterol Overuse: A Marker of Psychological Distress?](#) Joe K. Gerald, Tara F. Carr, Christine Y. Wei, Janet T. Holbrook, Lynn B. Gerald. J Allergy Clin Immunol Pract. 2015 Nov-Dec; 3(6): 957–962. Published online 2015 Sep 1. doi: 10.1016/j.jaip.2015.06.021. PMID: 264641773
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019 GINA Main Report. Available from: [www.ginasthma.org](http://www.ginasthma.org). (Accessed February 5, 2020)
3. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National Health, Lung, and Blood Institute (US); 2007 Aug. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK7232>
4. [High-Dose Albuterol by Metered-Dose Inhaler Plus a Spacer Device Versus Nebulization in Preschool Children With Recurrent Wheezing: A Double-Blind, Randomized Equivalence Trial](#) Dominique Ploin, François R. Chapuis, Didier Stamm, Jacques Robert, Louis David, Pierre G. Chatelain, Guy Dutau, and Daniel Floret Pediatrics. August 2000, 106 (2) 311-317; DOI: <https://doi.org/10.1542/peds.106.2.311>

### Anticholinergics/Beta Agonists Combinations – Short Acting

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
albuterol/ipratropium	DUONEB (albuterol/ipratropium)
COMBIVENT RESPIMAT (albuterol/ipratropium)	

### Anticholinergics/Beta Agonists Combinations – Long Acting

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED STEP 1 AGENTS (PA REQUIRED)	NON-PREFERRED STEP 2 AGENTS (PA REQUIRED)
ANORO ELLIPTA (umeclidinium/vilanterol)	BEVESPI AEROSPHERE (glycopyrrolate/formoterol)	DUAKLIR PRESSAIR (aclidinium/formoterol)

STIOLTO RESPIMAT (tiotropium/olodaterol)		
---	--	--

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

##### Non-Preferred Step 1 Agents

- The member must have failed a 30-day trial of 2 preferred agents, as evidenced by paid claims or pharmacy printouts

##### Non-Preferred Step 2 Agents:

- The member must have failed a 30-day trial of Bevespi Aerosphere and 2 preferred agents, as evidenced by paid claims or pharmacy printouts
- Clinical justification must be provided explaining why the member is unable to use the preferred products (subject to clinical review).

### Therapeutic Duplication

- Anticholinergic medications are not covered with acetylcholinesterase inhibitors
  - The effects of an anticholinergic (blocks the effect of acetylcholine) and acetylcholinesterase inhibitors (prevents breakdown of acetylcholine) oppose each other, and the therapeutic effect of both products is diminished.

## Anticholinergics - Long-Acting

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
INCRUSE ELLIPTA (umeclidinium)	LONHALA MAGNAIR (glycopyrrolate)
SPIRIVA HANDIHALER (tiotropium)	TUDORZA PRESSAIR (aclidinium)
SPIRIVA RESPIMAT 1.25 MCG (tiotropium)	YUPELRI (revefenacin)
SPIRIVA RESPIMAT 2.5 MCG (tiotropium)	

### Electronic Step Care and Concurrent Medications

- Spiriva Respimat 1.25 mg: A total of 30 days of a long-acting beta agonist (in combination or alone) must be paid within 40 days prior to the Spiriva Respimat 1.25 mg date of service

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale
  - Spiriva Respimat 1.25 mg is indicated for asthma
  - Spiriva Respimat 2.5 mg is indicated for COPD

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of at least 2 preferred long-acting anticholinergic agents (in combination or alone), as evidenced by paid claims or pharmacy printouts.
- Lonhala Magnair (glycopyrrolate) only:
  - The member must have failed a 30-day trial of Yupelri, as evidenced by paid claims or pharmacy printouts.



- Clinical justification must be provided explaining why the member is unable to use the preferred products (subject to clinical review).

### Therapeutic Duplication

- Anticholinergic medications are not covered with acetylcholinesterase inhibitors
  - The effects of an anticholinergic (blocks the effect of acetylcholine) and acetylcholinesterase inhibitors (prevents breakdown of acetylcholine) oppose each other, and the therapeutic effect of both products is diminished.

## Beta Agonists – Long-Acting

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
arformoterol	BROVANA (arformoterol)
formoterol	PERFOROMIST (formoterol)
SEREVENT DISKUS (salmeterol)	
STRIVERDI RESPIMAT (olodaterol)	

## Biologics

### Anti-IL-5 biologics

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CINQAIR (reslizumab) – <i>Medical Billing Only</i>	NUCALA (mepolizumab)
FASENRA (benralizumab)	

### Anti-IL-4/13 biologics

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DUPIXENT (dupilumab)	

### Eosinophil-directed biologics

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
XOLAIR (omalizumab) SYRINGES	
XOLAIR (omalizumab) VIALS – <i>Medical Billing Only</i>	

### Thymic Stromal Lymphopoietin (TSLP) blocker

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TEZSPIRE (tezepelumab-ekko) VIALS – <i>Medical Billing Only</i>	

### Prior Authorization Criteria

#### Prior Authorization Form - Asthma

##### Initial Criteria - Approval Duration: 3 months

- The requested medication must be prescribed by, or in consult with, an allergist/immunologist or pulmonologist
- The member must have failed at least one exacerbation requiring use of oral corticosteroids in the previous year despite continued compliant use of a high dose inhaled steroid in combination with a long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) as evidenced by paid claims or pharmacy printouts

### Anti-IL-5 biologics:

- The member has eosinophilic phenotype with eosinophil count  $\geq 150$  cells/mcL within the past 90 days
- Nucala: The member must have failed a 3-month trial of a preferred Anti-IL-5 biologic, as evidenced by paid claims or pharmacy printouts

### Eosinophil-directed biologics:

- The member has a serum total IgE level, measured before the start of treatment, of  $\geq 30$  IU/mL and  $\leq 700$  IU/mL in members age  $\geq 12$  years or  $\geq 30$  IU/mL and  $\leq 1300$  IU/mL in members ages 6 to  $< 12$  years.
- The member has had a positive skin test or in vitro reactivity to a perennial aeroallergen

### Renewal Criteria - Approval Duration: 12 months

- The member must have achieved a significant reduction in asthma exacerbations and utilization of rescue medications since treatment initiation since starting treatment with the requested medication, as evidenced by medical documentation (e.g., chart notes) attached to the request (subject to clinical review).

## Corticosteroids – Inhaled

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ASMANEX (mometasone) TWISTHALER	ALVESCO (ciclesonide)
budesonide suspension	ARMONAIR DIGIHALER (fluticasone)***
FLOVENT DISKUS (fluticasone)	ARNUITY ELLIPTA (fluticasone)
FLOVENT HFA (fluticasone) – Brand Required	ASMANEX HFA (mometasone)
PULMICORT FLEXHALER (budesonide)	fluticasone HFA
	PULMICORT RESPULES (budesonide)
	QVAR REDIHALER (beclomethasone)

### Electronic Duration Verification:

- Budesonide Suspension 1mg/2mL is payable for 30 days every 75 days. For diluted nasal rinses, please use 0.5mg/2mL instead of 1mg/2mL for doses 1mg per day or higher.
  - Guidelines recommend that once control is achieved, dose should be titrated down to minimum dose required to maintain control. For doses 1.5mg per day or lower, please use 0.5mg/2mL strength.

### Prior Authorization

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of each preferred inhaler of a unique active ingredient, as evidenced by paid claims or pharmacy printouts.
- Armonair Digihaler Only:
  - The member must have failed a 30-day trial of Asmanex HFA, as evidenced by pharmacy claims or pharmacy printouts.
  - Clinical justification must be provided explaining why the member is unable to use the preferred products (subject to clinical review).

## Steroid/Long-Acting Beta Agonist (LABA) Combination Inhalers

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ADVAIR DISKUS (fluticasone/salmeterol) – Brand Required	AIRDUO DIGIHALER (fluticasone/salmeterol)
ADVAIR HFA (fluticasone/salmeterol)	AIRDUO RESPICLICK (fluticasone/salmeterol)
DULERA (mometasone/formoterol)	BREO ELLIPTA (fluticasone/vilanterol) – Brand Required

SYMBICORT (budesonide/formoterol) – <i>Brand Required</i>	budesonide/formoterol
	fluticasone/salmeterol
	fluticasone/vilanterol
	WIXELA INHUB (fluticasone/salmeterol)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 30-day trial of each preferred agent, as evidenced by paid claims or pharmacy printouts
- For COPD diagnosis only: The member must currently be taking a long acting antimuscarinic agent

## Steroid/Anticholinergics/Long-Acting Beta Agonists Combinations

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TRELEGY ELLIPTA (fluticasone/umeclidinium/vilanterol)	BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed two 30-day trials of the following in unique combinations as part of a maximized triple therapy, as evidenced by paid claims or pharmacy printouts:
  - Long-Acting Anticholinergics
  - Long-Acting Beta Agonist
  - Inhaled Steroid

#### Non-Preferred Agents Criteria:

- The member must have failed a 30-day trial of the preferred product, as evidenced by paid claims or pharmacy printouts:

## Cystic Fibrosis

### Cystic Fibrosis – Inhaled Antibiotics

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
BETHKIS (tobramycin)	ARIKAYCE (amikacin/nebulizer)
KITABIS PAK (tobramycin/nebulizer) - <i>Brand Required</i>	CAYSTON (aztreonam)
tobramycin in 0.225% sodium chloride	TOBI (tobramycin) in 0.225% sodium chloride
	TOBI PODHALER (tobramycin)
	tobramycin/nebulizer

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Tobi Podhaler only:
  - The member must have failed two 28-day trials of tobramycin nebulized agents, as evidenced by paid claims or pharmacy printouts.
- Cayston only:
  - The member must be colonized with *Pseudomonas aeruginosa*.

- The member must have had a 28-day trial of tobramycin as evidenced by paid claims or pharmacy printouts.
- Arikayce only:
  - The member must be colonized with *Mycobacterium avium* complex (MAC).
  - The member must have not achieved negative sputum cultures after a minimum duration of 6 consecutive months of background treatment with a macrolide, a rifamycin, and ethambutol

## Cystic Fibrosis – CFTR Modulators

CLINICAL PA REQUIRED
KALYDECO (ivacaftor)
ORKAMBI (lumacaftor/ivacaftor)
SYMDEKO (tezacaftor/ivacaftor)
TRIKAFTA (elexacaftor/tezacaftor/ivacaftor)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have a CFTR mutation that the requested medication is FDA-approved to treat, as evidenced by medical documentation (e.g., chart notes, genetic testing) that is attached to the request

## Cystic Fibrosis – Osmotic Agent

CLINICAL PA REQUIRED
BRONCHITOL (mannitol) INHALER

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale

### Electronic Age Verification

- The member must be 18 years or older

### Prior Authorization

#### Initial Criteria - Approval Duration: 12 months

- Documentation of the Bronchitol Tolerance Test must be submitted

## Idiopathic Pulmonary Fibrosis

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
OFEV (nintedanib)	ESBRIET (pirfenidone)
pirfenidone	

### Prior Authorization

#### Initial Criteria - Approval Duration: 12 months

- The requested medication must be prescribed by, or in consult with, a pulmonologist or rheumatologist.
- The prescriber must submit documentation of the following:
  - The member must have forced vital capacity (FVC)  $\geq$  40% of predicted within prior 60 days

- The member must have carbon monoxide diffusing capacity (DLCO, corrected for hemoglobin) of 30% to 79% of predicted

## Interstitial Lung Disease

### First Line Therapy

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
azathioprine	ACTEMRA (tocilizumab)
cyclophosphamide	
mycophenolate mofetil (MMF)	

### Progressive Disease

PREFERRED AGENTS (NO PA REQUIRED)	PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
RITUXAN (rituximab) – Medical Billing Only	OFEV (nintedanib)	

### Prior Authorization

#### Initial Criteria - Approval Duration: 12 months

- The requested medication must be prescribed by, or in consult with, a pulmonologist or rheumatologist.
- The prescriber must submit documentation of the following:
  - The member must have forced vital capacity (FVC)  $\geq$  40% of predicted within prior 60 days
  - The member must have carbon monoxide diffusing capacity (DLCO, corrected for hemoglobin) of 30% to 79% of predicted.

## Rheumatology

### Axial Spondyloarthritis/Ankylosing spondylitis

#### TNF Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AVSOLA (infliximab-axxq) – Medical Billing Only	INFLECTRA (infliximab-dyyb) – Medical Billing Only
CIMZIA (certolizumab)	infliximab – Medical Billing Only
ENBREL (etanercept)	REMICADE (infliximab) – Medical Billing Only
HUMIRA (adalimumab)	SIMPONI (golimumab)
RENFLEXIS (infliximab-abda) – Medical Billing Only	SIMPONI (golimumab) ARIA – Medical Billing Only

#### Interleukin (IL) – 17 Inhibitors

PREFERRED AGENTS (ELECTRONIC STEP REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TALTZ (ixekizumab)***	COSENTYX (secukinumab)

#### Janus Kinase (JAK) Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
XELJANZ IR (tofacitinib) 5 mg, oral solution	RINVOQ ER (upadacitinib)
	XELJANZ IR (tofacitinib) 10 mg
	XELJANZ XR (tofacitinib)

## Electronic Step Care and Concurrent Medications

- Taltz: A total of 84 days of a TNF Inhibitor must be paid within 120 days prior to Taltz's date of service

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Cosentyx Only: The member must have failed a 90-day trial of Taltz, as evidenced by paid claims or pharmacy printouts.
- Rinvoq ER Only: The member must have failed 90-day trials of Xeljanz and another preferred product, as evidenced by paid claims or pharmacy printouts.
- Simponi Only: The member must have failed a 3-month trial of a TNF inhibitor, as evidenced by paid claims or pharmacy printouts.
- Inflectra, infliximab, Remicade, Xeljanz IR 10 mg, Xeljanz XR Only: See [Preferred Dosage Form](#) Criteria

## Behçet syndrome

### Phosphodiesterase 4 (PDE4) Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
OTEZLA (apremilast)	

### TNF Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AVSOLA (infliximab-axxq) – <i>Medical Billing Only</i>	INFLECTRA (infliximab-dyyb) – <i>Medical Billing Only</i>
ENBREL (etanercept)	infliximab – <i>Medical Billing Only</i>
HUMIRA (adalimumab)	REMICADE (infliximab) – <i>Medical Billing Only</i>
RENFLIXIS (infliximab-abda) – <i>Medical Billing Only</i>	

### Prior Authorization Criteria

- See [Preferred Dosage Form](#) Criteria

## Cryopyrin Associated Periodic Syndrome (CAPS)

*Includes: Familiar Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, and Neonatal Onset Multisystem Inflammatory Disease (NOMID) or Chronic Infantile Neurological Cutaneous and Articular (CINCA) Syndrome*

### Interleukin (IL) -1 Receptor Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
KINERET (anakinra)	ARCALYST (riloncept)
	ILARIS (canakinumab) – <i>Medical Billing Only</i>

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a specialist in the area of the member's diagnosis.

- The member has failed a 3-month trial of Kineret, as evidenced by paid claims or pharmacy print outs.
- The member has elevated pretreatment serum inflammatory markers (e.g., C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) serum amyloid A(SAA))
- The member has at least two of the following symptoms (as evidenced by documentation):
  - Urticaria-like rash
  - Cold/stress triggered episodes
  - Sensorineural hearing loss
  - Musculoskeletal symptoms of arthralgia/arthritis/myalgia
  - Chronic aseptic meningitis
  - Skeletal abnormalities of epiphyseal overgrowth/frontal bossing

## Familial Mediterranean Fever (FMF)

### Colchicine

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
COLCRYS (colchicine) TABLETS – <i>Brand Required</i>	colchicine capsules
	colchicine tablets
	GLOPERBA (colchicine) ORAL SOLUTION
	MITIGARE (colchicine) CAPSULE

### Interleukin (IL) -1 Receptor Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
KINERET (anakinra)	ARCALYST (rilonacept)
	ILARIS (canakinumab) – <i>Medical Billing Only</i>

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a specialist in the area of the member's diagnosis.
- The member experiences one or more attacks each month despite receiving maximally tolerated dose of colchicine for at least 6 months, as evidenced by paid claims or pharmacy print outs and clinical documentation.
- The member has failed a 3-month trial of Kineret, as evidenced by paid claims or pharmacy print outs.

## Giant Cell Arteritis (Temporal Arteritis)

### Interleukin (IL) -6 Receptor Inhibitors

CLINICAL PA REQUIRED
ACTEMRA (tocilizumab)
ACTEMRA (tocilizumab) – <i>Medical Billing Only</i>

### Prior Authorization Criteria

See [Medications that cost over \\$3000/month](#) Criteria



## Hyperimmunoglobulin D Syndrome/Mevalonate Kinase (MVK) Deficiency

### Symptomatic Treatment

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
NSAIDs	
glucocorticoids	
KINERET (anakinra)	

### Preventative Treatment

CLINICAL PA REQUIRED
ILARIS (canakinumab)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a specialist in the area of the member's diagnosis.
- The member has failed a 3-month trial of Kineret, as evidenced by paid claims or pharmacy print outs.
- The member is experiencing frequent and/or severe attacks that have significantly diminished quality of life

## Juvenile Idiopathic Arthritis

### Juvenile Idiopathic Arthritis – Enthesitis-Related Arthritis (ERA)

#### TNF Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ENBREL (etanercept)	
HUMIRA (adalimumab)	

#### Interleukin (IL) – 17 Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	COSENTYX (secukinumab)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member has failed a 3-month trial of a TNF inhibitor, as evidenced by paid claims or pharmacy print outs.

### Juvenile Idiopathic Arthritis – Polyarticular Course

#### TNF Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ENBREL (etanercept)	SIMPONI ARIA (golimumab) – <i>Medical Billing Only</i>
HUMIRA (adalimumab)	

### Interleukin (IL) -6 Receptor Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	ACTEMRA (tocilizumab)
	ACTEMRA (tocilizumab) – <i>Medical Billing Only</i>

### T-cell Costimulation Blocker

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ORENCIA (abatacept) – 125 mg/mL syringe	ORENCIA (abatacept) - 50 mg/0.4 mL and 87.5 mg/0.7 ml syringes
	ORENCIA (abatacept) – <i>Medical Billing Only</i>

### Janus Kinase (JAK) Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
XELJANZ IR (tofacitinib) 5 mg, oral solution	XELJANZ IR (tofacitinib) 10 mg
	XELJANZ XR (tofacitinib)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member has failed a 3-month trial of a TNF inhibitor, as evidenced by paid claims or pharmacy print outs.
- Xeljanz IR 10mg, Xeljanz XR Only: See [Preferred Dosage Form](#) Criteria

## Juvenile Chronic Arthritis – Systemic Onset

### Interleukin (IL) -1 Receptor Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	ILARIS (canakinumab) – <i>Medical Billing Only</i>

### Interleukin (IL) -6 Receptor Inhibitors

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ACTEMRA (tocilizumab)	
ACTEMRA (tocilizumab) – <i>Medical Billing Only</i>	

### TNF Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ENBREL (etanercept)	
HUMIRA (adalimumab)	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Actemra: See [Medications that cost over \\$3000/month](#) Criteria
- Ilaris: The member has failed a 3-month trial of Actemra, as evidenced by paid claims or pharmacy print outs.

### References:

1. Dewitt, E.M., Kimura, Y., Beukelman, T., Nigrovic, P.A., Onel, K., Prahalad, S., Schneider, R., Stoll, M.L., Angeles-Han, S., Milojevic, D., Schikler, K.N., Vehe, R.K., Weiss, J.E., Weiss, P., Ilowite, N.T., Wallace,

## Psoriatic Arthritis

### *TNF Inhibitors*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CIMZIA (certolizumab)	SIMPONI (golimumab)
ENBREL (etanercept)	SIMPONI (golimumab) ARIA – <i>Medical Billing Only</i>
HUMIRA (adalimumab)	

### *Phosphodiesterase 4 (PDE4) Inhibitor*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
OTEZLA (apremilast)	

### *Janus Kinase (JAK) Inhibitor*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
XELJANZ IR (tofacitinib) 5 mg, oral solution	RINVOQ ER (upadacitinib)
	XELJANZ IR (tofacitinib) 10 mg
	XELJANZ XR (tofacitinib)

### *T-cell Costimulation Blocker*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ORENCIA (abatacept) – 125 mg/mL syringe	ORENCIA (abatacept) – <i>Medical Billing Only</i>

### *Interleukin (IL)-23 Inhibitor*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	SKYRIZI (risankizumab)
	TREMFYA (guselkumab)

### *Interleukin (IL)-12/IL-23 Inhibitor*

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	STELARA (ustekinumab)

### *Interleukin (IL) – 17 Inhibitors*

PREFERRED AGENTS (ELECTRONIC STEP REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
TALTZ (ixekizumab)***	COSENTYX (secukinumab)

### *Electronic Step Care and Concurrent Medications*

- Taltz: A total of 84 days of a TNF Inhibitor must be paid within 120 days prior to Taltz's date of service.

### *Prior Authorization Criteria*

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed a 90-day trial of each of the following, as evidenced by paid claims or pharmacy printouts:
  - TNF inhibitor

- Interleukin (IL) – 17 inhibitor
- Xeljanz IR 10mg, Xeljanz XR Only: See [Preferred Dosage Form](#) Criteria

## Rheumatoid Arthritis

### Anti-CD20 Monoclonal Antibodies

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
RITUXAN (rituximab) – <i>Medical Billing Only</i>	

### T-cell Costimulation Blocker

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ORENCIA (abatacept) – 125 mg/mL syringe	ORENCIA (abatacept) – <i>Medical Billing Only</i>

### Interleukin (IL) -1 Receptor Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
KINERET (anakinra)	

### Interleukin (IL) -6 Receptor Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	ACTEMRA (tocilizumab)
	ACTEMRA (tocilizumab) – <i>Medical Billing Only</i>
	KEVZARA (sarilumab)

### Janus Kinase (JAK) Inhibitor

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
XELJANZ IR (tofacitinib) 5 mg, oral solution	OLUMIANT (baricitinib)
	RINVOQ ER (upadacitinib)
	XELJANZ IR (tofacitinib) 10 mg
	XELJANZ XR (tofacitinib)

### TNF Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CIMZIA (certolizumab)	SIMPONI (golimumab)
ENBREL (etanercept)	SIMPONI (golimumab) ARIA – <i>Medical Billing Only</i>
HUMIRA (adalimumab)	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- Xeljanz IR 10mg, Xeljanz XR Only: See [Preferred Dosage Form](#) Criteria
- The member must have had a 3-month trial of each of the following, as evidenced by paid claims and pharmacy printouts:
  - TNF Inhibitor
  - JAK inhibitor
  - T-cell Costimulation Blocker

## Adult-Onset Still's Disease

### Interleukin (IL) -1 Receptor Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
KINERET (anakinra)	ARCALYST (rilonacept)
	ILARIS (canakinumab) – <i>Medical Billing Only</i>

### TNF Inhibitors

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
AVSOLA (infliximab-axxq) – <i>Medical Billing Only</i>	INFLECTRA (infliximab-dyyb) – <i>Medical Billing Only</i>
RENFLEXIS (infliximab-abda) – <i>Medical Billing Only</i>	infliximab – <i>Medical Billing Only</i>
	REMICADE (infliximab) – <i>Medical Billing Only</i>

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a specialist in the area of the member's diagnosis.
- The member must have had a 3-month trial of each of Kineret, as evidenced by paid claims and pharmacy printouts:
- Remicade, infliximab, and Inflectra Only: See [Preferred Dosage Form](#) Criteria

## Tumor Necrosis Factor Receptor Associated Periodic Syndrome

CLINICAL PA REQUIRED
ILARIS (canakinumab)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- The requested medication must be prescribed by, or in consult with, a specialist in the area of the member's diagnosis.
- Documentation must be attached to confirm one of the following:
  - Genetic testing confirming pathogenic variants in the tumor necrosis factor receptor 1 (TNFR1) gene (TNF receptor superfamily member 1A, TNFRSF1A).
  - Both of the following:
    - Elevated serum inflammatory markers (e.g., C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) serum amyloid A(SAA))
    - History of recurrent fever, prominent myalgias, migratory rash, and periorbital edema

## Osteoporosis

### Antiresorptive Agents

#### Bisphosphonates

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
-----------------------------------	------------------------------------

alendronate	ACTONEL (risedronate)
alendronate oral solution	ATELVIA (risedronate DR)
ibandronate	FOSAMAX (alendronate)
risedronate IR	risedronate DR

### Prior Authorization Criteria

- Risedronate DR Only: See [Preferred Dosage Form](#) Criteria

### Calcitonins

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
calcitonin, salmon nasal spray	calcitonin, salmon vial
MIACALCIN (calcitonin, salmon) VIAL – Medical Billing Only	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months

- The member must be experiencing pain from an acute osteoporotic fracture
  - An FDA advisory panel concluded that the benefits of calcitonin do not outweigh its potential risks as an osteoporosis drug due to increased risk of malignancy. Bisphosphonates are more effective agents.

### Estrogen Agonist/Antagonist

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
raloxifene	EVISTA (raloxifene)

### Monoclonal Antibodies

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
PROLIA (denosumab) – Medical Billing Only	

## Anabolic Agents

### Parathyroid Hormone (PTH)

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
FORTEO (teriparatide)	teriparatide

### PTH-related protein

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	TYMLOS (abaloparatide)

### Monoclonal Anti-sclerostin Antibody

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	EVENITY (romosozumab-aqqg) – Medical Billing Only

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 2 years (1 year for Evenity)

- The member must have a current BMD T-score  $\leq -2.5$  OR new fracture (as evidenced by submitted documentation) after a 6-month trial of each of the following, as evidenced by paid claims or pharmacy printouts:
  - alendronate or risedronate
  - teriparatide
- Member must be at high risk of fracture, confirmed by documentation of at least one of the following:
  - The member with a history of hip or vertebral fracture
  - The member with a T-score of  $-2.5$  or lower at the femoral neck or spine
  - The member has a T-score of between  $-1.0$  and  $-2.5$  at the femoral neck or spine and a ten-year hip fracture risk of  $\geq 3\%$  as assessed with the FRAX
  - 10-year risk of a major osteoporosis-related fracture of  $\geq 20\%$  as assessed with the FRAX

## Substance Use

### Nicotine / Tobacco Dependence Treatment

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
bupropion SR	NICODERM CQ (nicotine) PATCH
CHANTIX (varenicline)	NICORETTE (nicotine polacrilex) GUM
nicotine lozenge	ZYBAN (bupropion SR)
nicotine patch	
nicotine polacrilex gum	
NICOTROL (nicotine polacrilex) INHALER	
NICOTROL (nicotine polacrilex) SPRAY	

#### Concurrent Medication and Step Care

- A total of 14 days of nicotine patch, Chantix, or Zyban must be paid within 40 days prior to Nicotrol Nasal Spray, nicotine lozenge, Nicotrol inhaler, or nicotine gum's date of service.
  - Better outcomes are associated with concurrent use of short acting and long-acting tobacco cessation products.
- A total of 14 days of nicotine patch, gum, lozenge, inhaler, or spray must be paid within 40 days prior to Zyban's date of service.
  - Better outcomes are associated with concurrent use of short acting and long-acting tobacco cessation products. Nicotine products can help bridge treatment until Zyban becomes effective.

#### Electronic Duration Verification

- A total of 12 consecutive weeks will be covered for all other products, every 6 months

Chantix: If the following conditions apply, please call for an override by calling provider relations at 1-800-755-2604:

- Patient is abstinent from tobacco
- Treatment duration is requested to be extended to 24 consecutive weeks

#### Therapeutic Duplication

- nicotine gum, lozenge, inhaler, and spray will not be paid concurrently
- Zyban will not be paid with other forms of bupropion



## Underutilization

- Nicotine Patch, Chantix, and Bupropion must be used adherantly and will reject on point of sale for late fill

## Opioid Use Disorder

### Alpha-2 Adrenergic Agonists

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
clonidine	LUCEMYRA (lofexidine)
guanfacine	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have had a 30-day trial of each preferred agent, as evidenced by paid claims or pharmacy printouts.
- Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review)

### Opioid Antagonist

PREFERRED AGENTS (NO PA REQUIRED)
naltrexone tablets
VIVITROL (naltrexone microspheres) INJECTION

### Naloxone Rescue Medications

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
KLOXXADO (naloxone) NASAL SPRAY	naloxone nasal spray – labeler 00093
nalmefene injection	ZIMHI (naloxone) SYRINGE
naloxone injection	
naloxone nasal spray – labeler 00781	
NARCAN (naloxone) NASAL SPRAY – <i>Brand Preferred</i>	

### Electronic Duration Verification

- One dose per 365 days is covered without prior authorization

The following information will need to be submitted as a follow up for the override by either emailing [medicaidpharmacy@nd.gov](mailto:medicaidpharmacy@nd.gov) or documenting on [General Prior Authorization Form](#):

- The provider must attest that it is known that the previous dose was taken by the member (and not diverted or given to another member)
- One of the following criteria must be met (A, B, or C)
  - The previous dose has expired
  - The dose was used by member for illicit drug use
  - The member is currently taking opioids and meets one of the following criteria:
    - The opioid dose must have been decreased
    - The provider has provided medical justification why the opioid dose as not been decreased

## Prior Authorization Criteria

### Initial Criteria - Approval Duration: 12 months

- The member must have had a 30-day trial of each preferred agent, as evidenced by paid claims or pharmacy printouts.
- Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review)

## Opioid Partial Agonist

### Therapeutic Duplication

- One strength of one medication is allowed at a time
- Opioid partial agonists are not allowed with:
  - methadone
  - carisoprodol
  - opioids

If 1 and 2 are met, please call for an override by calling provider relations at 1-800-755-2604 (chart notes will be required for requests beyond one fill):

1. The request is for one of the following:
  - A one-time fill request where pain cannot be reasonably treated with non-opioid therapy (e.g., surgery)
  - A request exceeding a one-time fill and a treatment plan has been provided with expected duration of use and why non-opioid therapy is not an option (subject to clinical review) or a taper plan is provided
2. One of the following is met:
  - Prescribers of both opioid prescription and MAT are aware of each other and agree to opioid therapy
  - MAT therapy has discontinued, and the prescriber of the opioid is aware of previous MAT treatment and confirms opioid therapy is required

### Underutilization

- Buprenorphine and buprenorphine/naloxone must be used compliantly and will reject on point of sale for late fill
- To request an override, submit a [Opioid Use Disorder Underutilization Form](#). Both the 1<sup>st</sup> and 2<sup>nd</sup> pages must be filled out.

## Mono Product

### Oral Agents

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
	buprenorphine tablets++

++ Clinically Non-Preferred: Naloxone is added to buprenorphine to prevent misuse. When taken correctly, a baby will have little to no absorption of naloxone which a growing body of evidence show is safe. Taking combination product during pregnancy or breastfeeding means that products don't need to be switched to a different medication after the baby is born during this high anxiety time. Risk of withdrawal to a neonate is a labeled warning on each product. Pregnancy and breastfeeding are not listed as contraindications on either product.

## Prior Authorization Criteria

### [Prior Authorization Form – Opioid Dependence](#)

#### Initial Criteria - Approval Duration: Until end of pregnancy / breastfeeding

- The member must be pregnant or breastfeeding, and estimated delivery date/duration of need for breastfeeding must be provided.

#### Non-Oral Agents

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
SUBLOCADE (buprenorphine)	

### Combination Product

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
buprenorphine-naloxone tablets	BUNAVAIL FILM (buprenorphine/naloxone)
	buprenorphine/naloxone film
	SUBOXONE FILM (buprenorphine/naloxone)
	ZUBSOLV (buprenorphine/naloxone)

## Prior Authorization Criteria

- See [DAW \(Dispense As Written\) Criteria](#)

## Obstetrics/Gynecology

### Endometriosis Pain

CLINICAL PA REQUIRED
MYFEMBREE (relugolix, estradiol, and norethindrone acetate)
ORILISSA (elagolix)

## Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months

- The member must have failed the following trials (A and B), as evidenced by paid claims or pharmacy printouts:
  - A. A 3-menstrual cycle trial of mefenamic acid or meclufenamate, celecoxib, ibuprofen 1800 mg/day or equivalent high dose NSAID
  - B. A 3-menstrual cycle trial of an oral estrogen-progestin or progestin contraceptives

#### Renewal Criteria - Approval Duration: 18 months

- Documentation must be submitted of improvement in pain score from baseline

## Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale.

# Estrogens

## Injectable

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DELESTROGEN (estradiol valerate) INJECTION – <i>Brand Required</i>	estradiol valerate injection
DEPO-ESTRADIOL (estradiol cypionate) INJECTION	PREMARIN (estrogens, conjugated) INJECTION

## Oral

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
estradiol tablet	ACTIVEVELLA (estradiol-norethindrone) TABLET
estradiol-norethindrone tablet	AMABELZ (estradiol-norethindrone) TABLET
MENEST (estrogens, esterified) TABLET	BIJUVA (estradiol-progesterone) CAPSULE
norethindrone-ethinyl estradiol tablet	ESTRACE (estradiol) TABLET
PREMARIN (estrogens, conjugated) TABLET	FEMHRT (norethindrone-ethyl estradiol) TABLET
PREMPHASE (estrogen, conj. m-progest) TABLET	FYAVOLV (norethindrone-ethinyl estradiol) TABLET
PREMPRO (estrogen, conj. m-progest) TABLET	JINTELI (norethindrone-ethinyl estradiol) TABLET
	LOPREEZA (estradiol-norgestimate) TABLET
	MIMVEY (estradiol-norgestimate) TABLET
	PREFEST (estradiol-norgestimate) TABLET

## Topical Cream/Gel/Spray

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ELESTRIN (estradiol) GEL MDP	DIVIGEL (estradiol) GEL PACKET
EVAMIST (estradiol) SPRAY	estradiol gel packet

## Topical Patch

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ALORA (estradiol) PATCH TWICE WEEKLY – <i>Brand Required</i>	CLIMARA (estradiol) PATCH WEEKLY
CLIMARA PRO (estradiol-levonorgestrel) PATCH – ONCE WEEKLY	DOTTI (estradiol) PATCH TWICE WEEKLY
COMBIPATCH (estradiol- norethindrone) PATCH – TWICE WEEKLY	estradiol patch twice weekly
estradiol patch weekly	LYLLANA (estradiol) PATCH TWICE WEEKLY
MENOSTAR (estradiol) PATCH ONCE WEEKLY	
MINIVELLE (estradiol) PATCH TWICE WEEKLY – <i>Brand Required</i>	
VIVELLE-DOT (estradiol) PATCH TWICE WEEKLY – <i>Brand Required</i>	

## Vaginal

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
estradiol vaginal cream	ESTRACE (estradiol) CREAM
ESTRING (estradiol)	estradiol vaginal tablet
PREMARIN (estrogens, conjugated) CREAM	FEMRING (estradiol)
VAGIFEM (estradiol) VAGINAL TABLET – <i>Brand Required</i>	YUVAFEM (estradiol) VAGINAL TABLET

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale.

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must have failed 30-day trials of at least two preferred products, as evidenced by paid claims or pharmacy printouts.

## Long-Acting Contraception

### Therapeutic Duplication

- One strength of one medication is allowed at a time

## Mifepristone

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale.

### [Prior Authorization Form - Mifepristone](#)

#### Initial Criteria - Approval Duration: 1 month

- Gestational age must be less than or equal to 70 days
- One of the following criteria must be met (A or B):
  - A. Pregnancy must have resulted from an act of rape or incest, and one of the following (I or II)**
    - I. A written statement signed by the provider must be submitted stating that the rape or act of incest has been reported to the appropriate law enforcement agency, or in the case of a minor who is a victim of incest, to an agency authorized to receive child abuse and neglect reports and it must be indicated to whom the report was made.
    - II. A written statement signed by the member and the provider must be submitted stating that the member's pregnancy resulted from rape or incest and by professional judgement, the provider agrees with the statement.
  - B. Both of the following must be met (I and II)**
    - I. The member must suffer from a physical disorder, physical injury, or physical illness, including a life-endangering physical condition caused by or arising from the pregnancy itself, that would as certified by a provider, place the member in danger of death unless an abortion is performed
    - II. A written statement signed by the provider must be provided indicating why, in the provider's professional judgement, the life of the member would be endangered if the fetus were carried to term

## Nausea/Vomiting – Pregnancy

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
DICLEGIS (doxylamine/vitamin B6) – <i>Brand Required</i>	BONJESTA (doxylamine/vitamin B6)
meclizine	doxylamine/vitamin B6
metoclopramide	
ondansetron	

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: until due date

- Member's due date must be provided
- The prescriber must submit medical justification explaining why the member cannot use a preferred product (subject to clinical review)

## Progesterone Injectable

PREFERRED AGENTS (CLINICAL PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
MAKENA (hydroxyprogesterone caproate) – <i>Brand Required</i>	hydroxyprogesterone caproate

### Prior Authorization Criteria

#### [Prior Authorization Form - Makena](#)

#### Initial Criteria - Approval Duration: week 20 to week 37 of pregnancy

- The week of pregnancy and due date must be indicated on request (must be 20 weeks or greater).
- Clinical justification must be provided explaining why medication is medically necessary

## Non-Injectable

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
progesterone capsule	

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale.

## Uterine Fibroids

CLINICAL PA REQUIRED
MYFEMBREE (relugolix, estradiol, and norethindrone acetate)
ORIAHNN (elagolix, estradiol, and norethindrone acetate)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 6 months

- The member must have failed the following trials (A and B), as evidenced by paid claims or pharmacy printouts:
  - A. A 3-menstrual cycle trial of mefenamic acid or meclufenamate, celecoxib, ibuprofen 1800 mg/day or equivalent high dose NSAID
  - B. A 3-menstrual cycle trial of an oral estrogen-progestin or progestin contraceptives

#### Renewal Criteria - Approval Duration: 18 months

- Documentation must be submitted of improvement in pain score from baseline

### Electronic Diagnosis Verification

- Pharmacy must submit prescriber supplied diagnosis with the claim at point of sale.

## Vaginal Infections

### Bacterial Infections

#### Oral

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
fluconazole tablet	

#### Vaginal

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CLEOCIN (clindamycin) SUPPOSITORY	CLEOCIN (clindamycin) CREAM
clindamycin cream	METROGEL-VAGINAL (metronidazole)
CLINDESSE (clindamycin) CREAM	VANDAZOLE (metronidazole) GEL
metronidazole gel	XACIATO (clindamycin phosphate) GEL
NUVESSA (metronidazole) GEL	

### Fungal Infections

#### Oral

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
fluconazole tablet	BREXAFEMME (ibrexafungerp) TABLETS
SOLOSEC (secnidazole) GRANULE PACKET	VIVJOA (oteseconazole) CAPSULES
tinidazole tablet	

#### Vaginal

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
terconazole cream	GYNAZOLE 1 (butoconazole) CREAM
terconazole suppository – labeler 00713	terconazole suppository – labeler 45802

#### Prior Authorization Criteria

##### Initial Criteria - Approval Duration: 12 months

- The member must have failed 30-day trials of all preferred agents of unique ingredients, as evidenced by paid claims or pharmacy printouts.
- Vivjoa Only:
  - The member must have failed a six-month trial of oral fluconazole maintenance prophylaxis treatment
  - The member must not be of reproductive potential defined as:
    - The member is postmenopausal
    - The member is known to not be of reproductive potential (e.g., history of tubal ligation, salpingo-oophorectomy, or hysterectomy)

## Preferred Dosage Forms List:

#### Prior Authorization Criteria

##### Initial Criteria - Approval Duration: 12 months



- The member must meet FDA-approved label for use (e.g., use outside of studied population will be considered investigational)
- Clinical justification must be provided explaining why the member is unable to use the preferred agents (subject to clinical review).
- The member must have failed a trial duration of 30 days (or less if duration is FDA approved) of each preferred agent (listed in boxes below) within the past 2 years, as evidenced by paid claims or pharmacy printouts.

## Azathioprine

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
azathioprine 50 mg	azathioprine 75 mg
	azathioprine 100 mg

## Brisdelle (paroxetine)

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
paroxetine tablets	paroxetine mesylate 7.5 mg capsules

## butalbital-acetaminophen-caffeine

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
butalbital-acetaminophen-caffeine tablets	butalbital-acetaminophen-caffeine capsules
VTOL LQ (butalbital-acetaminophen-caffeine) SOLUTION	ESGIC (butalbital-acetaminophen-caffeine) TABLET
	FIORICET (butalbital-acetaminophen-caffeine) CAPSULES
	ZEBUTAL (butalbital-acetaminophen-caffeine) CAPSULES

## citalopram

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
citalopram tablets	citalopram capsules
citalopram solution	

## cyanocobalamin

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
cyanocobalamin injection	NASCOBAL (cyanocobalamin) NASAL SPRAY

## Epinephrine

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
epinephrine – labeler 00093, 49502	epinephrine – labeler 11516
	EPIPEN (epinephrine)
	EPIPEN (epinephrine) JUNIOR
	SYMJEPI (epinephrine)

### *Electronic Duration Verification*

- 3 packs (initial and replacement doses) are covered every 180 days without prior authorization.

## gabapentin

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
gabapentin	GRALISE (gabapentin)
gabapentin	HORIZANT (gabapentin)
pramipexole	
ropinirole	

## glycopyrrolate

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CUVPOSA (glycopyrrolate) SOLUTION	DARTISLA ODT (glycopyrrolate)
glycopyrrolate	

## Jadenu (deferasirox)

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
deferasirox tablet for suspension	EXJADE (deferasirox tablet for suspension)
deferasirox tablets	deferasirox sprinkle
	JADENU (deferasirox) SPRINKLE
	JADENU (deferasirox) TABLETS

## Kits

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
FDA approved products prescribed separately	CAMPHOTREX 4%-10% ROLL-ON G (menthol/camphor)
	CENTANY AT (mupirocin)
	CICLOPIROX (ciclopirox/urea/camphor/methol)
	CICLODAN (ciclopirox/urea/camphor/methol)
	CICLODAN (ciclopirox/skin cleanser 28)
	CLINDACIN ETZ (clindamycin phos/skin clnsr 19)
	CLINDACIN PAC (clindamycin phos/skin clnsr 19)
	CLINDAVIX (clindamycin/dimethacone/zinc oxide)
	CLOBETEX (clobetasol/desloratadine)
	CYCLOPAK (cyclobenzaprine/lidocaine/prilocaine/glycerine)
	DERMACINRX ARM PAK (lidocaine/dimethacone)
	DERMACINRX LEXITRAL PHARMAP (diclofenac/capsicum oleoresin)
	DERMACINRX PHN PAK (lidocaine/emollient cmb No. 102)
	DERMACINRX SILAPAK (triamcinolone/dimeth/silicone)
	DERMACINRX SILAZONE (triamcinolone/silicones)
	DERMACINRX SURGICAL PHARMAP (mupirocin/chlorhexidine/dimeth)
	DERMACINRX THERAZOLE PAK (clotrimazole/betameth dip/zinc)
	DERMACINRX ZRM PAK (lidocaine/dimethicone)
	DERMALID 5% PATCH (lidocaine/elastic bandage)
	ELLZIA PAK (triamcinolone/dimethicone)
	ESOMEPRAZOLE KIT (esomeprazole mag/glycerin)
	ECONASIL (econazole/gauze/silicone)

	FLUOPAR (fluocinonide/dimethacone)
	FLUOVIX PLUS (fluocinonide/silicone, adhesive)
	GABACAINE KIT (gabapentin/lidocaine)
	INAVIX (diclofenac/capsaicin)
	INFAMMACIN (diclofenac/capsicum)
	KETODAN (ketoconazole/skin cleanser 28)
	LIDOPURE PATCH 5% COMBO PAC (lidocaine/kinesiology tape)
	LIDOTIN (gabapentin/lidocaine/silicone)
	LIPRITIN (gabapentin/lidocaine/prilocaine/dressing)
	LOPROX (ciclopirox/skin cleanser No. 40)
	MIGRANOW KIT (sumatriptan/menthol/camphor)
	MORGIDOX (Doxycycline/skin cleanser No. 19)
	NAPROTIN (naproxen/capsicum)
	NOPIOID-TC KIT (cyclobenzaprine/lidocaine/menthaine)
	NUVAKAAN KIT (lidocaine/prilocaine/silicone)
	NUSURGEPAK (mupirocin/chlorhexidine/dimethacone)
	NUTRIARX (Triamcinolone/dimethacone/silicone)
	PRILO PATCH KIT (lidocaine/prilocaine)
	PRIZOTRAL II (lidocaine/prilocaine/lidocaine)
	PRO DNA MEDICATED COLLECTION (lidocaine/glycerin)
	SALEX (salicylic acid/ceramide comb 1) CREAM KIT
	SALEX (salicylic acid/ceramide comb 1) LOTION KIT
	SILAZONE-II KIT (triamcinolone acetone/silicones)
	SOLARAVIX (Diclofenac/silicone, adhesive)
	SUMADAN KIT (sulfacetamide/sulfur/cleansr23)
	SUMAXIN CP KIT (sulfacetamide/sulfur/cleansr23)
	TICANASE KIT (fluticasone/sodium chloride/sodium bicarbonate)
	TRIVIX (Triamcinolone/dimethacone/silicone)
	TRIXYLITRAL (diclofenac/lidocaine/tape)
	XRYLIX 1.5% KIT (diclofenac/kinesiology tape)
	ZILACAINE PATCH 5% COMBO PA (lidocaine/silicone, adhesive)

## levothyroxine

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
levothyroxine tablet	Ermeza (levothyroxine) solution
THYQUIDITY (levothyroxine) ORAL SOLUTION	levothyroxine capsules
TIROSINT (levothyroxine) 13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg 100 mcg 112 mcg, 125 mcg, 137 mcg, and 150 mcg capsule – <i>Brand Required</i>	SYNTHROID (levothyroxine) TABLET
	TIROSINT (levothyroxine) 175 mcg and 200 mcg capsule
	TIROSINT (levothyroxine) solution

## metformin

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
metformin ER	FORTAMET (metformin)
RIOMET (metformin) ORAL SOLUTION	GLUMETZA (metformin)
RIOMET ER (metformin) ORAL SOLUTION	metformin ER gastric retention 24 hr
	metformin ER osmotic

## methotrexate

**Required trial duration:** 6 weeks

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
methotrexate	OTREXUP (methotrexate) AUTO-INJECTOR
XATMEP (methotrexate) SOLUTION	RASUVO (methotrexate) AUTO-INJECTOR
	REDITREX (methotrexate) SYRINGE
	TREXALL (methotrexate) TABLET

## montelukast

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
montelukast chewable tablets	montelukast granules
montelukast tablets	

### *Electronic Age Verification*

- Montelukast granules are preferred for ages 1 and under

## mupirocin

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
mupirocin ointment	mupirocin calcium cream

## nitroglycerin

**Required trial duration:** 1 dose while on preventative medication

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
nitroglycerin sublingual tablets	GONITRO (nitroglycerin) SUBLINGUAL PACKET
	nitroglycerin spray
	NITROLINGUAL (nitroglycerin) SPRAY

## Nocdurna (desmopressin)

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
desmopressin	NOCDURNA (desmopressin)

## Pregabalin

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
pregabalin	LYRICA (pregabalin)
	LYRICA CR (pregabalin)
	pregabalin ER

## Procysbi (cysteamine)

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
CYSTAGON (cysteamine)	PROCYSBI (cysteamine)
	PROCYSBI GRANULES (cysteamine)

## Steroids – Oral

Emflaza: See [Emflaza](#) Criteria on this document

Tarpeyo: See [Tarpeyo](#) Criteria on this document

Rayos required trial duration: 12 weeks with 2 AM dosing of prednisone

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
budesonide 3 mg EC capsules	ALKINDI (hydrocortisone) SPRINKLE CAPSULE
cortisone	budesonide 9 mg ER tablet
dexamethasone	EMFLAZA (deflazacort)
hydrocortisone	HEMADY (dexamethasone)
methylprednisone	MILLIPRED (prednisolone)
prednisolone sodium phosphate 5 mg/5 ml, 15 mg/5 ml, 25 mg/5 ml	ORTIKOS (budesonide)
prednisone solution	prednisone intensol
prednisone tablets	prednisolone sodium phosphate ODT
	prednisolone sodium phosphate 10 mg/5 ml, 20 mg/5 ml solution
	RAYOS (prednisone)
	TAPERDEX (dexamethasone)
	TARPEYO (budesonide EC)
	UCERIS (budesonide)

## tacrolimus

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
tacrolimus	ASTAGRAF XL (tacrolimus)
	ENVARUSUS ER (tacrolimus)

## ursodiol

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (PA REQUIRED)
ursodiol capsule	RELTONE (ursodiol) CAPSULE
ursodiol tablet	URSO 250 (ursodiol) TABLET
	URSO FORTE (ursodiol) TABLET

# Preferred Diabetic Supply List (PDSL)

## Electronic Step Care and Concurrent Medications

- One of the following must apply:
  - A total of a 25-day supply of one of the following must be paid within 150 days prior to diabetic supplies' date of service:
    - agents that cause hypoglycemia (insulin or sulfonylureas)
    - agents that indicate pregnancy (folic acid or prenatal vitamins)

If the following condition applies, please call for a 6-month override by calling provider relations at 1-800-755-2604:

- The member has diabetes and is newly diagnosed, acutely ill, or has a significant change in health status causing blood sugar variability despite not being on a agent causing hypoglycemia or having a gestational diabetes diagnosis
- The ADA guidelines point out the lack of clinical utility and cost-effectiveness of routine Self-Monitoring of Blood Glucose (SMBG) in non-insulin treated members. Both the Society of General Internal Medicine and the Endocrine Society recommend against routine SMBG for type 2 diabetes members not on insulin or agents that cause hypoglycemia.

## Test Strips

### Quantity Limits

- 200 test strips are covered every 30 days

Manufacturer Name	NDC	Product Description
LifeScan Inc.	53885-0244-50	OneTouch Ultra Blue
LifeScan Inc.	53885-0245-10	OneTouch Ultra Blue
LifeScan Inc.	53885-0270-25	One Touch Verio Test Strip
LifeScan Inc.	53885-0271-50	One Touch Verio Test Strip
LifeScan Inc.	53885-0272-10	One Touch Verio Test Strip
LifeScan Inc.	53885-0994-25	OneTouch Ultra Blue
Ascensia Diabetes Care	00193-7080-50	Contour Blood Glucose Test Strips
Ascensia Diabetes Care	00193-7090-21	Contour Blood Glucose Test Strips
Ascensia Diabetes Care	00193-7311-50	Contour Next Blood Glucose Test Strips
Ascensia Diabetes Care	00193-7312-21	Contour Next Blood Glucose Test Strips

## Meters

### Quantity Limits

- 1 meter is covered every 365 days

Manufacturer Name	NDC	Product Description
LifeScan Inc.	53885-0044-01	OneTouch Verio Flex Blood Glucose Meter

LifeScan Inc.	53885-0046-01	OneTouch Ultra 2 Blood Glucose Meter
LifeScan Inc.	53885-0657-01	OneTouch Verio Blood Glucose Meter
LifeScan Inc.	53885-0927-01	OneTouch Verio Reflect System
Ascensia Diabetes Care	00193-7377-01	Contour Next Blood Glucose Meter
Ascensia Diabetes Care	00193-7252-01	Contour Next EZ Blood Glucose Meter
Ascensia Diabetes Care	00193-7189-01	Contour Blood Glucose Meter
Ascensia Diabetes Care	00193-9545-01	Contour Blood Glucose Meter
Ascensia Diabetes Care	00193-9628-01	Contour Next EZ Blood Glucose Meter
Ascensia Diabetes Care	00193-7553-01	Contour Next EZ Blood Glucose Meter
Ascensia Diabetes Care	00193-7818-01	Contour Next One Blood Glucose Meter

## Continuous Glucose Monitors (CGM)

### Quantity Limits

- NDC 08627005303- Dexcom G6 Sensor: 3 ten-day sensors/box= up to qty 9/90-day supply
- NDC 08627001601- Dexcom G6 Transmitter: 1= 90-day supply (4 transmitters/365 days allowed)
- NDC 08627009011- Dexcom G6 Receiver: 1= 250-day supply (1 receiver/365 days allowed)
- NDC 08627007701- Dexcom G7 Sensor: 1 ten-day sensor/box= up to qty 9/90-day supply
- NDC 08627007801- Dexcom G7 Receiver: 1= 250-day supply (1 receiver/365 days allowed)

Manufacturer Name	NDC	Product Description
Dexcom, Inc.	08627-0016-01	Dexcom G6 Transmitter
Dexcom, Inc.	08627-0053-03	Dexcom G6 Sensor
Dexcom, Inc.	08627-0091-11	Dexcom G6 Receiver
Dexcom, Inc.	08627-0077-01	Dexcom G7 Sensor
Dexcom, Inc.	08627-0078-01	Dexcom G7 Receiver

### Prior Authorization Criteria

#### [Continuous Glucose Monitor \(CGM\) Prior Authorization Form](#)

### Prior Authorization Criteria

#### Initial Criteria - Approval Duration: 12 months

- The member must meet **one of the following** criteria (1, 2, or 3):
  1. The member uses **one of the following** insulin regimens, as evidenced by paid claims or pharmacy print outs:
    - Intensive insulin regimen - 3 or more insulin injections per day consisting of short acting and long-acting insulin doses
    - Humulin R U-500
    - Short acting insulin using an insulin pump
  2. The member is pregnant with pre-existing or gestational diabetes
  3. The member has recurrent hypoglycemia due to one of the following diagnoses and CGM is recommended by a medical geneticist, or an endocrinology specialist as evidenced by chart notes:
    - Inborn errors of metabolism/metabolic syndrome with risk of hypoglycemia (e.g., glycogen storage disease (GSD), hereditary fructose intolerance (HFI), fatty acid oxidation disorders, gluconeogenesis disorders, ketogenesis disorders)



- Hyperinsulinemia syndromes (e.g., Insulinoma, Persistent Hyperinsulinemia Hypoglycemia of Infancy (PHHI), Non-insulinoma Pancreatogenesis Hypoglycemia Syndrome (NIPHS), Nesideoblastosis)
- In addition, members with Type 2 Diabetes (not on Humulin R U-500 or insulin pump) must meet **one of the following** criteria:
  - The member has been on short-acting and long-acting insulin for at least 6 months, as evidenced by refill history with paid claims or pharmacy print outs and is adjusting dose based on glucose levels, as evidenced by submitted chart notes.
  - The member was unable to achieve goal (A1c < 7%) despite triple combination therapy consisting of long-acting insulin dose of at least 10 units per day combined with two other non-insulin antihyperglycemic agents (oral or injectable), at the maximum tolerated dose with good adherence at least 3 months, as evidenced by refill history with paid claims or pharmacy printouts.
- The prescriber must attest to **all the following**:
  - The member will maintain regular provider visits to review glycemic control every 3-6 months.
    - CGM data will be reviewed at provider office visits
    - CGM data will be used in the clinical decision-making process and documented in chart notes
- The prescriber must provide most recent A1c for members with diabetes.
- The member must not have life expectancy of less than 12 months.

Renewal Criteria - Approval Duration: 12 months

*For diagnosis of diabetes:*

- Time-in-Range (TIR) percentage must be submitted
- The most recent A1c must be submitted for members with diabetes.
- One of the following must be met:
  - *Approval 12 months:*  
A1c and/or TIR must progress toward or be within goal (A1c < 7% or TIR > 70%) from last approval:
    - Progress note must be submitted for 1 visit within the past year indicating CGM data was reviewed by provider to evaluate/adjust therapy
  - *Approval 6 months:*  
A1c and/or TIR is outside of goal and has worsened (for A1c, worsened is defined as > 0.1% increase) from last approval.
    - A treatment plan to improve control has been submitted
    - Progress notes must be submitted for 2 visits within the past year indicating CGM data was reviewed by provider to evaluate/adjust therapy and member is following treatment plan for adjusting insulin doses based on CGM glucose readings

## Test Strip Requests after CGM approval

For replacement inquiries, sensor overpatches, and troubleshooting please contact Dexcom Global Technical Support at 1-844-607-8398 or visit <https://www.dexcom.com/contact>

- ND Medicaid will cover 200 test strips per year to facilitate instances where Dexcom G6 is not displaying blood sugar readings that correspond with the symptoms member is experiencing or that are consistently outside of the 20 rule: [Is my Dexcom sensor accurate?](#)
- The following criteria will apply if Dexcom G6 has previously been paid, but will no longer be used and regular test strip quantities are requested:
  - The member must be seen for education by a diabetic specialist or educator
  - Documentation must be submitted noting what caused the CGM failure and education / mitigation efforts that have been taken to prevent the failure, including the following as applicable:
    - Stickiness: Skin adhesive and / or overpatches have been trialed without success
    - Sensor not working: at least 2 sensor replacements have been trialed

## CGM Supplies Coverage FAQ

---

### **Does ND Medicaid cover Dexcom G6 daily calibration?**

- No, the unique Dexcom G6 sensor code must be entered that is printed on each sensor's adhesive label during the startup period so finger sticks and calibration are not required.
- [Does the Dexcom G6 Continuous Glucose Monitoring \(CGM\) System require calibrations?](#)

### **Will test strips be covered in addition to Dexcom G6?**

- Yes, ND Medicaid will cover 200 test strips per year to facilitate instances where Dexcom G6 is not displaying blood sugar readings that correspond with the symptoms member is experiencing or that are consistently outside of the 20 rule.
- [Is my Dexcom sensor accurate?](#)

### **Does ND Medicaid cover additional sensors, transmitters, or receivers if mine is faulty or broken?**

- For replacement inquiries, sensor overpatches, and troubleshooting please contact Dexcom Global Technical Support at 1-844-607-8398 or visit <https://www.dexcom.com/contact>

### **If my patient is currently on a CGM that is not Dexcom G6, is there a grandfathering period?**

- No, the member should be converted to Dexcom G6 billed on the pharmacy side to obtain ND Medicaid coverage.

### **Does ND Medicaid cover Dexcom G6 for members in Long Term Care facilities?**

- If a member has Medicare Part B, Medicare Part B will need to be billed primary and ND Medicaid may cover the remainder as a crossover claim with medical billing.
- If a member does not have Medicare Part B, an override will need to be obtained for coverage.
- In all cases, the member must meet prior authorization criteria for coverage.

### **How is CGM billed for Medicaid Expansion members?**

- Dexcom will need to be billed to ND Medicaid for Dexcom G6 for Medicaid Expansion members.
- Grandfathered Medicaid Expansion members: ND Medicaid renewal prior authorization criteria will need to be met for coverage continuation beyond the 1 year grandfathering period.

### **How is CGM billed for Special Health Services (SHS) members eligible for ND Medicaid?**

- Dexcom will need to be billed to ND Medicaid for Dexcom G6 for SHS members. The group will need to be changed from the SHS group to the ND Medicaid group.
- Grandfathered Special Health Services members: ND Medicaid renewal prior authorization criteria will need to be met for coverage continuation beyond the 1 year grandfathering period.
- Members receiving CGM other than Dexcom G6 will need to continue to work with SHS for CGM coverage.

## *Billing FAQ*

### **If I bill Medtronic Guardian sensors under the code A9276 on the medical benefit, will this still be covered?**

- No, the code will only be covered for members with primary insurance plans that require CGM to be billed on the medical side. Members will need to be converted to Dexcom G6 billed on the pharmacy side to obtain ND Medicaid coverage.

### **Will ND Medicaid cover Dexcom G6 through medical billing?**

- ND Medicaid requires Dexcom to be billed through pharmacy NCPDP D.0 billing.
- Exceptions may be made for cases where primary insurance requires Dexcom to be billed with medical billing.

## *Other Insurance FAQ*

### **If primary insurance only covers CGM other than Dexcom G6, will ND Medicaid pay the copay?**

- If primary insurance excludes coverage of a Dexcom G6, ND Medicaid may make an exception to cover a non-preferred CGM if the copay is nominal. Documentation of the exclusion must be submitted with the prior authorization request.
- If primary insurance does cover Dexcom G6, the member will need to switch to Dexcom G6 for ND Medicaid to pay the copay.

### **Does ND Medicaid cover Dexcom G6 if member has primary insurance, but it does not cover CGM?**

- ND Medicaid may cover Dexcom G6 as a primary payer if CGM is wholly excluded from the primary insurance benefit. Documentation stating the exclusion from the primary insurance must be submitted with the prior authorization request.
- ND Medicaid will not cover CGM as a primary payer if a prior authorization is denied for medical necessity by the primary insurance.

**Will ND Medicaid cover Dexcom G6 if member meets primary insurance prior authorization criteria, but does not meet ND Medicaid prior authorization criteria?**

- ND Medicaid will not cover Dexcom G6 if ND Medicaid prior authorization criteria is not met, regardless of approval status with primary insurance. Under rare circumstances, exceptions may be made if the copay is nominal as long as the member maintains primary insurance coverage with a Dexcom G6 benefit.

## Tubeless Insulin Pumps

### Quantity limits:

- NDC 08508200032- Omnipod DASH Intro Kit – 1 per 30-day supply (payable 1 per 365 days)
- NDC 08508200005- Omnipod DASH Refill Pods – 10 pods per 30-day supply
- NDC 08508300001- Omnipod 5 Intro Kit - 1 per 30-day supply (payable 1 per 365 days)
- NDC 08508300021- Omnipod 5 Refill Pods - 10 pods per 30-day supply

Requests for greater than 10 pods per 30 days must include clinical justification vs using a tubed pump. If requested quantity exceeds 15 pods per 30 days, request will be denied for Omnipod. Member may still be eligible for tubed pump (requires separate medical prior authorization).

Manufacturer Name	NDC	Product Description
Insulet, Inc.	08508-2000-32	Omnipod DASH Intro Kit
Insulet, Inc.	08508-2000-05	Omnipod DASH Refill Pods
Insulet, Inc.	08508-3000-01	Omnipod 5 Intro Kit
Insulet, Inc.	08508-3000-21	Omnipod 5 Refill Pods

### Prior Authorization Criteria

#### [Tubeless Insulin Pump \(Omnipod\) Prior Authorization Form](#)

##### Initial Criteria - Approval Duration: 12 months

- The member must have Diabetes Type 1
- The member must be less than 21 years old
- The member must be receiving multiple daily injections of insulin (at least 3 injections per day)
- The member has documented frequency of blood glucose-testing an average of 4 times per day or use of CGM during the 2 months prior to request
- The prescriber must attest to all the following:
  - The prescriber is trained in the data management platform used with the Omnipod System.
  - The member will maintain regular provider visits to review Omnipod data every 3-6 months.
  - The member has been adherent to provider appointments for past 6 months
  - The member or caregiver has the mental, physical, auditory, visual, and motivational ability to manage the pump.
  - The member will receive Omnipod training from Omnipod System Trainer or a healthcare provider.
  - The member must have received diabetic education within past year
- The prescriber must provide most recent A1C and/or Time-in-Range percentage

- The member had not received a tubed insulin pump within the past 4 years or must be experiencing elevated glucose levels from disconnecting due to contact or swimming sports

Renewal Criteria - Approval Duration: 12 months

- The member must be less than 21 years old unless request is for continuation of coverage where ND Medicaid has previously paid for Omnipod
- The most recent A1C and/or Time-in-Range percentage must be submitted
- The member has documented frequency of blood glucose-testing an average of 4 times per day or use of CGM during the 2 months prior to request
- Omnipod data has been reviewed with member as evidenced by submitted progress note within the past 6 months
- The member must be using a compatible rapid acting insulin

## Omnipod Coverage FAQ

---

For replacement inquiries or troubleshooting please contact Insulet Customer Care team at 1-800-591-3455 or visit <https://na.myomnipod.com/contact>.

### **Does ND Medicaid cover insulin pens, syringes, or vials if Omnipod is discontinued?**

- Transition should be coordinated with diabetic specialist or educator
- Current vials of rapid acting insulin should be exhausted before switching to pens. See Insulin category for a list of preferred products.
- Current supply of pods should be exhausted prior to switching to injections.

### **Does ND Medicaid cover additional pods or Personal Diabetes Manager (PDM) if mine is faulty or broken?**

- For replacement inquiries or troubleshooting please contact Insulet Customer Care team at 1-800-591-3455 or visit <https://na.myomnipod.com/contact>.

### **Does ND Medicaid cover additional pods, Personal Diabetes Manager (PDM), replacement USB cords or rechargeable batteries if mine is lost or stolen?**

- For replacement inquiries or troubleshooting please contact Insulet Customer Care team at 1-800-591-3455 or visit <https://na.myomnipod.com/contact>.
- PDMs, USB cords, and rechargeable batteries may be replaced once every 365 days.
- Pods are not replaceable.

### **Will ND Medicaid cover Omnipod through medical billing?**

- ND Medicaid requires Omnipod to be billed through pharmacy NCPDP D.0 billing.

### **How is Omnipod billed for Medicaid Expansion and Special Health Services (SHS) ND Medicaid eligible members?**

- Omnipod will need to be billed to ND Medicaid for Medicaid Expansion members.
- Omnipod will need to be billed to ND Medicaid for SHS members who are eligible for ND Medicaid. The group will need to be changed from the SHS group to the ND Medicaid group.
- ND Medicaid has pre-emptively entered initial prior authorizations for SHS members utilizing Omnipod for 1 year. ND Medicaid renewal prior authorization criteria will need to be met for coverage continuation beyond the grandfathering period.

### **Does ND Medicaid cover Omnipod for members in Long Term Care facilities?**

- If a member is eligible for Medicare, Medicare Part D will need to be billed primary.
- If member is not eligible for Medicare, the member must meet prior authorization criteria for coverage.

### **Does ND Medicaid cover Omnipod if member has primary insurance, but it does not cover tubeless pumps?**

- ND Medicaid may cover Omnipod as a primary payer if insulin pumps are wholly excluded from the primary insurance benefit. Documentation stating the exclusion from the primary insurance must be submitted with the prior authorization request.
- ND Medicaid will not cover Omnipod as a primary payer if a prior authorization is denied for medical necessity by the primary insurance or primary insurance only covers tubed pumps.

**Will ND Medicaid cover Omnipod if member meets primary insurance prior authorization criteria, but does not meet ND Medicaid prior authorization criteria?**

- ND Medicaid will not cover Omnipod if ND Medicaid prior authorization criteria is not met, regardless of approval status with primary insurance. Under rare circumstances, exceptions may be made if the copay is nominal as long as the member maintains primary insurance coverage with a Omnipod benefit.

# Appendix A

## Prior Authorization Review Dates

Date	Category
12/07/2022	Prurigo Nodularis
12/07/2022	Endometriosis Pain
12/07/2022	Hematopoietic Syndrome of Acute Radiation Syndrome (NPlate)
12/07/2022	Amyloidosis
12/07/2022	Amyotrophic Lateral Sclerosis (ALS)
12/07/2022	Chelating Agents
09/07/2022	Presbyopia
09/07/2022	Hypertrophic Cardiomyopathy
09/07/2022	Cushing's Syndrome
09/07/2022	Vernal Keratoconjunctivitis
09/07/2022	Wilson's Disease
06/01/2022	Familial Cholestasis Pruritis
03/02/2022	Chronic Kidney Disease
03/02/2022	Lupus
12/01/2021	Atopic Dermatitis/Eczema
12/01/2021	Non-Stimulants for ADHD
09/01/2021	Heart Failure
09/01/2021	Nasal Polyps
09/01/2021	Chronic Idiopathic Urticaria
09/01/2021	Uterine Fibroids
09/01/2021	Sedative/Hypnotics - Hetlioz
06/02/2021	Sickle Cell Disease
06/02/2021	Fabry Disease
06/02/2021	Imcivree
06/02/2021	Bowel preparation agents
03/03/2021	Evrysdi
03/03/2021	Hereditary angioedema
03/03/2021	Irritable bowel syndrome
12/02/2020	Agents for the treatment of diabetic gastroparesis
12/02/2020	Oriahnn
12/02/2020	Dojolvi
09/02/2020	Palforzia

09/02/2020	Mytesi
09/02/2020	Antifibrinolytic agents
09/02/2020	ACL inhibitors (Nexletol, Nexlizet)
09/02/2020	Cystic fibrosis agents
06/03/2020	Conjupri
03/04/2020	Glucagon agents
03/04/2020	Ofev for treatment of scleroderma with interstitial lung disease
12/04/2019	antifungal agents for aspergillus and candidiasis infections
12/04/2019	eosinophilic asthma agents
09/04/2019	short-acting opioid analgesic agents
09/04/2019	agents for the treatment of thrombocytopenia
09/04/2019	agents for the treatment of interstitial cystitis
09/04/2019	agents for the treatment of narcolepsy
06/05/2019	Sivextro
06/05/2019	Nuzyra
06/05/2019	agents for treatment of osteoporosis
06/05/2019	agents for treatment of hyperkalemia
06/05/2019	agents for treatment of Parkinson's disease
04/09/2019	Orilissa
04/09/2019	agents for treatment of vaginal anti-infectives
04/09/2019	agents for treatment of glaucoma
04/09/2019	agents for treatment of dry eye syndrome
12/05/2018	glyburide and Avandia
12/05/2018	Lucemyra
12/05/2018	Palynziq
12/05/2018	Roxybond
12/05/2018	Siklos
06/06/2018	Anzemet and Zuplenz
06/06/2018	biosimilar agents
06/06/2018	topical corticosteroid agents
06/06/2018	Dupixent
06/06/2018	Gocovri
06/06/2018	Tussicaps
03/07/2018	Skelaxin
03/07/2018	Eucrisa
09/06/2017	Proglycem
09/06/2017	Biltricide
03/01/2017	prednisolone ODT, Millepred, Veripred
03/01/2017	metformin OSM
03/01/2017	testosterone oral
12/07/2016	Namenda XR
12/07/2016	Dihydroergotamine
12/07/2016	Tetracycline
12/07/2016	Spiriva Respimat 2.5 mcg

12/07/2016	ophthalmic corticosteroids
12/07/2016	erythropoiesis-stimulating agents
09/07/2016	kits
09/07/2016	dipeptidyl peptidase-4 (DPP-4) inhibitors
09/07/2016	immunoglobulins
09/07/2016	topical agents used to treat plaque psoriasis
09/07/2016	platelet aggregation inhibitors
09/07/2016	antihyperuricemics
06/01/2016	Glumetza
06/01/2016	naloxone rescue medications
06/01/2016	naltrexone
06/01/2016	Edecrin
06/01/2016	interleukin-5 antagonist monoclonal antibodies
06/01/2016	acitretin
06/01/2016	lice medications
06/01/2016	NK1 receptor antagonists
06/01/2016	Tirosint
03/02/2016	insulins
03/02/2016	steroid inhalers
03/02/2016	digestive enzymes
03/02/2016	nasal steroids
03/02/2016	otic anti-infectives
03/02/2016	ulcer anti-infectives
12/02/2015	Marinol
12/02/2015	skin pigment products
12/02/2015	inhaled corticosteroid/LABA combination products
12/02/2015	Movantik
12/02/2015	medications used to treat irritable bowel syndrome/OIC
12/02/2015	medications used to treat ulcerative colitis
12/02/2015	SGLT2 products
12/02/2015	immediate release oxycodone
12/02/2015	inhaled anti-infectives for cystic fibrosis
12/02/2015	leukotriene modifiers
09/02/2015	cholesterol lowering drugs/PCSK9 inhibitors
09/02/2015	injectable anticoagulants
09/02/2015	Akynzeo
09/02/2015	Nuessa
09/02/2015	Cholbam
06/03/2015	Otezla
06/03/2015	Xtoro
06/03/2015	Hemangeol
06/03/2015	Lemtrada
06/03/2015	agents used to treat idiopathic pulmonary fibrosis
06/03/2015	GLP-1 receptor agonists



06/03/2015	topical therapies for onychomycosis
12/03/2014	testosterone products
12/03/2014	phosphate binders
12/03/2014	Zontivity
12/03/2014	Evzio
09/03/2014	Northera
09/03/2014	Oral Allergen Extracts
06/02/2014	Cathflo
06/02/2014	Intranasal Cyanocobalamin Products
06/02/2014	Luzu
06/02/2014	Noxafil
06/02/2014	Bethkis
03/03/2014	Statins
03/03/2014	Vecamyl
12/03/2013	Brisdelle
12/03/2013	Nitroglycerin Lingual Spray/Sublingual Tablets
12/03/2013	Agents Used to Treat COPD
12/03/2013	Epinephrine Auto-Injection Devices
12/03/2013	Pulmozyme
09/09/2013	Rayos
09/09/2013	Diclegis
09/09/2013	Sitavig
09/09/2013	Onmel
09/09/2013	Giazo
06/03/2013	Fulyzaq
06/03/2013	Xeljanz
03/11/2013	Genitourinary Smooth Muscle Relaxants
03/11/2013	Agents Used to Treat Multiple Sclerosis
12/03/2012	Actinic Keratosis
12/03/2012	Moxeza
09/17/2012	Kalydeco
09/17/2012	Kuvan
09/17/2012	Elaprase
06/04/2012	Lorzone
06/04/2012	Provigil
06/04/2012	Kapvay
06/04/2012	Dexpak/Zemapak
06/04/2012	Xifaxan
06/04/2012	Vanos
03/05/2012	Pulmonary Arterial Hypertension Agents
03/05/2012	Topical Acne Agents
03/05/2012	Benign Prostatic Hyperplasia Agents Brendan
03/05/2012	Juvisync/Combination Products
03/05/2012	Gralise

12/05/2011	Dificid
12/05/2011	New Oral Anticoagulants
12/05/2011	agents used to treat Hereditary Angioedema
09/12/2011	Asacol HD
09/12/2011	Ophthalmic Antihistamines
09/12/2011	Horizant
09/12/2011	Daliresp
09/12/2011	narcotics with high dose APAP
06/06/2011	Nuedexta
06/06/2011	Nexiclon
06/06/2011	Topical ketoconazole products
03/07/2011	Statins
03/07/2011	Gilenya
03/07/2011	Xyrem
12/06/2010	agents used to treat Hepatitis C
12/06/2010	ODT preparations
12/06/2010	Oravig
12/06/2010	Zyclara
12/06/2010	Clorpres
12/06/2010	Livalo
12/07/2009	Hemophilia
12/07/2009	Sancuso
12/07/2009	Relistor
12/07/2009	Nuvigil
12/07/2009	Nucynta
09/14/2009	Uloric
09/14/2009	Moxatag
09/14/2009	Targeted Immune Modulators
06/01/2009	Aczone
12/01/2008	Triptans
12/01/2008	Vusion
09/08/2008	Chantix
09/08/2008	Carisoprodol
02/04/2008	Ophthalmic Anti-infectives
08/20/2007	High-Cost Medications
08/20/2007	Ketek
08/20/2007	Xopenex
08/20/2007	Tekturna
08/20/2007	Synagis
08/20/2007	Amrix
06/04/2007	Qualaquin
12/11/2006	Exubera
12/11/2006	Solodyn and Oracea
12/11/2006	Oxycontin

11/13/2006	Generic medications
11/13/2006	Vigamox and Zymar
11/13/2006	Boniva
05/01/2006	Growth Hormone
05/01/2006	Sedative/Hypnotics Agents
02/13/2006	Actoplus met
11/07/2005	Revatio
08/08/2005	Zanaflex capsule